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Executive Summary 
Much attention has been paid in state economic development circles to the importance of biosciences as 
an engine for innovation and technology growth in the 21st century. The genomic revolution, and the 
resulting advances in bioscience knowledge, are generating multiple potential bio-pathways to 
innovation-based economic development.  
 
Figure ES-1: Genomic and Biomass Resources for the Biosciences. 
 
To facilitate understanding of Iowa’s core bioscience competencies and opportunities and its current 
economic base, the Iowa Department of Economic Development engaged Battelle’s Technology 
Partnership Practice (TPP) to perform economic and core competency analysis of the biosciences in Iowa. 
Battelle examined the state’s existing biosciences industry, broadly defined for this study to include most 
aspects of agriculture, e.g., agricultural machinery and equipment, agricultural processing, etc., because it 
is an important component of the “biosciences cluster” that also includes supplier chains and end 
customers. It includes key industry segments such as medical devices, drugs and pharmaceuticals, and 
research and testing. The economic analysis section of this report analyzes trends, current strengths, and 
emerging subsectors of the biosciences cluster in Iowa.  
For the core competency analysis, Battelle used quantitative data sources (bioscience grant funding data, 
research output data, patent data, etc.) in combination with more than 220 qualitative fieldwork interviews 
in Iowa among faculty, administrators, trade and business associations, industry, and others to develop an 
in-depth profile of the State’s core bioscience competencies. The results show that Iowa has broad and 
substantial bioscience expertise in each of the core bioscience areas. Because of the need for a strong 
research base as a prerequisite for any state to succeed in the biosciences, these documented competencies 
position Iowa with the potential to advance in bioscience-based economic development. 
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IOWA BIOSCIENCES ECONOMIC CLUSTER 
Introduction 
Bioscience is a set of knowledge-based industry sectors that, together, form a cluster of established and 
emerging opportunities. It is a set of industries with roots in academic and clinical discovery as well as 
engineering and ecological advancements. The innovative nature of the industry has positioned bioscience 
as a growing sector of the economy. The industry has given rise to new establishments and increasing 
employment. Over the past four years, bioscience industry has grown by 4.6 percent across the United 
States, adding close to 270,000 jobs nationally, using the definition of biosciences used in this report.1 
Case studies have documented the links between research and development activity and economic 
growth.2  
The inherent diversity of the bioscience sector is a strong factor contributing to the growing industry 
focus. The cross cutting technologies embedded in the bioscience has led to many companies to pursue 
market opportunities in associated technologies, from bio-engineered foods and fuels to advanced new 
botanical medicines, from breeding healthier animals to mapping the human genome—each contributing 
to the advancement of life science activities, whether related to plant, animal, or human health discoveries 
and opportunities.  
The bioscience industry is a strong driver for the U.S. and Iowa economies, diversifying the base, offering 
good, well-paying jobs, and contributing to overall economic productivity. There are a number of reasons 
to target Iowa’s bioscience industry for economic development: 
1. The bioscience industry is a significant part of the Iowa economy. In 2002, bioscience employment 
accounted for 7.0 percent of total employment in Iowa, exceeding the national average. The health 
services, food and kindred products, and chemical product subsectors comprising the bioscience sector 
account for large shares of Iowa’s gross state product (GSP).  
2. The bioscience industry has a wide-ranging impact on industries not typically perceived to be linked 
with bioscience technology. The innovative nature of the bioscience industry has positioned it as a value 
adding sector of the economy. The diverse industrial applications of the biosciences can be attributed to 
the innovative capacity of the industry in both the agriculturally related and clinical related fields.  
3. The bioscience industry is a tremendous source of well-paying jobs. The average salary of a bio-
science worker was more than $10,000 more than the statewide average annual wage in 2002, 
significantly above the statewide average wage.  
                                                   
1 The bioscience industry in this analysis includes the following subsectors: agricultural services, agricultural 
processing, organic and agricultural chemicals, drugs and pharmaceuticals, agricultural machinery equipment, 
medical equipment and supplies, research and testing, and hospitals. 
2
 The National Commission on Entrepreneurship examined the link between university R&D spending and new 
business starts. The authors found that the lag time between the investment of research and development dollars and 
economic growth is shorter than previously expected. A significant number of new firms spring up within the first 
year after the funding and the growth trend continues for at least five years, albeit at a lower rate after the first year. 
The full report can be found at: http://www.nasvf.org/web/allpress.nsf/pages/5415. 
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Table ES-1: Average Iowa Annual Wages per Employee 2002. 
 
Definition 
To address the diversity of the bioscience industry in this analysis, it was divided into three sectors: 
agricultural, medical, and plant-life sciences. The agricultural sector consists of those industrial 
subsectors involved in developing, supporting, and manufacturing new farming and food production 
technologies for advancing health and nutrition. The medical sector consists of those industrial subsectors 
involved in manufacturing and developing clinical techniques aimed at and directed toward advancing 
human health care. The plant-life sciences sector consists of those industrial subsectors involved in 
research, testing, developing, and manufacturing clinical and agronomic techniques and products for 
improving the functions of living organisms.  
The eight major subsectors of the bioscience industry identified for this economic analysis report appear 
in Figure ES-2. The eight subsectors of bioscience activity each encompass a wide variety of industrial 
activity upon which Iowa is well situated to further build and strengthen its overall bioscience base 
(Figure ES-3).  
Average Iowa Annual Wages per Employee 2002* 
Organic and Ag Chemicals   $52,760 
Ag Machinery and Equipment   $51,672 
Ag Processing     $46,318 
FIRE      $40,471  
Biosciences     $39,253 
Wholesale Trade     $38,300  
Manufacturing       $38,230  
US Total Private Sector    $36,517 
Transportation and Utilities    $35,708  
Information     $34,830  
Construction      $34,777  
Iowa Total Private Sector    $29,158  
Professional Business Services   $28,630  
Ag/Natural Resources and Mining   $25,364  
* Wages are based on 2002 ES-202 data from the Bureau of 
Labor Statistics (BLS) and the Iowa Workforce Develop-
ment, Employment Statistics Bureau. 2002 Information for 
the U.S. was retrieved from BLS and is considered 
preliminary according to the Department of Labor. 
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Figure ES-2: Broadly Defined Iowa “Bioscience” Industry.  
 
Figure ES-3: Detailed Description of Bioscience Industry Breakout. 
Agricultural Processing
Organic & Agricultural 
Chemicals
Drugs & Pharmaceuticals
Research & Testing
Hospitals & Labs
Agricultural Services
Agricultural Machinery
Medical Equipment & 
Supplies
Agricultural 
Related
Medical Related
Plant-Life 
Sciences
Agricultural Processing
• Corn, flour, and rice milling
• Soybean processing
• Oil refining, blending, and 
processing
Organic & Agricultural 
Chemicals
• Ethyl Alcohol manufacturing
• Pesticides 
• Nitrogenous / phosphatic fertilizer
• Organic based chemicals and fibers
Drugs & Pharmaceuticals
• Medicinal & botanicals
• Pharmaceutical preparations
• Veterinarian vaccines / diagnostics
• Biological products manufacturing
Research & Testing
• Seed testing laboratories
• Agricultural research
• Biological research
• Veterinarian testing
Hospitals & Labs
• Medical laboratories
• Diagnostic Imaging 
• General medical hospitals
Bioscience
Agricultural Services
• Soil preparation
• Planting / cultivating services
• Livestock services
Agricultural Machinery
• Farm machinery and equipment
• Food production machinery
Medical Equipment & Supplies
• Laboratory apparatus
• Surgical instruments / appliances
• Electromedical apparatus
 Iowa Bioscience Path for Development 
 
 
xv
Iowa Bioscience Industry Cluster 
Overall, in the four-year period analyzed, the industry experienced a period of decline and then growth. In 
2002, the Iowa bioscience industry employed 82,849 individuals across 1,856 establishments. Although 
this level of employment represents a drop from the 1998 level, the industry has demonstrated above 
average growth since 2000. Key conclusions from this analysis include the following: 
Despite Iowa’s bioscience industry decline overall since 1998, recent trends since 2000 indicate 
a growth rate that is above the national average. 
Although the bioscience employment base fluctuated over time, the industry remained a sizable 
portion of Iowa’s economy throughout the four years analyzed. 
The current level of Iowa’s bioscience employment concentration is considered to be regionally 
specialized. 
Iowa Bioscience Cluster Subsectors 
Iowa’s bioscience subsectors can be categorized into four classes based upon their performance from 
1998 to 2002 (Figure ES-4). The four categories are based on the subsector’s growth relative to U.S. 
growth and the subsector’s location quotient. The four classifications of subsectors are stars, emerging 
potential, transitional, and divergent. Subsectors classified as stars or emerging are vital for the overall 
industry and its future development potential. These subsectors are often seen as the driving force behind 
the industry’s success. Subsectors classified as transitional or divergent are in a stage of either becoming 
less important or are evolving to once again become stars. Though the four-year trend is not irreversible, 
these subsectors demonstrate current characteristics that may threaten the long-term viability of the 
industry base.3 
Detailed Cluster Subsector Strengths 
It is useful to further isolate particular strengths of the subsectors within these industry segments as 
shown in Figure ES-5.  
Industries that fall within the confluence of all three circles are considered major bioscience subsector 
strengths. These industries exhibited very large employment bases, significant specializations, and growth 
over the last year that surpassed U.S. growth rates. These industries demonstrate the potential for the state 
to create new opportunities and niches in the bioscience industry that can be leveraged to jump-start other 
promising industry segments. The diversity of the bioscience industry clearly indicates that advancements 
within particular subsectors can be leveraged to strengthen others. By focusing on its existing strengths, 
Iowa can build a promising future in the biosciences.  
 
                                                   
3
 A detailed table of Iowa’s bioscience subsector performance can be found in Appendix A. 
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Figure ES-4: Iowa Bioscience Subsector Performance, 1998-2002. 
 
Figure ES-5: Assessment of Iowa’s Detailed Industry Strengths within the Bioscience Subsectors.  
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IOWA RESEARCH CORE COMPETENCY ANALYSIS IN THE BIOSCIENCES 
Iowa National Position in the Biosciences 
From the standpoint of academic funding for R&D, the State of Iowa is performing well for its size. With 
$439.8 million in research funds, Iowa ranks 24th in total university R&D funding (according to the 
National Science Foundation)—notably exceeding its population rank of 30th. 
Within the academic R&D arena, the state is performing particularly well in the biosciences, with 
66 percent of all academic research funds falling under this definition. This level of performance places 
Iowa 21st in the nation. Also, Iowa ranks well across the three major macro-categories of bioscience 
R&D, ranking 19th in Medical Sciences, 20th in Agricultural Sciences, and 22nd in Biological Sciences. 
In all three cases Iowa’s performance exceeds its ranking among the states in population. 
Iowa’s comparatively strong performance in bioscience R&D cannot, however, be taken for granted. 
Bioscience is a key target for growth in many states and in recent years, Iowa’s total growth in bioscience 
funding has not kept pace with that of the nation—resulting in a slightly declining bioscience R&D 
market share of total academic R&D. 
Iowa’s Quantitative Bioscience Strengths 
The biosciences are broad and no state has core strengths in every aspect of them. In Iowa, quantitative 
data on funding by discipline, publications citations and numbers of grants serves to highlight some of the 
fields in which Iowa has a specialization. 
National Institutes of Health (NIH) data show that the University of Iowa College of Medicine performs 
particularly well in funding for 
• Orthopaedics (where it ranks 3rd in the nation) 
• Public Health and Preventative Medicine (ranked 5th) 
• Otolaryngology—Ear, Nose and Throat (5th) 
• Pediatrics (8th) 
• Anesthesiology (10th) 
• Biostatistics and related Math Sciences (11th). 
Iowa State University also received NIH awards, but performs particularly strongly in accessing National 
Science Foundation (NSF) and U.S. Department of Agriculture (USDA) awards. Iowa State performs 
well in multiple disciplines, including biological infrastructure, environmental biology, integrative 
biology and neuroscience, and molecular and cellular biosciences. Iowa State’s USDA funding highlights 
its work in veterinary medicine and animal sciences. 
The Institute for Scientific Information (ISI) publishes statistics on the publications frequency and impact 
of academic institutions. Within Iowa, several university disciplines are strong performers on ISI metrics. 
The data show that Iowa is particularly powerful in 
• Clinical Immunology and Infectious Diseases 
• Agriculture and Agronomy 
• Anesthesia and Intensive Care 
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• Otolaryngology 
• Entomology and Pest Control 
• Ophthalmology. 
Other disciplines that are strong in terms of citations include Agricultural Chemistry, Dentistry, Oral 
Surgery and Medicine, Microbiology, Veterinary Medicine, and Animal Health. 
Both the grants funding and ISI data serve to highlight several factors: 
• There is significant institutional depth in a broad range of bioscience, biomedical, and related 
disciplines. Both Iowa State University and The University of Iowa contribute to this depth. 
• Iowa has strengths in the three primary components of bioscience—human medicine, veterinary 
medicine/animal health, and plant sciences/agricultural science. 
• The University of Iowa is particularly strong and productive in Clinical Immunology and Infectious 
Diseases, Immunology, Otolaryngology, Ophthalmology, Anesthesia and Intensive Care, and Clinical 
Psychology and Psychiatry. 
• Iowa State University has demonstrable impact in Agriculture/Agronomy and Entomology and Pest 
Control. The University also has a strong concentration in Agricultural Chemistry, Animal and Plant 
Sciences, Veterinary Medicine and Animal Health, and Food Sciences and Nutrition. 
• Both the University of Iowa and Iowa State University have strengths in environment/ecology 
research. 
A quantitative analysis was completed, using Battelle’ own proprietary Starlight™ cluster analysis 
software system. Starlight™ uses pattern recognition algorithms on text data (grant abstracts) to find 
areas in which a critical mass of research is occurring. This analysis identified six “meta clusters” of 
research in Iowa comprising: 
  Cell and Molecular Studies 
  Crop and Soil Analysis 
  Disease and Infection Studies (both human and animal/agricultural) 
  Genetics 
  Neural Studies 
  Vascular Analytics. 
Iowa’s performance in the Cell/Molecular Studies and Genetics fields (with 510 grants and 259 grants 
respectively) is particularly noteworthy given the importance of these disciplines to modern bioscience 
progress. Strengths in these disciplines are provided by both The University of Iowa and Iowa State 
University. 
Taking all of the quantitative data into account, Iowa has the broadly based core focus areas shown in 
Table ES-2 and human medicine/health core focus areas shown in Table ES-3. 
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Table ES-2: Broadly Based Core Focus Areas Suggested by Quantitative Data. 
Federal Research Grants 
Starlight Cluster 
Analysis 
Core Focus Areas 
NIH NSF USDA 
Publication 
& Citation 
Strength  
(ISI Data) Grants Patents 
Academic 
Reputation 
(U.S. News & 
World Report 
Rankings) 
Plant Breeding and 
Genetics        
Biotechnology and 
Applied Microbiology        
Immunology and 
Infectious Disease        
Agricultural Equipment 
Engineering        
Food Safety and 
Nutrition        
Materials Science        
Agricultural Chemicals        
Entomology and Pest 
Control        
Veterinary Medicine 
and Animal Health        
 
Table ES-3: Human Medicine/Health Core Focus Areas Suggested by Quantitative Data. 
Federal Research 
Grants 
Starlight 
Cluster 
Analysis Core Focus Areas 
NIH NSF USDA 
Publication 
& Citation 
Strength  
(ISI Data) Grants 
Academic 
Reputation 
(U.S. News & 
World Report 
Rankings) 
Best Hospitals  
(U.S. News & 
World Report 
2003 
Rankings) 
Anesthesiology        
Audiology        
Biostatistics        
Cardiovascular        
Neurosciences, Neurology 
& Neurosurgery        
Nursing 
       
Oncology 
       
Ophthalmology 
       
Orthopaedics        
Otolaryngology        
Pediatrics        
Public Health & 
Preventative Medicine        
Radiology & Radiation 
Diagnostics        
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Qualitative Assessment of Iowa Bioscience Strengths 
The analysis of quantitative data sets a context for understanding where Iowa’s core competencies in 
bioscience research are focused. To further investigate these fields and deepen our understanding of the 
core bioscience focus areas in Iowa, extensive qualitative interviews were conducted with university 
administrators, faculty, scientists, clinicians, industry executives, and development agencies in the state. 
These interviews are essential in developing an understanding of how the data on publications and grant 
awards translate into on-the-ground focus areas in Iowa. They also contribute to a far stronger 
understanding of institutional directions and plans for the future. 
After performing the qualitative interviews, conclusions were formed that placed each of the identified 
strength areas into one of three categories: 
• Established Strengths—comprising the “powerhouse” disciplines in which Iowa has a clear 
leadership position to build upon. 
• Strong and Growing Areas—comprising fields that are fast growing in general (such as genetics 
and bioinformatics in which the state is particularly strong, but must be developed further) but less 
fully established than the preceding category. 
• Emerging and Notable—comprising smaller or embryonic programs that still show significant 
potential for bioscience development in Iowa. 
Based on this categorization, the qualitative assessment resulted in the following summary chart, 
Figure ES-6: 
 
Figure ES-6: Qualitative Summary Chart. 
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Core Platforms for Iowa Bioscience Development 
The quantitative and qualitative data served to identify core areas of strength and expertise in Iowa 
biosciences. Not all of these, however, can form the basis of platforms upon which economic develop-
ment can be built. Rather, the project team’s experience and expertise, in combination with market data, 
helped determine which core competencies, or combinations of core competencies, may form solid 
technology platforms for economic progress. 
Battelle’s quantitative and qualitative analysis reveals multiple core competency areas within academic 
R&D in Iowa—most notably centered on Iowa State University and The University of Iowa, with some 
supporting strengths at the University of Northern Iowa (notably in the BioEconomy and Integrated 
Biosecurity platforms). These core competency areas are summarized in Figure ES-7, which shows the 
strengths identified by Battelle’s quantitative and qualitative analyses, together with recommended 
technology platforms for resulting bioscience development. 
 
Figure ES-7: Iowa’s Validated Research Strengths Leading to Recommended Platforms. 
As Figure ES-7 shows, Battelle sees opportunity for Iowa to develop its bioscience economy upon 
multiple short or near-term “platforms”. These include:  
  BioEconomy Platform—Using plant and animal biomass and waste streams to generate chemicals, 
energy, fuels, and materials for industrial and commercial applications.  
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  Integrated Drug Discovery, Development, Piloting and Production Platform—Leveraging Iowa’s 
strengths in basic biomedical research, drug development, and GMP production into an integrated 
pipeline of new drugs and therapeutics. 
  Advanced Food Products Platform—Using Iowa’s established strengths in plant and animal 
sciences, production agriculture, food science, nutrition, and processing technology to develop and 
produce functional foods and nutraceuticals. 
  Integrated Post-Genomic Medicine Platform—Using Iowa’s genomics expertise and specific 
disease/disorder skills, in conjunction with epidemiologic data and Iowa’s stable population, to 
produce rapid advances in post-genomic medicine and associated discoveries. 
  Animal Systems Platform—Using Iowa’s bioscience expertise to establish a leadership position in 
the modeling of animal systems and in the development of technologies and applications for 
transgenic animals, chimeric animals, and cloning. 
  Integrated Biosecurity Platform—Deploying the strengths of Iowa’s institutions in human, animal 
and plant disease prevention, protection, and treatment to establish an integrated approach to securing 
the environment, food production systems, human health and safety. 
These six areas represent broad platforms upon which a significant R&D, business base, and bioscience 
economy may be built in Iowa in the near to short-term. They each specifically draw upon Iowa’s 
institutional expertise in multiple fields, since it is multidisciplinary research that increasingly is gaining 
importance in driving funding, new study areas, technologies, commercializable innovations, and 
discoveries. In each case, the analysis shows that these platforms match well to large and rapidly growing 
projected domestic and international markets. In most cases the markets are characterized in terms of 
having expanding multibillion dollar existing and emerging potential. 
In addition to the broad technology platforms, several additional areas of emerging, longer-term 
opportunity represent additional sector development potentials. The identified areas consist of relatively 
compact groups of people working in leading edge fields, new formative centers just recently pulled 
together, or established areas of expertise in which further investment in infrastructure and/or personnel 
are required to sustain or accelerate development momentum.  
These four longer-term additional opportunity areas are 
  Host-Parasite Biology and Systems—Examining the interaction and symbiotic beneficial relation-
ships between hosts and parasitic organisms, with an initial emphasis on immunologic response. 
  Instrumentation, Devices and Sensors—Using Iowa’s skills in engineering, chemistry, biology and 
related fields to produce novel tools for instrumentation, analysis, invasive and non-invasive imaging, 
diagnostics, and biosensors. 
  Formation of a Cardiovascular Research Institute—Mirroring Iowa’s success with The University 
of Iowa’s Comprehensive Cancer Center to build a similarly resourced and dedicated scientific 
institute for advancing cardiovascular and cardiopulmonary research and development. 
  Formation of a Free Radical Research Institute—Cementing Iowa’s existing world leadership 
position in free radical and oxygen biology research within a formal institute with associated facilities 
and funding. 
Battelle’s assessment of Iowa’s position in the biosciences highlights a state that has significant promise 
to be among the nation’s bioscience research leaders in selective fields. Iowa institutions have substantive 
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strengths in the “three principal legs of the bioscience stool”— human, animal, and plant biosciences. In 
particular, the bioscience operations of both Iowa State University and The University of Iowa show 
fundamental bioscience technology platform strengths that can be further enhanced by increased 
collaborations between the institutions and with industry.4 
Challenges in Realizing Iowa’s Bioscience Potential 
The primary goals of the research were to identify bioscience core competencies and determine key 
platforms for bioscience-based economic development in the State of Iowa. While not a primary research 
goal, this study also served to identify barriers and challenges to bioscience development in Iowa. The 
principal observed challenges are grouped by theme below: 
Bioscience Visibility 
It is important that all three legs of the bioscience stool be recognized as important to the future economic 
growth of Iowa, namely: human, animal and plant biosciences. Agricultural biosciences have much higher 
legislative and public visibility in the state than do human medical sciences. While it is good that 
agricultural bioscience is recognized for its significant value to the current and future health of the Iowa 
economy, attention also needs to be raised to the equally strong position of Iowa in human bioscience 
R&D. 
Structuring for Bioscience Development 
The primary research universities in the State are not on equal footing when it comes to organizational 
structure and support for bioscience development. Iowa State University has made important progress in 
forming new Institutes and Centers that correspond well in their focus and strengths to both the goals of 
technology-based economic development and the primary platforms recommended in this report. In 
addition to being well structured to progress bioscience development, Iowa State also benefits from a 
research foundation and technology transfer/commercialization operation that is adequately staffed and 
cutting edge in approach and partnering arrangements with industry. The University of Iowa is more 
traditional in its structure, with the bulk of its bioscience work still taking place in academic departments.  
Table ES-4 compares Iowa universities on various metrics of technology transfer performance (as 
compiled by the Association of University Technology Transfer Managers [AUTM]).  These data 
compare the performance of the University of Iowa and Iowa State University with the median and top 
quartile of U.S. universities on selective measures developed by Battelle.  It should be noted that our 
study has focused on core competencies and that one important consideration in realizing economic 
benefits from these competencies and platforms is having the ability to transfer and commercialize 
discoveries from the research base into the commercial sector.  This study did not involve an in-depth 
review of either the technology transfer function or technology commercialization gaps that need to be 
addressed, both subjects of a fuller bioscience development strategy. 
 
                                                   
4
 Platforms are not intended to supplant or replace the existing structure of Iowa State University in its agbioscience 
work. Battelle notes that Iowa State University has established a well-structured suite of Centers under the umbrella 
of the Plant Sciences Institute and other formal Presidential initiatives, and recognition of this is shown in our 
analysis and recommendations on pages 89–92. It is highly important to Iowa’s future in the BioEconomy that the 
ISU Plant Sciences Institute and its related centers continue to be funded and grown. 
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Table ES-4: Iowa Technology Transfer Performance 
FY 2002 AUTM Licensing Data 
Metric 
 University of 
Iowa Research 
Foundation 
Iowa State 
University 
University of 
Northern Iowa 
AUTM Median 
For 
Universities 
AUTM Top 
Quartile for 
Universities 
Sponsored Research 
Expenditures $288,808,000 $212,100,000 $2,878,356 $127,497,469 $285,697,000 
Invention Disclosures 
Received  88 100 1 47 104 
Patent Applications Filed  77 64 1 36 87 
Patents Issued   30 29 1 10 26 
Licenses & Options 
Executed  37 287 0 9 27 
Licenses Generating 
Income  115 416 3 22 63 
Gross License Income $7,932,531 $10,826,616 $23,500 $851,155 $3,799,628 
Startups    3 2 N.A. 1 3 
          
    
Disclosures per $10 M 
Sponsored R&D  3.05 4.71 3.47 3.69 3.64 
Patents Issued per $10 M 
Sponsored R&D  1.04 1.37 3.47 0.78 0.91 
Licenses Executed per 
$10 M Sponsored R&D 1.28 13.53 0.00 0.71 0.95 
License Income per $10 
M Sponsored R&D $274,665 $510,449 $81,644 $66,759 $132,995 
Average Revenue per 
License  $68,979 $26,026 $7,833 $38,689 $60,312 
Startups per $10 M 
Sponsored R&D  0.10 0.09 N.A. 0.08 0.11 
Startups per License 
Executed  0.08 0.01 N.A. 0.11 0.11 
 
Bioscience Funding for Academe and Industry 
While Iowa is performing quite well for its size in the attraction of federal bioscience funding, state 
government financial support has declined significantly during the past five years. The result has been 
program cuts, faculty salary freezes, an inability to invest in new technologies and infrastructure, and a 
general fear for the future among the Iowa education and scientific community. At a time when higher 
education research institutions represent a strong economic investment, Iowa has had to lower rather than 
increase investment. A lack of sufficient state funding could put at risk some of the core strengths and 
resulting technology platforms identified in this report as key.  Faculty and scientists may be attracted to 
higher-paying jobs and more richly endowed laboratories and facilities in states where investments 
continue to be made in spite of revenue shortfalls. 
On the commercialization front, financing for start-ups, spinoffs, and younger bioscience firms has been 
difficult to secure in Iowa. There is an evident lack of pre-seed, seed and venture capital available in Iowa 
to fund new ventures in the biosciences. Lack of local capital resources is limiting entrepreneurship on 
campuses and reducing the volume of innovation-based companies in the state. The scarcity of venture 
capital was confirmed in interviews with multiple start-up companies in the state. 
Recent state initiatives to address capital gaps, including formation of a fund of funds, the Iowa Values 
Fund, and tax incentives for investors will be helpful, and will better position Iowa to secure sufficient 
funding for these biosciences ventures. 
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Bioscience Entrepreneurship 
Bioscience-based economic development is understood by many in academia to be a key priority for the 
state. However, faculty in the state are confused as to what is expected of them in terms of faculty 
entrepreneurship, intellectual property generation, and idea commercialization. Many feel that their 
traditional research and teaching roles are threatened by a perceived requirement to start and run 
companies. Reassurance needs to be provided that while universities are expected to be economic 
development engines through the generation of discoveries and ideas, it is not necessarily the faculty 
themselves that must be the founders and managers of any resulting commercial enterprises. A set of 
policies is required that would relieve faculty of the burden of commercializing their concepts, whereby 
faculty can disclose their discoveries and have a team of commercialization experts assess marketability 
and ultimately form companies around the most viable concepts. Faculty should be free to be technical 
advisors to companies that their inventions promote, and to help move their research discoveries into the 
commercial realm. An appropriate rewards system for faculty engagement in applied and commercial 
research should also be encouraged at each university. 
Limitations on Iowa’s commercialization of bioscience also are imposed by an apparent lack of 
experienced bioscience entrepreneurs and managers who can fulfill management duties in new start-ups, 
or provide mentoring to new bioscience enterprises. Lack of experience makes new businesses a more 
high risk venture and makes the attraction of venture funds and capital that much more difficult. 
Successful commercialization of bioscience discoveries and technologies in Iowa may require a 
comprehensive review of policies and relaxed return expectations at the IP-generating universities. By 
adopting policies that are more flexible for companies forming and operating in-state, the Regent 
universities may enhance the economic development potential. The research institutions are operating 
under reduced state funding and are limited in their ability to grant flexible arrangements in licensing with 
industry. An appropriate set of incentives may be needed to assist research universities  in spurring 
enhanced company formation and local technology licensing. 
Iowa’s Commercial Bioscience Base 
Iowa higher education institutions appear to be making good attempts to link their research to the needs of 
industry in the state. For example, Iowa State University has incorporated industry advisors and advisory 
boards as key components of its institutes and centers. However, these efforts are hindered somewhat by a 
lack of a commercial base in many areas of biotechnology, pharmaceuticals, medical devices and even 
food processing. Building a base in these areas will certainly not happen overnight and will place 
constraints on the pace at which bioscience development will progress in Iowa. 
The one area of bioscience in Iowa in which short-term progress is being made in commercialization and 
new company formation is in the BioEconomy arena. BioEconomy companies generally need to be close 
to their required biomass inputs, and the agricultural richness of Iowa in combination with the strong 
university-based R&D in the field is producing results. The formation of the BIOWA Development 
Association with members from the corporate community, agriculture community, state universities and 
state agencies is a very positive step forward. 
Certainly, barriers exist to realizing the full potential of these platforms, but none of them, in Battelle’s 
opinion, are insurmountable. Other states—Arizona, Missouri, Georgia, Michigan—have developed a 
comprehensive state biosciences strategy that includes the economic analysis and core competencies 
identification contained in this report, as well as systematically identifying ways to position a state in 
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technology and in talent and capital formation. Iowa may wish to build on this work with a similar effort 
to complete a biosciences roadmap for the state.  
A formal development and funding strategy needs to be developed to provide a roadmap for offsetting 
and circumventing barriers and to provide a step-by-step path for achieving tangible and sustainable 
bioscience development results. 
Conclusion: Bioscience is a Clear Target of Opportunity for Iowa 
Iowa is strong and diversified in its bioscience R&D base and has a small but growing commercial base in 
certain related disciplines (most notably related to BioEconomy initiatives). The R&D basics are in place 
across agricultural-bioscience, animal science, and human/medical bioscience, and the leading 
universities are already working on collaborations to help advance their bioscience work. 
Iowa’s core competencies in the biosciences lend themselves to the development of several distinct 
development platforms, each of which has large-scale market potentials. These platforms include distinct 
opportunities in 
• The BioEconomy—A platform for near-term investment and development in which university R&D 
and commercial strengths come together to generate great promise for the future. 
• Advanced Food Products—Another near-term opportunity in which Iowa’s expertise in agriculture, 
food production, and processing can be leveraged with a depth of expertise in genomic-sciences and 
nutrition to make important progress in functional foods and nutraceuticals. 
• Animal Systems—Using the transgenics skills of Iowa State and The University of Iowa to establish 
a leadership position in transgenic animals and associated applications. This may have a longer 
development cycle than some of the other platforms. 
• Integrated Biosecurity—Working to leverage Iowa’s expertise in plant, animal and human diseases 
to produce integrated approaches and models to the protection of agro, food and bio-systems. An 
opportunity that should be considered near-term to take advantage of current homeland security 
funding and imperatives. 
• Drugs—Investing in the near-term in The University of Iowa to create a drug discovery center that 
will complete an integrated pipeline from basic sciences research to discovery, trials, and production 
in an integrated academic environment. Also, investing in Iowa State will support biologics produc-
tion facilities. This platform has the potential to generate a homegrown drugs and biologics industry 
in Iowa. 
• Post-Genomic Medicine—Another highly important near-term opportunity to build upon the 
University of Iowa’s strengths in bioinformatics, genomics, post-genomic sciences, health 
informatics, epidemiology, and clinical practice to accelerate discoveries in pharmacogenetics and the 
potential for personalized medicine. 
Other investments and priorities may also be considered by Iowa, most notably the formation of institutes 
to enhance Iowa’s leadership and expertise in cardiovascular research, free radicals research, host/parasite 
biology, and bioscience electronics, instrumentation, devices and sensors. In Iowa’s future, it will be key 
to link near- and long-term platforms and the underlying research foundations with the development of a 
critical mass of firms connected to and improving their competitiveness through these research drivers 
and platforms. 
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Introduction: Biosciences 
AN ERA OF THREATS AND ECONOMIC OPPORTUNITY 
As the 21st century moves forward, fundamental forces are at work that severely impact the ability of 
states to maintain their normal economic modus operandi. The U.S. economy is facing a time of great 
change. In our nation, where states have the freedom to chart their own courses through the free market 
economy, the pace of change is likely to produce winners and losers as some make the correct decisions 
and investments while others make the wrong ones or fail to react at all.  
For the past 200 years, the U.S. economy has sustained a general trend of economic growth and standard 
of living increases for its population; this progress largely has occurred through the innovation of 
Americans and ever higher levels of productivity in agriculture, industry, and commerce. Over the last 
decade, however, it has become increasingly apparent that America’s economic leadership cannot be 
taken for granted. Global competition is intensifying and economic indicators are showing multiple 
disturbing trends: 
• The United States has a growing and negative balance of trade. The nation is consuming many more 
goods produced by competing nations than it is selling overseas. For the 12 months ending in 
January, 2003, the United States recorded a goods trade deficit of $496 billion. Even the information 
technology sector is declining. The trade deficit is not a short-term anomaly; it is now a sustained 
trend.  
• The United States is the world’s largest debtor nation, with Bureau of Economic Analysis data 
showing an accumulated U.S. foreign debt of $3.3 trillion in 2002. 
• Educational performance in grades K-12 has fallen behind that of most competing developed nations. 
In terms of educational performance per dollar spent, U.S. educational productivity has declined 
dramatically rather than increasing as it should. 
At the heart of the problem is a nation that is consuming more than it produces, falling deeper into debt to 
foreigners to pay for its consumption, and lacking the education and workforce performance required to 
increase productivity and reverse the negative trends. 
These same trends operate at the state level. Iowa’s traditional economic base in agriculture and 
manufacturing is threatened. Commodity crops, such as soybeans, are facing increased competition from 
foreign producers, such as Brazil, while manufactured products face increased competition from Asian 
and European producers. Macro-economic trends have resulted in a significant State of Iowa budget 
shortfall which, according to Iowa State University economists, is the product of declining corporate tax 
revenue. 
Within an environment of stiff and increasing competition, the State of Iowa must be able to make 
informed decisions regarding the right investments for its economic future. Therefore, the Iowa 
Department of Economic Development engaged Battelle’s Technology Partnership Practice (TPP) to 
perform economic and core competency analyses of the biosciences in Iowa. Research performed by 
the TPP indicates that the key determinant of the future wealth of U.S. states lies within their 
ability to innovate and produce economic output based upon that innovation. Creating an economic 
structure conducive to innovation and more importantly, innovation commercialization, is increasingly 
central to the future sustainability of state economies.  
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The U.S. economy always has been nourished by inventiveness and creativity, so the “innovation 
economy” per se is not new; rather innovation has become the primary impetus of economic growth and 
competitiveness among developed nations. Two fundamental forces are driving technology and 
knowledge advancement as determinants of economic success: 
• The rapidly accelerating pace of scientific discoveries and the technologies that are developed from 
these discoveries. For example, advances in genetics have accelerated dramatically the discovery 
process in the biosciences. The opportunity to accelerate the discovery and development processes, 
along with the ability to protect and profit from intellectual property, has led to an innovation race 
among competing countries, regions, and states. 
• World markets are global and pressure is increasing on the United States to maintain its high-wage, 
high-skill employment base through technology gains and productivity increases. 
THE BIO-CENTURY 
Much attention has been paid in state economic development circles to the importance of biosciences as 
an engine for innovation and technology growth in the 21st century. Many states have developed bio-
science plans, but much of the focus has been on applying bioscience to human health (e.g., pharma-
ceuticals, diagnostics, medical devices, instruments, and replacement tissue). While applications of 
bioscience to human health hold significant economic potential, so too does the application of bioscience 
to agricultural productivity, agricultural and food products, companion animal health, and new 
materials, chemicals and biologics developed via biomass pathways. The plant and animal biosphere 
contains a huge repository of genes; the novel combination, mining, and use of which has the potential to 
stimulate change in a broad range of industries, from medicinal and food products to advanced materials 
and energy sources. Traditional bioscience and bioengineering disciplines also have a great deal to 
contribute in new production and processing technologies, improved products from agricultural com-
modities and biological materials, and the novel application of bioresources to as yet undiscovered 
economic uses.  
The presence and ongoing operation of bioscience research and development institutions in a state likely 
can provide a comparative advantage for growing its economy. Iowa has the opportunity to greatly 
enhance its economic performance and the future quality of life of Iowans through participation in all 
major sectors of the biosciences economy. Iowa’s major research institutions have strengths in human, 
animal, and plant biosciences, and an industry base that can be leveraged for future economic growth and 
prosperity. 
Competitive advantages will go to those countries, states, and regions that use interdisciplinary collabo-
ration and technologies to drive cutting edge innovations. Iowa has an existing culture of interdisciplinary 
academic research, and an emerging culture of industry-university collaborations that can enhance growth 
and advancement. 
In the following two sections of this report, Iowa’s current economic base of private firms in the bio-
sciences is described; the bioscience industries are defined; and trends in growth, comparisons to the 
nation, and identification of the key elements of Iowa’s current bioscience complex are reported. Battelle 
has identified core research areas, “mega” research clusters, and the corresponding six technology 
platforms in which Iowa can excel based on its current and emerging research and applications endeavors. 
In the future it will be key to link both these platforms and the underlying research foundations with the 
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development of a critical mass of firms in Iowa connected to and improving their competitiveness through 
these research drivers and platforms.  
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Economic Analysis 
INTRODUCTION 
Bioscience is a set of knowledge-based industry sectors that, together, form a cluster of established and 
emerging opportunities. This cluster is constantly altered and reinvented as scientists, engineers, and 
researchers gain new insights into the ways living organisms function. It is a set of industries with roots in 
academic and clinical discovery as well as engineering and ecological advancements. These technological 
breakthroughs take shape in new and innovative products used in everyday life. This explains, in part, the 
reason why public officials, private investors, and academic scholars have watched developments in 
bioscience with intense interest. 
The industry’s ability to reinvent itself continually indicates the potential that the biosciences have to spur 
new economic activity. The promise of new life-altering discoveries has made bioscience a high value-
adding industry sector. Countless new commercial prospects emerge with every new breakthrough and 
discovery.  
The innovative nature of the industry has positioned bioscience as a growing sector of the economy. The 
industry has given rise to new establishments and increasing employment. Over the past four years, 
bioscience industry has grown by 4.6 percent across the United States, adding close to 270,000 jobs 
nationally as defined in this study.5 Continual technological research and product development has lead to 
new and pioneering products. New market opportunities have been created as a result of technology 
transfer and commercialization activities. Case studies have documented the links between research and 
development activity and economic growth.6  
The inherent diversity of the bioscience sector is a strong factor contributing to the growing industry 
focus. The cross-cutting technologies embedded in the biosciences have led many companies to pursue 
market opportunities in associated technologies, from bio-engineered foods and fuels to advanced new 
botanical medicines, from breeding healthier animals to mapping the human genome—each contributing 
to the advancement of life science activities, whether related to plant, animal, or human health discoveries 
and opportunities.  
The United States is a world leader in many areas of the biosciences—bioscience research, designing and 
producing new technologies, healthier agricultural and food commodities, new drugs and surgical 
procedures. Since interactions between researchers and practitioners are vital for continued advancement 
and progress within the sector, the biosciences have tended to concentrate in certain regional economies 
where such relationships are prevalent. Nevertheless, other areas also support substantial centers of 
bioscience activity and are engaging in promulgating, supporting, and enhancing this most promising set 
of industry segments. 
                                                   
5 The bioscience industry in this analysis includes the following sectors: agricultural services, agricultural 
processing, organic and agricultural chemicals, drugs and pharmaceuticals, agricultural machinery equipment, 
medical equipment and supplies, research and testing, and hospitals. 
6
 The National Commission on Entrepreneurship examined the link between university R&D spending and new 
business starts. The authors found that the lag time between the investment of research and development dollars and 
economic growth is shorter than previously expected. A significant number of new firms spring up within the first 
year after the funding and the growth trend continues for at least five years, albeit at a lower rate after the first year. 
The full report can be found at: http://www.nasvf.org/web/allpress.nsf/pages/5415 
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The State of Iowa can develop its bioscience expertise and become a value-adding asset for the industry. 
The opportunity exists to support current emerging subsectors in the bioscience industry and reinforce 
existing specializations.  
This economic analysis section examines the bioscience industry within the State of Iowa as it existed in 
2002, describes the general performance of the bioscience sector in the last four years, and compares it 
with national trends. This analysis identifies emerging and existing subsector industry strengths which, 
along with the research core competencies analysis to be described later, provide the basis for linking 
research excellence to economic opportunity in Iowa. 
WHY FOCUS ON THE BIOSCIENCES? 
The bioscience industry is a strong driver for the U.S. and Iowa economies, diversifying the economic 
base, offering good, well-paying jobs, and contributing to overall economic productivity. However, with 
national and global competition intensifying, the state’s performance within particular segments of the 
biosciences is not necessarily the pattern for the future. Therefore, it is appropriate that the private and 
public sectors jointly consider and address ways to ensure Iowa’s competitive base and future in this 
biosciences industry cluster. 
There are a number of reasons to target Iowa’s bioscience industry for economic development: 
1. The bioscience industry is a significant part of the Iowa economy. In 2002, bioscience employment 
accounted for 7.0 percent of total employment in Iowa, exceeding the national average of 5.6 percent of 
total private sector employment. The strength that Iowa demonstrates in this technologically advancing 
industry suggests that this sector of the economy is an asset for the state upon which to build. 
Another way to observe the impact of the bioscience industry on the state economy is in the examination 
of the Gross State Product (GSP) of Iowa. Table 1 illustrates the important role that subsectors critical to 
bioscience play in the Iowa economy. The health services, food and kindred products, and chemical 
product subsectors comprising the bioscience sector account for large shares of Iowa’s GSP. In fact, in 
Iowa, each subsector has a larger share of GSP compared with the United States.  
 
Table 1: Bioscience Share of Gross State Product, 2001. 
 
2001 Gross State Product 
Industry
(millions of 
current dollars)
Percent Share 
of Total GSP
(millions of 
current dollars)
Percent Share 
of Total GSP
Total Gross State Product 90,942 100.00% 10,137,190 100.00%
Farms 2,831 3.11% 80,596 0.80%
Ag. services, forestry, and fishing 623 0.69% 60,054 0.59%
Food and kindred products 3,788 4.17% 123,683 1.22%
Chemicals and allied products 2,880 3.17% 163,456 1.61%
Health services 5,653 6.22% 589,788 5.82%
Source: U.S. Bureau of Economic Analysis, 2001 Gross State Product by Industry Category, Released April 2003
Iowa United States
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2. The bioscience industry has a wide-ranging impact on industries not typically perceived to be linked 
with bioscience technology. Examining the bioscience industry from a macroeconomic perspective 
reveals that the industry is a broad-based sector of the economy. Industries increasingly are integrating 
new technologies in a variety of ways to raise productivity and product capabilities. The innovative nature 
of the bioscience industry has positioned it as a value-adding sector of the economy.  
The diverse industrial applications of the biosciences can be attributed to the innovative capacity of the 
industry in both the agriculturally related and clinical related fields. New market opportunities have 
emerged as a result of scientific and technological innovations and discoveries. New food technologies 
have led to methods to control food-borne pathogens and enrich the nutritional value of crops (e.g., 
vitamin-A-enriched rice). Genetically modified crops resistant to insects and diseases produce higher 
yields, lower production costs, and reduce the use of pesticides and chemical fertilizers. Materials 
produced from maize are being used to create polylactide plastics, which are then used in clothing and 
packaging. New precision farming equipment is incorporating advanced electronic systems to monitor 
soil conditions to improve crop yields and reduce harmful environmental impacts.  
Medical technologies also drive the biosciences. New electro-medical devices are used to monitor heart 
and brain activity. Bio-engineered drugs are manufactured to target specific human genes to prevent 
diseases such as Alzheimer’s or heart disease. Hospital and medical laboratories are investigating new 
ways to use the Internet to reduce medical costs and improve healthcare delivery. All of these advances 
demonstrate that the bioscience industry has the potential to stimulate new economic activity across 
several industry sectors.  
3. The bioscience industry is a tremendous source of well-paying jobs. Compared with other major Iowa 
industries, bioscience is one of the highest paying industries in the state. The average wage of a bio-
science worker in 2002 was more than $10,000 more than the statewide average annual wage and 
surpassed such sectors as manufacturing, information, construction, and finance, insurance, and real estate 
(FIRE) (Table 2). Because bioscience is a diversified industry, comprises a substantial share of state 
economic activity, and is a source of high-paying jobs, it is reasonable to support initiatives that focus on 
this industry. 
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Table 2: Average Iowa Annual Wages per Employee 2002. 
DEFINITION OF IOWA’S BIOSCIENCES CLUSTER 
Varying industrial classifications could be used to define the bioscience sector of the economy. Currently 
there is no commonly accepted definition. Categorization is difficult due to the diversity of bioscience 
activity. The industry is dynamic and encompasses a wide variety of industrial applications. Continual 
innovation further complicates the industry definition. Bioscience advancements constantly are being 
applied in new and different ways, creating new industry segments such as genetically improved foods or 
alternate energy sources such as agriculturally based fuels.  
To address the diversity of the bioscience industry in this analysis, it was divided into three sectors: 
agricultural, medical, and plant-life sciences. The agricultural sector consists of those industrial 
subsectors involved in developing, supporting, and manufacturing new farming and food production 
technologies for advancing health and nutrition. Four subsectors of the bioscience industry were identified 
as part of the agricultural sector: (1) agricultural services, (2) agricultural machinery and equipment, 
(3) agricultural processing, and (4) organic and agricultural chemicals. This area is one of the most 
difficult in which to establish boundaries and parameters. This area is one of the most difficult in which to 
establish boundaries and parameters.  Battelle used Iowa’s covered employment and wage (CEW, or 
ES-202 as it is sometimes referred to) data series to determine where individual firms were classified and 
to ensure that only those firms known to be agriculture biorelated were included. 
The medical sector consists of those industrial subsectors involved in manufacturing and developing 
clinical techniques aimed at and directed toward advancing human health care. Two subsectors of the 
bioscience industry were identified as part of the medical sector: (1) medical equipment and supplies, and 
(2) hospitals and medical laboratories. 
Average Iowa Annual Wages per Employee 2002* 
Organic and Ag Chemicals   $52,760 
Ag Machinery and Equipment   $51,672 
Ag Processing     $46,318 
FIRE      $40,471  
Biosciences     $39,253 
Wholesale Trade     $38,300  
Manufacturing       $38,230  
U.S. Total Private Sector    $36,517 
Transportation and Utilities    $35,708  
Information     $34,830  
Construction      $34,777  
Iowa Total Private Sector    $29,158  
Professional Business Services   $28,630  
Ag/Natural Resources and Mining   $25,364  
* Wages are based on 2002 ES-202 data from the Bureau of 
Labor Statistics (BLS) and the Iowa Workforce Develop-
ment, Employment Statistics Bureau. 2002 Information for 
the U.S. was retrieved from BLS and is considered 
preliminary according to the Department of Labor. 
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The plant-life sciences sector consists of those industrial subsectors involved in research, testing, develop-
ing, and manufacturing clinical and agronomic techniques and products for improving the functions of all 
living organisms. Two subsectors of the bioscience industry were identified as part of the plant-life 
sciences sector: (1) research and testing, and (2) drugs and pharmaceuticals. Figure 1 shows the three 
sectors and subsectors in the bioscience industry. 
 
Figure 1: Broadly Defined Iowa Bioscience Industry. 
 
The North American Industrial Classification System (NAICS) was chosen as the most appropriate means 
to identify industry subsectors associated with bioscience activity. Based on an analysis of six-digit 
NAICS codes, 46 industries were selected and organized according to eight major subsectors of the 
bioscience industry.7  
The eight major subsectors of the bioscience industry identified for this economic analysis report appear 
in Figure 2. The eight subsectors of bioscience activity each encompass a wide variety of industrial 
activity upon which Iowa is well situated to further build and strengthen its overall bioscience base.  
Clearly, this definition of bioscience subsumes much of the supplier chain—a key characteristic of cluster 
analysis—including such subsectors as agricultural machinery, agricultural processing, and agricultural 
chemicals.  In defining the cluster, not more narrow industry segments, it is possible that enclaves of 
economic activity related to the bioscience industry were not included in this list.  NAICS does not fully 
incorporate the wide variety of industrial activity that falls within the scope of the bioscience industry.  
Characterizing an industrial sector solely on the basis of aggregated industrial data inevitably results in 
certain data gaps. 
                                                   
7
 A detailed list of the 46 NAICS codes used to define the Iowa bioscience industry can be found in Appendix B. 
Agricultural Processing
Organic & Agricultural 
Chemicals
Drugs & Pharmaceuticals
Research & Testing
Hospitals & Labs
Agricultural Services
Agricultural Machinery
Medical Equipment & 
Supplies
Agricultural 
Related
Medical Related
Plant-Life 
Sciences
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Figure 2: Detailed Description of Bioscience Industry Breakout. 
 
It must be understood that no one data source can fully account for all economic activity related to a 
particular industrial sector. This analysis strived to select the best data system in which to characterize the 
bioscience industry and capture the largest portions of industry activity. The North American Industrial 
Classification System was chosen as the most appropriate data system. 
DATA AND METHODOLOGY 
This economic analysis report primarily examined the economic changes that took place between 1998 
and 2002. Battelle used the CEW data series to examine changes that occurred in employment, 
establishments and wages.8  
                                                   
8
 Reported monthly employment data represent the number of covered workers who worked during, or received pay 
for, the pay period which included the 12th day of the month. Reported annual average employment is an average of 
the corresponding monthly employment levels. Reported number of establishments represents the number of estab-
lishments whose activities were reported to the Unemployment Insurance system for the quarter. An establishment is 
an economic unit, such as a farm, mine, factory, or store, which produces goods or provides services. It is typically 
at a single physical location and engaged in one, or predominantly one, type of economic activity for which a single 
industrial classification may be applied. Reported annual average number of establishments is an average of the 
corresponding quarterly number of establishment levels. Reported quarterly total wages are the wages paid by 
Unemployment Insurance covered employers during the calendar quarter, regardless of when the services were 
performed. Reported total annual wages are the sum of the total wages reported for the corresponding quarters. Total 
wage values reported in this database have been rounded and are reported in thousands of dollars. 
Agricultural Processing
• Corn, flour, and rice milling
• Soybean processing
• Oil refining, blending, and 
processing
Organic & Agricultural 
Chemicals
• Ethyl Alcohol manufacturing
• Pesticides 
• Nitrogenous / phosphatic fertilizer
• Organic based chemicals and fibers
Drugs & Pharmaceuticals
• Medicinal & botanicals
• Pharmaceutical preparations
• Veterinarian vaccines / diagnostics
• Biological products manufacturing
Research & Testing
• Seed testing laboratories
• Agricultural research
• Biological research
• Veterinarian testing
Hospitals & Labs
• Medical laboratories
• Diagnostic Imaging 
• General medical hospitals
Bioscience
Agricultural Services
• Soil preparation
• Planting / cultivating services
• Livestock services
Agricultural Machinery
• Farm machinery and equipment
• Food production machinery
Medical Equipment & Supplies
• Laboratory apparatus
• Surgical instruments / appliances
• Electromedical apparatus
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The Iowa Workforce Development, Employment Statistics Bureau, was the primary source for gathering 
data relevant to the state. The United States Department of Labor, Bureau of Labor Statistics (BLS) was 
the primary source for gathering data relevant to the United States. 
The CEW data, or ES-202 as it is sometimes referred to, is a cooperative program involving the BLS and 
State Employment Security Agencies (SESA). The QCEW program produces a comprehensive tabulation 
of employment and wage information for workers covered by state unemployment insurance (UI) laws 
and Federal workers covered by the Unemployment Compensation for Federal Employees (UCFE) 
program. Publicly available files include data on the number of establishments, monthly employment, and 
quarterly wages, by NAICS industry, by county, by ownership sector, for the entire United States. These 
data are aggregated to annual levels, to higher industry levels (NAICS industry groups, sectors, and 
supersectors), and to higher geographic levels (national, state, and Metropolitan Statistical Area [MSA]).9  
Since 2001, ES-202 data has used the North American Industry Classification System. The new federally 
mandated classification system reflects recent changes in the economy. The new system was developed to 
better identify new and emerging industries. Industries that primarily create and disseminate a product 
subject to copyright, such as information technology, are now better identified under the new system.  
Prior to 2001, ES-202 data was reported using the Standard Industrial Classification (SIC) system. 
Unfortunately, the NAICS and SIC systems do not directly correspond with one another. This makes it 
extremely difficult to translate one classification system into the other. Fortunately, the Iowa Employment 
Statistics Bureau has developed a computational methodology whereby the state calculated historic 
employment, establishment, and wage data. The state provided Battelle with data estimates for the 
selected NAICS codes. 
Battelle used the County Business Patterns data series to calculate estimated national data for the years 
prior to 2001.10 County Business Patterns data is one of the first publicly available data sets to report 
economic information according to NAICS for multiple years. County Business Patterns makes it 
possible to use the most up-to-date industry classification system and also examine changes over time 
dating back to 1998. Using this information, Battelle was able to calculate estimated employment, estab-
lishment, and wage data for the bioscience industry and its associated eight subsectors. The estimations 
made it possible to calculate changes that had occurred in the bioscience industry in the years preceding 
2001.11 
                                                   
9
 Major exclusions from UI coverage include self-employed workers, most agricultural workers on small farms, all 
members of the Armed Forces, elected officials in most states, most employees of railroads, some domestic workers, 
most student workers at schools, and employees of certain small nonprofit organizations. 
10
 County Business Patterns is an annualized data set that provides sub-national employment, establishment, and 
payroll information. The data is assembled from several databases maintained by the Census Bureau and other 
Federal Government agencies. Data is extracted from the Business Register, the Annual Company Organization 
Survey, the Economic Census, the Annual Survey of Manufactures, and Current Business Surveys, as well as from 
the administrative records of the Internal Revenue Service (IRS), the Social Security Administration (SSA), and the 
Bureau of Labor Statistics (BLS). Relying on data collected by the government ensures a high degree of reliability 
and uniformity for comparison purposes. 
11
 Battelle used employment, establishment, and annual wage information from the County Business Patterns data 
series for the years ranging from 1998 through 2001. Battelle analyzed data changes using 2001 as the base year. 
The assumption was that annual changes in the data for County Business Patterns would be proportional to ES-202. 
This is why the 2001 data was critical, because it was the one year in common to both ES-202 and the County 
Business data set. Understanding that the County Business Patterns data is a different data set than the ES-202 data 
series, but faced with the need for timely and accurate data to analyze the bioscience industry, Battelle was confident 
that by calculating the proportional relationship as opposed to using raw absolute numbers, a rough estimate of 
industry activity prior to 2001 was captured. 
 Iowa Bioscience Path for Development 
 
 
12 
ECONOMIC ANALYSIS OF IOWA’S BIOSCIENCE CLUSTER 
Overall, in the four-year period analyzed, the industry 
experienced a period of decline and then growth. In 
2002, the Iowa bioscience industry employed 82,849 
individuals across 1,856 establishments. Although this 
level of employment represents a drop from the 1998 
level, the industry has demonstrated above average 
growth since 2000, despite the economic downturn that 
began in March, 2001.12 Therefore, examining the Iowa 
bioscience industry performance between 1998 and 2002 
requires a careful analysis.  
Despite Iowa’s bioscience industry decline since 1998, 
recent trends since 2000 indicate a growth rate that is 
above the national average. Between 1998 and 2000, 
the industry experienced massive employment losses 
compared with the nation. Iowa’s bioscience employ-
ment base dropped by more than 4,600 employees, 
representing a 10.1 percent decline. In sharp contrast, 
the industry at the national level grew. Although 
marginal, the nation experienced bioscience employment growth at a rate of 0.9 percent. 
Above-average employment growth between 2000 and 2002 helped offset large employment losses 
between 1998 and 2000. The Iowa bioscience industry employment rebounded somewhat in the two years 
since 2000. Bioscience employment grew by 5.3 percent at the state level, regaining 4,179 jobs since 
2000. Even more promising is that this growth rate was above the national average. The bioscience 
industry across the United States grew at a rate of 3.7 percent between 2000 and 2002. Table 3 illustrates 
the bioscience industry’s overall performance in Iowa and the nation. 
                                                   
12
 The National Bureau’s Business Cycle Dating Committee maintains a chronology of the U.S. business cycle. The 
chronology identifies the dates of peaks and troughs that frame economic recession or expansion. The period from a 
peak to a trough is a recession and the period from a trough to a peak is an expansion. According to the chronology, 
the most recent peak occurred in March 2001, ending a record-long expansion that began in 1991. The most recent 
trough occurred in November 2001, inaugurating an expansion. 
http://www.nber.org/cycles/november2001/recessnov.html 
"New plant biotech firms and research 
facilities are being created throughout the 
United States. The number of agricultural 
and food scientists are increasing as 
workers are attracted to the biotech 
sector’s above-average wages, and a large 
number of individual states are reaping the 
benefits of this investment and job-related 
activity. While 41 of 50 states had some 
type of biotech initiative by 2001, those 
that have aggressively adopted and 
invested in biotechnology are reaping the 
greatest rewards."  
 
Dr. C. Ford Runge, director of the Center 
for International Food and Agricultural 
Policy and Distinguished McKnight 
University Professor of Applied Economics 
and Law. 
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Table 3: State and National Bioscience Comparison, 1998-2002. 
 
Even with the recent growth trend, the bioscience industry in Iowa declined overall during the 1998 to 
2002 time span. Bioscience employment in Iowa has dropped by 5.3 percent since 1998. The growth 
experienced between 2000 and 2002 did not make up for the large losses between 1998 and 2000. 
Nationally, the 1998 to 2002 timespan represented a period of 4.6 percent growth for U.S. bioscience 
employment.  
Although the bioscience employment base fluctuated over time, the industry has remained a sizable 
portion of Iowa’s economy throughout the four years analyzed. Bioscience employment concentrations 
over the four-year period consistently accounted for a larger share of state private-sector employment than 
at the national level. Bioscience employment in Iowa is responsible for 7.0 percent of total state private-
sector employment. Nationally, the bioscience industry accounts for 5.6 percent of total private-sector 
employment.  
Biosciences  Total Private Sector Biosciences
 Total Private 
Sector
Establishments
1998 2,468 92,099 82,476 7,557,865
2000 1,951 98,845 81,772 7,697,470
2002 1,856 83,340 86,273 7,852,549
% Change  98-00 -20.9% 7.3% -0.9% 1.8%
 00-02 -4.9% -15.7% 5.5% 2.0%
 98-02 -24.8% -9.5% 4.6% 3.9%
Employment
1998 87,517 1,186,935 5,803,281 102,708,722
2000 78,670 1,217,722 5,855,230 108,358,433
2002 82,849 1,185,668 6,072,130 107,618,787
% Change  98-00 -10.1% 2.6% 0.9% 5.5%
 00-02 5.3% -2.6% 3.7% -0.7%
 98-02 -5.3% -0.1% 4.6% 4.8%
Employees per Establishment
1998 35 13 70 14
2000 40 12 72 14
2002 45 14 70 14
Location Quotient
1998 1.30             n.a n.a n.a
2000 1.20             n.a n.a n.a
2002 1.24             n.a n.a n.a
Wages
1998 33,682 25,670 37,663 31,923
2000 36,127 27,570 41,165 35,470
2002 39,253 29,158 44,199 36,517
% Change  98-00 7.3% 7.4% 9.3% 11.1%
 00-02 8.7% 5.8% 7.4% 3.0%
 98-02 16.5% 13.6% 17.4% 14.4%
Percent Share of Private Sector of Employment
1998 7.4% n.a 5.7% n.a
2000 6.5% n.a 5.4% n.a
2002 7.0% n.a 5.6% n.a
Source: Battelle calculations based on ES-202 data from the US Department of Labor, Bureau of Labor 
Statistics and Iowa Workforce Development, Employment Statistics Bureau
IOWA UNITED STATES
Metric
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The current level of Iowa’s bioscience employment concentration is considered to be regionally 
specialized. The location quotient is a common measure of the concentration of an industry within an 
economic region. When the location is significantly above average, a location quotient above 1.20, the 
region is said to possess a specialization in the industry. The fact that bioscience employment in Iowa 
accounts for a larger share of private sector employment than the industry does at the national level 
results in an above average location quotient for Iowa. Applying the formula in Figure 3 indicates that 
Iowa possesses a regional specialization in the bioscience industry that is currently 1.2, and this number 
has declined since 1998.13 
Iowa’s location quotient has fluctuated over 
time, following the ebbs and flows of 
employment. Examining the change in the 
location quotient over time must be analyzed 
carefully because of the nature of the formula. 
Location quotient change could be a result of 
change in total employment and/or industry 
employment at the local and/or national level.  
The data reveal that over the four-year period 
between 1998 and 2002, Iowa’s location quotient in the bioscience industry eroded from 1.30 in 1998 to 
1.24 in 2002. Bioscience employment at the state level fell at a faster rate than total state employment. 
Dwindling state employment in both the private sector and the bioscience industry contrasts with the 
national trend. The United States experienced employment growth across both the private sector and the 
bioscience industry. The decline of bioscience employment in Iowa is the main reason for the industry’s 
decreasing employment concentration.  
IOWA BIOSCIENCE CLUSTER SUBSECTORS 
While the bioscience cluster industries are engaged in understanding living organisms and their functions, 
this understanding is mobile and applied across several platforms. This variety supports the importance of 
industry and technology convergence. It is critical to understand how convergence among different 
industry segments within and outside the cluster will affect the future of the biosciences. Bioscience 
convergence is especially relevant for traditional agricultural-oriented industries and clinical-oriented 
industries.  
                                                   
13
 Location quotients are a common measure of the concentration of particular industry in a region relative to the 
nation (reference area). The LQ consists of the ratio of the share of total regional employment that is in the particular 
industry and the share of total employment in the nation (reference area) that is in the particular industry. A LQ 
greater than 1.0 for a particular industry indicates that the region is relatively concentrated, whereas an LQ less than 
1.0 signifies a relative under-representation. A location quotient of above 1.20 denotes employment concentration 
well above the national average. Throughout this report, LQs are used to report regional industry concentrations 
relative to the United States as a whole. The minimum concentration threshold for declaring a regional specialization 
is a matter of judgment and varies somewhat in the relevant literature. In this analysis, regional specializations are 
defined by LQs of 1.2 or greater. 
LQRi = (Ri / RT) / (USi / UST)  
Where: 
  Ri = industry i employment for the region 
  RT = total employment for the region 
  USi = industry i employment for the nation 
  UST = total employment for the nation 
Figure 3: Location Quotient Formula. 
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Therefore, the diverse nature of the bioscience 
industry requires an analytical approach that 
accounts for the numerous applications of agricul-
tural and clinical technologies. Accurately depicting 
the bioscience industry requires examining both the 
underlying technologies and the products which 
enable and advance life-science knowledge. 
Examining each of these unique subsectors helps 
foster a better understanding of the overall industry. 
Dissecting the industry also helps identify specific 
areas of strength and opportunity to create synergies 
and facilitate future development potential for the 
entire industry sector. 
Iowa’s bioscience subsectors can be categorized into four classes based upon their performance from 
1998 to 2002, as shown in Figure 4. The four categories are based on (1) the subsector’s growth relative 
to U.S. growth and (2) the subsector’s location quotient. The four classifications of subsectors are stars, 
emerging potential, transitional, and divergent. Subsectors classified as stars or emerging are vital for 
the overall industry and its future development potential. These subsectors are often seen as the driving 
force behind the industry’s success. Subsectors classified as transitional or divergent are in a declining 
state. Though not irreversible, these subsectors demonstrate current characteristics that may threaten the 
long-term viability of the industry in Iowa.14  
 
Figure 4: Iowa Bioscience Cluster Subsector Performance, 1998-2002. 
                                                   
14
 A detailed table of Iowa’s bioscience subsector performance can be found in Appendix B. 
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Employment Statistics Bureau
Corn Belt states with higher adoption levels of 
biotech crops—South Dakota, Nebraska, 
Kansas, Minnesota and Iowa—have a greater 
proportion of agricultural and food science jobs 
than those with lower levels of adoption. For 
example, Iowa, one of the top five states in crop 
biotech adoption, has 50 agricultural and food 
science jobs per 100,000 jobs, more than lower 
adoption states. The average annual salary for 
these jobs in 2001 was $52,310—more than one 
and a half times the U.S. average of $34,020. 
 
-- The Council for Biotechnology Information: 
www.whybiotech.com 
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Stars 
The organic and agricultural chemicals subsector is the fastest growing subsector in Iowa relative to 
the United States and is regionally specialized. Between 1998 and 2002, the subsector almost doubled in 
size, adding more than 2,000 jobs. The subsector had an employment base of 4,416 in 2002 across 56 
establishments. This employment increase is substantial considering that at the national level the 
subsector experienced a 15.3 percent employment drop. The phenomenal growth in Iowa has positioned 
the subsector well above the national employment concentration level.  
The state’s employment concentration in organic and agricultural chemicals is 2.5 times greater than the 
national average. This level of employment makes organic and agricultural chemicals in Iowa signifi-
cantly specialized. In addition to the regional specialization, Iowa’s employment level represents an 
increasing concentration. The subsector’s fast-paced growth is a major reason contributing to the state’s 
growing specialization.  
Emerging Potential 
The drugs and pharmaceuticals subsector is the second fastest growing bioscience subsector and 
outpaced growth of this industry at the national level. Over the four-year time period between 1998 and 
2002, subsector employment in drugs and pharmaceuticals rose by 12.6 percent. The increase brought 
employment levels above 2,500 across 44 establishments. The growth that Iowa experienced in drugs and 
pharmaceuticals even surpassed the U.S. growth rate. Nationally, the drugs and pharmaceuticals subsector 
grew by 11.3 percent. The ability of drugs and pharmaceuticals to remain ahead of national employment 
growth rates has contributed to a rising employment concentration. However, the employment 
concentration level in Iowa remains 22 percent below the national average.  
The medical equipment and devices subsector experienced the second fastest employment growth rate 
in Iowa relative to the United States. Though growth was only half as much as the drugs and pharma-
ceutical subsector, medical devices was second only to organic and agricultural chemicals in terms of 
relative growth compared to the nation. Iowa’s employment base in the medical device subsector grew by 
6.1 percent. Across the nation, subsector employment in medical devices decreased by 0.6 percent. 
Despite the encouraging growth trend over the last four years, the medical device subsector in Iowa 
remains small. In 2002, the subsector employed 1,847. The employment concentration of the subsector is 
significantly below the national average. Iowa is 59 percent less concentrated than the nation is in the 
medical equipment and devices subsector. 
The hospitals and laboratories subsector is Iowa’s largest bioscience subsector and is growing. The 
Iowa hospital and laboratory subsector employed 41,882 in 2002. Although not often considered at the 
forefront in bioscience research or production, hospitals and laboratories are important contributors. In 
particular, health centers perform clinical trials and collaborate with companies on research and 
development.  
Since 1998, this subsector grew by 6.1 percent in Iowa, above the national rate of 4.4 percent. The growth 
provides the Iowa hospital and laboratories subsector with an employment level slightly below the 
national average. Typically, employment in hospitals and laboratories across most states and regions 
possesses a location quotient equivalent to the national average. This is to be anticipated because hospitals 
and laboratories generally service the local healthcare market except where specialized and/or academic 
teaching hospitals serve a broader, multi-state market.  
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Transitional 
The agricultural equipment and machinery subsector is the most specialized bioscience subsector in 
Iowa. In 2002, the subsector employed more than 10,000 workers across the state. This level of employ-
ment is far above the national level. The agricultural equipment and machinery subsector in Iowa 
possesses a location quotient of 11.83. This concentration level represents an employment base in the 
state that is more than 10 times the national level.  
This subsector has experienced sizable employment losses since 1998 at both the state and national level. 
Across the United States, employment in the agricultural equipment and machinery subsector decreased 
by 19.2 percent. Subsector employment in Iowa fell at a somewhat faster rate of 22.9 percent. Though the 
loss of employment was rather large in Iowa, it can be expected that a state as concentrated as Iowa 
inevitably will mirror the national trend. In spite of this decline, Iowa remains highly concentrated, an 
indicator of the state’s strength in the agricultural equipment and machinery subsector. 
The agricultural processing subsector is the largest agriculture-related bioscience subsector in terms of 
employment size and the second most regionally specialized subsector in Iowa’s bioscience industry. In 
2002, the agricultural processing subsector employed 19,458 across 976 establishments within the state. 
The subsector’s size is demonstrated by examining the average establishment size. The typical agri-
cultural processing establishment in Iowa employs 22 individuals. Nationally, the average establishment 
employs 16 individuals.  
In Iowa, the agricultural processing subsector typically more concentrated and is composed of larger 
firms. The state’s employment concentration in the agricultural processing subsector is more than 7 times 
greater than the national average. The location quotient of 7.34 clearly represents a strong regional 
specialization. 
Unfortunately, much like the experience of the agricultural equipment and machinery subsector, employ-
ment in the agricultural processing subsector has dropped in Iowa and across the country since 1998. Jobs 
in agricultural processing in Iowa fell by 21.0 percent between 1998 and 2002, compared with a 2.9 per-
cent decline nationally. Even with this loss of employment, the subsector remains significantly more 
specialized in Iowa. 
The agricultural services subsector is regionally specialized but experienced the second largest decline 
in employment. The agricultural services subsector is the smallest of all the bioscience subsectors, 
employing 1,187 in 2002. Although small in size, the subsector is significantly concentrated and is 
considered to be regionally specialized in Iowa. The subsector is more than twice as concentrated in Iowa 
versus the nation. 
The level of employment specialization is threatened by sizable employment losses. Between 1998 and 
2002, Iowa lost 31.8 percent of its employment base in agricultural services. The nation experienced a job 
loss that was far less severe. U.S. employment in agricultural services fell by only 0.5 percent.  
Divergent 
The research and testing subsector experienced the largest decrease in employment and is well below 
the national concentration average. Between 1998 and 2002, the subsector lost 37.3 percent of its 
employment base. This fast-paced decline contrasts sharply with strong growth at the national level. The 
U.S. research and testing subsector grew by 21.8 percent. Though not the smallest bioscience subsector in 
Iowa, the research and testing employment base is only slightly higher than agricultural services. In 2002, 
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the research and testing subsector employed 1,429 across 186 establishments, making it Iowa’s second 
smallest bioscience subsector.  
The rapidly dwindling employment base has drastically reduced the level of employment concentration in 
the state. Research and testing is almost 80 percent less concentrated in Iowa than in the nation and is 
extremely small. This makes it more difficult to position the subsector as a platform on which to build the 
state’s bioscience industry, even though research and testing is the industry subsector most closely 
identified with “biotechnology,” as distinct from the “biosciences” industry segment. 
Cluster Subsector Wages 
Analyzing the average annual wage per employee is another way of identifying critically important 
bioscience subsectors. Pinpointing subsectors which provide relatively high wages is an indication that 
the subsector is a high value-adding segment. By targeting economic development initiatives and job-
creating efforts at high-paying bioscience subsector positions, the state can concentrate its efforts on the 
highest value-adding segments and potentially raise the overall industry annual average wage per 
employee. Figure 5 illustrates the average annual wage per employee for each subsector in 2002.  
 
Figure 5: Bioscience Cluster Subsector Average Annual Wage per Employee, 2002. 
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Source: Battelle calculations based on ES-202 data from the US Department of Labor, Bureau of Labor 
Statistics and Iowa Workforce Development, Employment Statistics Bureau
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The graph clearly illustrates that agricultural machinery and equipment along with agricultural processing 
are major sources of current high-paying jobs in the biosciences in Iowa. These subsectors are well above 
the statewide average annual wage per employee, which stood at $29,158 in 2002. The subsectors are also 
above the bioscience average annual wage for the state and nation. The average annual wage per 
employee for agricultural machinery and equipment and agricultural processing is more than $4,000 
above the national average wage within each subsector.  
Although employment has not grown since 1998, these two subsectors experienced average annual wage 
increases. Agricultural processing saw wages grow by 13.1 percent and agricultural equipment and 
machinery experienced an 8.4 percent growth in wages. Both growth rates are above U.S. growth rates. 
Above-average annual wages combined with strong regional specializations within Iowa position the 
agricultural machinery and equipment subsector along with the agricultural processing subsector as 
important subsectors for the state’s future development efforts. 
Detailed Cluster Subsector Strengths 
While it is useful to further isolate particular strengths of these subsectors, industry-specific information 
should be approached cautiously. At such a detailed level, the data are often suppressed to avoid revealing 
information related to individual firms. The detailed analysis can also result in smaller absolute numbers, 
which exaggerate standard metrics and comparisons. In spite of these limitations, the disaggregated data 
can potentially reveal sources of subsector strength. 
Figure 6 depicts the performance of key NAICS industries in the state of Iowa. The industries were 
chosen based on three criteria:15  
• Industries with employment concentrations of 1.20 or more were considered regional specializations.  
• Industries that grew above the national growth rate were considered high growth.  
• Industries were classified as “large” based on employment size equal to or greater than 2,000. 
Industries that fall within the confluence of all three circles are considered major bioscience cluster 
subsector strengths. These industries exhibited very large employment bases, significant specializations, 
and growth over the last year that surpassed U.S. growth rates. It is essential to target these industries. 
Table 4 presents the data for those NAICS industries that possess at least two of the criteria used to 
identify strong detailed industry segments. 
Table 4 shows the industries that likely represent critical strengths of the Iowa bioscience sector. Each 
possesses a pair of critical characteristics from which the state can help bolster the entire bioscience 
cluster. Based on these metrics, these industries demonstrate the potential for the state to create new 
opportunities and niches in the bioscience industry that can be leveraged to jump-start other promising 
industry segments. The diversity of the bioscience industry within the cluster clearly indicates that 
advancements within particular subsectors can be leveraged to strengthen others. By focusing on its 
existing strengths, Iowa can build a promising future in the biosciences.  
                                                   
15
 To avoid overstating trends, only those industries with an employment level of at least 500 were analyzed. 
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Figure 6: Assessment of Iowa’s Biosciences Cluster Detailed Industry Strengths. 
 
 
Table 4: Detailed Iowa Biosciences Cluster Industry Strengths. 
Wet corn milling (311221)
Breakfast cereal manufacturing (311230)
Pesticide & other agricultural chemical manufacturing (325320)
Fertilizer Manufacturing (325314)
General medical and surgical hospitals (622110)
Testing laboratories (541380)
R&D in physical, engineering, & life sciences (541710)
Large
Speciali-
zation
High 
Growth
Soybean processing (311222)
Biological product manufacturing (325414)
Soil Preparation, planting, and cultivating (115112)
Farm Supplies Merchant Wholesalers (424910)
Other animal food manufacturing (311119)
Farm machinery and equipment manufacturing (333111)
Primary Target Industries - Large, Growing, and Regional Specialized
325320 Sizable:
 Employment stands at 2,982
High Growth: Employment increased by 228%
Regionally Specialized:
 LO stand at 14.39
311221 Wet corn milling Sizable:
 Employs 2,947
Growing:
 Increased by 0.3% while US declined
Extremely Specialized: LQ stand at 30.54
311230 Breakfast cereal manufacturing Employment: 2,077 workers
Growth:
 Employment rose by 5%
Specialized: Iowa possesses an LQ of 13.65
Large Anchors - Large Employment and Regionally Specialized
424910 Large Employment: 10,497 workers, the largest 
agricultural industry segment
Specialized: 8.66
Employment Growth:
333111 Farm machinery and equipment Large Employment:
 9,656 workers
Specialized:
 Maintains LQ of 15.36 despite losses
Growth:
 Employment fell by 2.8%, less than US decline
311119 Other animal food manufacturing Sizable: Employs 2,105
Concentrated:
 remained specialized with LQ of 5.82
Employment Change:
 Loss of 30.1% since ’98
Emerging Industries - High Growth +
622110 General medical and surgical hospitals Large Employment:
 40,675 workers
High Growth: Employment grew by 6.3%
LQ:
 Employment concentration is 5% below US average
325314 Fertilizer manufacturing Small: Employment stands at 565
High Growth:
 Employment rose by 128% 
Specialized: Iowa is 6 times more specialized than US
Pesticides & other agricultural chemical 
manufacturing
Farm Supplies Merchant Wholesalers
Source: Battelle calculations based on ES-202 data from the US Department of Labor, Bureau of Labor Statistics and Iowa Workforce 
Development, Employment Statistics Bureau
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Key Iowa Bioscience Subsectors 
    Employment
  2002 Location Growth
Subsector Employment Quotient 1998 - 2002
 
Organic & Agricultural Chemicals 4,416 3.51 93.0%
Agricultural Processing 19,458 7.34 -21.0%
Agricultural Machinery & Equipment 10,115 11.83 -22.9%
CONCLUSIONS 
The bioscience industry sector in Iowa is a large and regionally specialized sector of the state’s economy. 
The sector has demonstrated successes and shown encouraging industrial potential. Though overall 
employment between 1998 and 2002 lagged behind the United States, the better than average growth 
exhibited between 2000 and 2002 suggests that the bioscience industry represents an economic develop-
ment opportunity for Iowa. Development opportunities can have even more impact if industrial and 
academic initiatives are linked and focused around similar priorities. 
The economic analysis of the Iowa bioscience economy indicates that the industry is dominated by the 
agricultural-related subsectors. In particular, three subsectors are well-positioned to be the foundation of a 
comprehensive economic development strategy (Table 5). Organic and agricultural chemicals are a 
sizable, growing regional specialization that is extremely well-positioned to benefit from increases in 
ethanol production (an organic chemical). Agricultural processing is the largest of the agriculturally based 
bioscience subsectors. Despite loss of employment, the subsector demonstrates a solid base that is 
significantly more specialized than the nation and possesses an average annual wage per employee that is 
higher than the national average. Similarly, agricultural machinery and equipment exhibits a solid 
employment base and high average annual wage.  
 
Table 5. Key Iowa Bioscience Subsectors. 
 
The demonstrated success of these three subsectors positions the agricultural-related subsectors  as vital 
existing strengths of Iowa’s bioscience industry. State and regional stakeholders in the bioscience industry 
need to tailor development initiatives that specifically address these core strengths and further build the 
capacity to fully utilize these assets. 
Medical-related subsectors, though not yet core strengths, demonstrate emerging characteristics that place 
these subsectors in the category of potential drivers. Above-average employment growth relative to the 
United States indicates that these subsectors can be a crucial part of the bioscience industry’s future.  
Though agricultural services and research and testing are subsectors that have not shown strong growth 
rates or high levels of employment concentration, these subsectors remain important pieces of the 
bioscience industry in Iowa. Agricultural services and research and testing represent key industry 
segments necessary to ensure the overall strength and stability of Iowa’s biosciences sector. The diversity 
of the bioscience industry clearly indicates a high degree of interdependence among different industry 
segments.  
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To create a more durable and vibrant bioscience industry, the State of Iowa must target initiatives to 
support existing strengths and encourage and stimulate emerging subsectors. While Iowa must tailor 
initiatives to target those niches with the greatest promise of economic growth, the state must not lose 
sight of the inherent diversity of bioscience activity. The challenge that state leaders face is the need to 
balance initiatives between solidifying core areas within the biosciences and promoting new innovative 
industrial technologies that promise continual economic growth. 
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Biosciences Core Competency Assessment 
One of the required platforms for creating an understanding of the potential for bioscience development is 
a rigorous analysis of the bioscience-related research competencies found within Iowa upon which future 
bioscience economic advances may be made. Each state’s major research institutions have their own core 
research strengths and focus areas, and, as will be shown, Iowa is no exception.  
Without a strong research foundation found at universities, it is difficult for any state or region to initiate 
or sustain major industry development related to the biosciences. Universities are leaders in basic and 
applied bioscience research. Increasingly, universities are bringing enabling technologies to the forefront, 
helping advance bioscience-related applications in imaging, analytical instrumentation, processing 
technology, diagnostics, therapeutics, and materials science. Research centers not only are the key to the 
basic research discoveries that generate product leads for bioscience companies; they also contribute to an 
environment in which bioscience companies can flourish.  
Looking forward, the biosciences offer enormous potential for linking basic research innovations with 
new market opportunities. Table 6 describes the major potential breakthrough areas. 
 
Table 6: Potential Bioscience Breakthrough Areas. 
Human Biosciences Plant Biosciences Animal Biosciences 
• The prevention of diseases 
with underlying genetic 
causes 
• The development of early 
stage disease diagnostics  
• The ability to detect genetic 
predisposition to disease 
and develop prevention and 
treatment regimens 
• The production of advanced 
imaging technologies to 
promote new discovery and 
enhance therapeutic delivery 
• The discovery and 
development of new drugs 
and biologics for enhanced 
treatment outcomes 
• Drugs and therapies 
targeted to individual 
genomic characteristics 
leading to greatly improved 
outcomes and reduced side-
effects 
• Pest and disease resistant 
crops 
• Increased crop yield and 
desirable qualities 
characteristics 
• Lengthened growing 
seasons via cold resistance 
or reduced light 
requirements 
• Enhanced shape, texture, 
flavor and processability 
characteristics 
• Technologies to reduce the 
required application of 
fungicides, herbicides and 
insecticides 
• Functional foods and 
nutraceuticals 
• Plant genetic resources for 
development of biologics, 
drugs and pharmaceuticals 
• New approaches to animal 
disease diagnostics, 
prevention and treatment 
• Increased food animal meat 
yield and desirable quality 
characteristics 
• Improved technologies for 
food preservation and the 
prevention of spoilage and 
food-borne diseases 
• Genetic resources for 
development of biologics, 
drugs and pharmaceuticals 
for human and veterinary 
applications 
• Xenotransplantation and 
tissue engineering, providing 
organs and tissue for human 
medical applications via 
animal pathways 
• Development of engineered 
species, such as customized 
predator insects, to control 
pests and diseases 
 
 Iowa Bioscience Path for Development 
 
 
24 
Table 6: Potential Bioscience Breakthrough Areas (continued). 
Human Biosciences Plant Biosciences Animal Biosciences 
• The development of 
replacement tissue and 
organ systems to replace 
those injured or failing  
• The biological integration of 
advanced technologies, 
such as nanotechnology, 
biomaterials and MEMS 
devices 
• Advanced bioinformatics 
and health informatics tools 
to drive knowledge-based 
medicine. 
• The ability to eradicate, 
inoculate against and more 
effectively treat established 
and emerging infectious 
diseases 
• Enhanced biosecurity 
• Genetic resource 
(germplasm) preservation 
and storage technologies 
• Development of biosensors 
for industrial and commercial 
applications 
• “Biopharming” and the 
production of novel and 
useful chemicals via plant 
pathways 
• Development of sustainable 
bio-based fuels 
• Development of advanced 
biomaterials for use in 
construction and other 
industrial applications 
• Development of degradable 
plastics from plant starch, 
protein and fermentation-
produced monomers 
• Bioremediation and 
environmental protection via 
plants 
• Enhanced biosecurity 
• Development of biosensors 
for industrial and commercial 
applications 
• Bioremediation and 
environmental protection via 
microbial pathways 
• The use of animal waste and 
byproducts as renewable 
energy and chemical 
production resources 
• Enhanced biosecurity 
• The novel application of 
animal and plant genetic 
resources to new 
technologies such as 
biological computing 
 
As a result of potential discoveries and innovations in these areas, multiple forms of economic 
development may take place around the biosciences, including but not limited to the following: 
• The formation, growth and attraction of companies engaged in 
o Drug development and manufacturing 
o Biologics development and manufacturing 
o Vaccine production 
o Gene therapy development 
o Diagnostic test development and production 
o Diagnostics and imaging instrumentation manufacturing and development 
o Laboratory and diagnostics services and healthcare services 
o Medical implants and invasive devices 
o Tissue engineering and organ systems development 
o Seed and plant varietal development and production 
o Improved food animal species and enhanced animal health 
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o Agricultural and food processing technologies 
o Biomaterials and biocomposites development 
o Biofuels and bio-sourced chemicals 
o Production of novel and useful compounds via plant pathways 
o Agricultural equipment and precision agriculture devices 
o Bioinformatics and health informatics tools and software 
o Biosecurity 
o Waste management and environmental clean-up and protection 
o Nanotechnology and MEMS devices 
o Other bio and bio-related commercial applications yet to be developed or imagined. 
• The diversification of existing commodity producers, such as farms, into enhanced value-added 
products. 
• Direct economic benefits from research itself, brought by the attraction of external research funds and 
the scientists and staff they support. 
• Enhanced education and workforce development in and around biosciences and technology. 
Because research is the driving force behind bioscience innovation and commercialization, it is 
imperative that Iowa’s decisions regarding science and technology policy for advancing the 
biosciences be built upon a formal understanding of the state’s bioscience research core 
competencies. To develop a profile for Iowa, Battelle performed a formal, in-depth assessment and 
evaluation of the state’s bioscience core competencies and resulting technology platforms—a task that 
Battelle has undertaken for other states and universities.  
METHODOLOGICAL APPROACH TO ASSESSING IOWA’S CORE RESEARCH 
COMPETENCIES  
Underpinning the successful translation of bioscience research strengths into economic development 
opportunities requires recognition of the importance of “market-driven” processes. The traditional model 
of commercialization assumes a “research-driven” approach to commercialization. This research-driven 
commercialization process proceeds in a pipeline fashion from basic research leading to a major scientific 
breakthrough, to applied research leading to product development, and ending with industrial manufac-
turing and marketing. The shortcomings of the research-driven approach are that it is too divorced from 
commercialization and product development needs and has uncertain economic value. The market-driven 
approach recognizes that commercialization is a highly interactive process involving close ties between 
research activities and business development activities. Success depends, as the Council on Competitive-
ness points out, “on a team effort that includes carefully focused research, design for manufacturing, 
attention to quality and continuous market feedback.”16  
                                                   
16
 Council on Competitiveness, Picking Up the Pace: The Commercial Challenge to American Innovation (Washington, DC: 
Council on Competitiveness), pp. 9-10. 
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As seen in Figure 7, the components of a core 
competency area can bring together basic research, 
enabling technology, and applied research 
activities with a “line of sight” that moves 
seamlessly to address clinical needs and market 
opportunities, and can form robust technology 
platforms. Core competency areas that lack this 
linkage and connection to needs and market 
opportunities offer more limited development 
opportunities. 
Defining Core Competencies 
There is no one single source of information that serves to identify core research competencies and focus 
areas. Rather, a variety of integrated and complementary analyses are required to help identify an 
institution’s current position and areas of focus that may lead or contribute to Iowa’s future bioscience 
growth. 
In identifying core research focus areas in the biosciences, Battelle’s objective was to identify those fields 
where there is an ongoing critical mass of activity along with some measure of excellence. This does not 
mean, however, that other fields of bioscience excellence may not be present within Iowa institutions. 
What it does mean is that these other bioscience strengths are found in relatively limited pockets and so 
offer more limited opportunities upon which to build—but may still contribute in some manner.  
To take the analysis further, Battelle chose to apply an industrially focused core competency definition 
that is widely used by technology-based firms. As defined by Hamel and Prahalad, in “Competing for the 
Future,”17 a competence is a bundle of skills and technologies, rather than a single discrete skill or 
technology. It represents the sum of learning across individual skill sets and individual organizational 
units. 
Three tests can be used to identify a core competency: 
1. Is it a significant source of competitive differentiation? Does it provide a unique signature for the 
state? 
2. Does it transcend a single business? Does it cover a range of businesses, both current and new? 
3. Is it hard for competitors to imitate? 
Approach to Identifying Iowa’s Bioscience Research Core Competencies 
Battelle identified core research focus areas using both quantitative and qualitative methods (see also 
Figure 8): 
• Quantitative assessment uses statistical information on extramural grants, publications, and patent 
activities—as well as application of Battelle’s proprietary software tool “Starlight™” to identify 
research clusters—to develop an understanding of the trends and characteristics of bioscience 
research within Iowa institutions. 
                                                   
17
 Hamel, G. and Prahalad, C. K.  1994.  Competing for the Future. Harvard Business School Press: Boston, MA. 
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Figure 7. Line of Sight. 
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• Qualitative work includes 
extensive field-work inter-
views with key adminis-
trators, scientists, and 
researchers across the 
research drivers found in Iowa 
institutions. 
The questions that the Battelle 
team explored in the core 
competency assessment focused 
on the following: 
• What is Iowa’s overall 
volume of bioscience research 
and what trends, positive or 
negative, are being 
demonstrated? 
• In which fields of bioscience and related activities are Iowa R&D institutions receiving significant 
levels of funding, especially funding from “gold standard” sources such as the National Institutes of 
Health (NIH), the U.S. Department of Agriculture (USDA), National Science Foundation (NSF), etc.?  
• In what bioscience and related fields do Iowa academic institutions demonstrate a substantive and 
influential record of publication? 
• In what bioscience areas is Iowa generating patents and intellectual property? 
• What areas of bioscience and related fields do Iowa’s institutions self-identify as core competencies?  
• Based on identified core competencies, what development opportunities can be identified for the 
near-term (over the next five years) for growing the biosciences and related industries and 
technologies in Iowa? 
• Which bioscience core competencies show the most promise for becoming growth poles for 
incorporation into Iowa’s statewide technology and economic development policy? 
• Which core areas of bioscience focus require additional investment in order to realize their 
development potential? 
In evaluating the answers to these questions, the Battelle team can provide insights into the Iowa 
biosciences research base and draw implications as to how these research strengths may best intersect 
with the state’s industry and economic base, economic competitiveness factors, and market trends. 
  Qualitative Analysis:
Use of extensive field interviews to 
identify how core competencies 
can be translated into sources of 
innovative technologies/products 
for development. 
Key characteristics:
– Applications orientation
– Address current as well as new, 
emerging market opportunities
– Interdisciplinary and often cross-
institutional
  Market analysis to link research 
to platforms
  Identification of gaps, options 
and opportunities - What is 
needed to strengthen and further 
build platforms
  Quantitative Analysis:
Use of “Starlight” clustering 
analysis of grant awards and 
publications analysis to identify 
research areas where both 
concentration of activity and 
excellence are demonstrated by 
having:
– A significant number of research 
grants awarded. 
– A broad base of principal 
investigators 
– A significant source of competitive 
differentiation
– Covers a range of businesses, both 
current and new
Figure 8: Quantitative/Qualitative Analysis. 
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Quantitative Assessment of the Iowa Bioscience Base: 
Trends and Developments 
As a first step in assessing the biosciences position of Iowa, Battelle reviewed published statistics that 
allow the position of Iowa institutions to be compared to those of other leading bioscience institutions. 
Several sources of information typically are accessed by Battelle in assessing comparative bioscience 
positioning: 
• External, national research funding sources, including NSF, USDA, and NIH grant funding 
• Institute for Scientific Information (ISI) science publications citation index statistics 
• Proprietary Battelle Starlight™ analysis tools for mining research abstract information and patent 
abstract information for clusters of research expertise and focus. 
For purposes of this study Battelle used the latest comparative data available on all 50 states from federal 
agencies. While individual universities in Iowa have later data, it could not be used because it would not 
allow us to make comparisons with the nation and other states. In addition, this analysis is affected by the 
disproportionate federal research investments in human/medical research compared to plant, animal and 
related agriculture research. Because of the disproportionate amount of federal research dollars flowing 
through NIH, as compared to, for example, USDA, the reader should not conclude that the University of 
Iowa, whose medical school is the state’s primary recipient of NIH funds, is more successful than Iowa 
State, where USDA has a much smaller research budget to allocate to research universities.   
SIZE OF THE IOWA BIOSCIENCE RESEARCH BASE 
In terms of total university-based R&D activity, Iowa stands 24th in the nation, with $439.8 million in 
total research funding across seven research universities (as recorded by the NSF for 2001, Table 2). This 
level of R&D in Iowa outpaces the state’s overall ranking in population, which stands at 30th.  
Iowa historically has performed relatively well in terms of academic biosciences R&D. In 2003, 
66 percent ($291 million) of the $439.8 million in total Iowa university-based research was within the 
biosciences—placing Iowa 21st in the nation. Also, Iowa has sustained a strong position, relative to its 
population base, in multiple areas of bioscience R&D, with national rankings as follows: 
• 19th in “medical sciences” ($138 million) 
• 20th in “agricultural sciences” ($50 million) 
• 22nd in “biological sciences” ($84 million). 
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Table 7: Iowa Biosciences-Related Funding. 
R&D Funding at Iowa Universities 
(Rank of State of Iowa vs. Other States - For 7 Iowa Colleges & Universities) 
Field FY 2001 % U.S. Rank 
TOTAL OF ALL ACADEMIC DISCIPLINES  $ 439,810  1.3% 24 
LIFE SCIENCES TOTAL  $ 290,912  1.5% 21 
  Agricultural Sciences  $  49,993  2.2% 20 
  Biological Sciences  $  84,185  1.4% 22 
  Medical Sciences  $ 137,689  1.4% 19 
  Other Life Sciences  $  19,045  2.5% 15 
OTHER CRITICAL SCIENCES     
  Chemical Engineering  $   3,558  0.9% 32 
  Chemistry  $   9,625  1.0% 30 
 
Iowa’s ability to attract research funds is reflected in an overall rank of 24th for all academic disciplines 
combined, compared with Iowa’s population ranking of 30th. In Bio/Life-Science disciplines the state 
performs particularly well, while it also achieves a ranking appropriate for its size in chemistry and 
chemical engineering (two disciplines of great importance in current and future BioEconomy initiatives). 
As the pie charts in Figure 9 illustrate, the percent of each type of bioscience and associated sciences 
R&D in Iowa is quite similar to that within each field in the nation as a whole except that Iowa has a 
significantly higher than average concentration in agricultural sciences (16 percent versus 11 percent 
nationally). 
While Iowa has performed comparatively well in bioscience research in relation to its size, it has started 
falling off the national pace. Since 1996, Iowa has experienced a slowly declining share of U.S. academic 
biosciences R&D funds. This trend is illustrated in Figure 10. 
Key data relating to Iowa’s recent performance in the biosciences is highlighted in Table 8 and further 
explains how Iowa has not kept pace with national bioscience research funding trends. The data show that 
Iowa has a greater concentration of total academic R&D in the biosciences than the national average, and 
also that bioscience academic R&D spending per capita is considerably above the U.S. average. This 
comparative concentration in bioscience is declining somewhat as Iowa’s growth in bioscience R&D 
funding has not kept pace with the growth rate of U.S. bioscience research. To put it another way, if 
Iowa’s bioscience R&D increase from 1997 to 2001 kept pace with overall U.S. growth, Iowa would have 
received approximately $8 million more in bioscience R&D funding in FY 2001. 
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Figure 9: Share of Bioscience-Related R&D for Iowa and the U.S. 
 
Figure 10: Academic R&D in Iowa as a Percentage of U.S. Academic R&D. 
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Table 8: Recent Bioscience Performance in Iowa and the U.S. 
Metric Iowa United States 
Total Academic R&D, FY 2001 $439,810,000 $32,652,261,000 
Total Bioscience R&D, FY 2001 $290,912,000 $19,145,970,000 
Bioscience as a % of All Academic R&D 66.1% 58.6% 
Annual Academic Bioscience R&D Per Capita, FY 2001 $99.22 $67.10 
% Increase in Academic Bioscience R&D, FY ’97-01 37.7% 41.5% 
 
To further examine this issue, Figure 11 depicts life science funding to the seven Iowa institutions 
included in the NSF data, by general category (including bioscience funding and funding in chemistry and 
chemical engineering), for 1997 through 2001.18 The figure shows that in each category, Iowa has 
achieved an increase in the level of R&D spending at its academic institutions during this period. 
 
Figure 11: Academic Life Sciences R&D Spending at 7 Iowa Institutions, FY 1997-2001. 
A more detailed examination by federal agency of the funding trends is shown in Figure 12 (most recent 
available data is from 1996 to 2000). Figure 12 shows that actual declines in U.S. Environmental 
Protection Agency (and DOE) funding, slower growth in NSF funding, and much slower growth in 
USDA funding,19 all contributed to the overall slower bioscience research funding growth rate for the 
state. However, in HHS (NIH) funding, Iowa’s growth continued to outpace that of the nation. 
                                                   
18
 The 7 institutions include Iowa State University, University of Iowa, University of Northern Iowa, Drake University, Grinnell 
College, Maharishi University of Management, and Des Moines University-Osteopathic Medical Center. 
19
 It should be noted that USDA funding tends to fluctuate considerably from year to year. 
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Figure 12: Percentage Change in Federal Agency R&D Funding at Universities and Colleges in Iowa and the 
U.S., FY 1996-2000. 
      
Iowa’s overall position in one of the “gold standards” of bioscience funding, the National Institutes of 
Health, shows that Iowa ranks 25th in total NIH awards (Figure 13). This performance exceeds the state’s 
population ranking (where it stands at 30th). 
 
Figure 13: Total NIH Funding and Number of Awards, FY 2002. 
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Quantitative Assessment of the Iowa Bioscience Base: Identification 
of Potential Core Competency Areas 
The previous section highlighted basic trends in academic bioscience R&D activity within Iowa. In this 
section, the analysis is extended to examine the specific areas of bioscience and bioscience-related 
activities that are receiving extramural funding. The volume of funding and numbers of investigators are 
used to indicate the most active bioscience fields in Iowa’s research institutions. NIH, USDA, and NSF 
data are primarily used for this analysis.  
In addition, the ISI Citations database—a source providing detail on research “output” in terms of number 
of papers published, by discipline, and the average number of citations received per paper—was used. ISI 
maintains a detailed database of U.S. scientific papers and associated citations, allowing Iowa’s academic 
paper output in biosciences and related disciplines to be compared with national norms and indexed for 
relative impact. ISI data also allows for the calculation of the relative concentration of individual 
bioscience fields within institutions against national norms. 
These statistical sources were used to derive an overview of research core competencies and to give a 
more specific description of the bioscience expertise within Iowa academic R&D institutions. An area is 
identified as a core competency area when it has the following: 
• A significant number of bioscience-related research grants awarded through rigorous peer-review 
processes such as those at the NSF, USDA and NIH 
• A broad base of principal investigators, along with prominent biomedical researchers who hold 
multiple peer-review grants 
• A substantial level and impact of publications.  
RESEARCH CORE COMPETENCY AREAS SUGGESTED BY FEDERAL FUNDING DATA  
Examining NIH, USDA and NSF funding more closely, at the department level, suggests specific areas of 
strength in Iowa. 
Table 9 summarizes the national ranking of departments within Iowa institutions that are recipients of 
NIH funding (with The University of Iowa separated into the College of Medicine versus other depart-
ments aggregated across the University). Table 10 shows the number of awards by department (for those 
receiving 10 or more awards) between FY 1997 and FY 2003. 
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Table 9: NIH Awards Rank by Department. 
Institution Department  NIH Rank (Within Top 30) 
Among Medical Schools (FY 2002) 
Orthopaedics 3 
Public Health & Preventative Medicine 5 
Otolaryngology 5 
Pediatrics 8 
Anesthesiology 10 
Biostatistics & Other Math Sciences 11 
Urology 12 
Radiation-Diagnostic/Oncology 13 
Anatomy/Cell Biology 23 
Internal Medicine/Medicine 24 
Psychiatry 25 
Neurology 30 
The University of Iowa 
College of Medicine 
Dermatology 30 
Among Universities (FY 2000) 
Pediatrics 7 
Orthopedic Surgery 9 
Anesthesiology  11 
Nursing (2002 Data) 11 
Otolaryngology 13 
Radiology 14 
Public Health & Preventative Medicine 15 
Dermatology  16 
Anatomy 19 
Medicine 25 
Neurology  26 
Other Health Professions 26 
Dentistry 27 
The University of Iowa 
Psychiatry  27 
Social Sciences  3 
Zoology 14 
Iowa State University of 
Science and Technology 
Nutrition 25 
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Table 10: NIH Awards by University Department. 
The University of Iowa Awards 
Anatomy And Cell Biology 36 
Biochemistry 45 
Biological Sciences 34 
Cardiovascular Center 11 
Chemistry 22 
Dows Institute For Dental Research 12 
Epidemiology 12 
Internal Medicine 274 
Microbiology 39 
Neurology 26 
Orthopaedic Surgery 14 
Otolaryngology 15 
Pathology 28 
Pediatrics 78 
Pharmacology 18 
Physiology And Biophysics 35 
Preventative Medicine & Environmental Health 43 
Psychiatry 56 
Psychology 49 
Radiation Research Laboratory 11 
Radiology 27 
Speech Pathology And Audiology 16 
Iowa State University of  
Science & Technology Awards 
Biomedical Sciences 11 
 
While the NIH is the largest funder of bioscience research in the U.S., both the NSF and the USDA also 
provide significant bioscience R&D funds. The USDA funding is, of course, particularly important to 
land grant institutions, such as Iowa State University, who have a substantial R&D infrastructure 
supporting animal and plant biosciences. Table 11 summarizes NSF awards in Iowa, while Table 12 
shows awards by the USDA. 
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Table 11: NSF Awards by NSF Program Areas (Those with 10 or More Awards). 
The University of Iowa Awards Iowa State University Awards 
Bioengineering & Environmental 
Systems 
10 Biological Infrastructure 16 
Molecular and Cellular Biosciences  16 Environmental Biology  20 
    Integrative Biology and Neuroscience  18 
    Molecular and Cellular Biosciences  21 
 
Table 12: USDA Awards by Federal Center or University Department (Those with 10 or More Awards 
Provided to Iowa Institutions). 
United States Department of 
Agriculture (USDA)* Awards Iowa State University Awards 
Agricultural Research Service 20 Agronomy 18 
National Animal Disease Center 30 Animal Science 20 
    Plant Pathology 10 
    Veterinary Medicine 80 
*USDA Has Only Different Centers, Not Departments   
 
The NIH data show that The University of Iowa College of Medicine ranks in the top 10 in the nation in 
terms of 
• Orthopaedics (#3) 
• Public Health and Preventative Medicine (#5) 
• Otolaryngology (#5) 
• Pediatrics (#8) 
• Anesthesiology (#10) 
The University of Iowa College of Medicine also has a strong placing in biostatistics and other math 
sciences, an important area of modern biomedical research (ranking 11th in the nation). 
In terms of NSF awards, Iowa State University is a strong performer with awards spread across biological 
infrastructure, environmental biology, integrative biology and neuroscience, and molecular and cellular 
biosciences. Iowa State also is a major recipient of funding from the USDA, especially in the areas of 
Veterinary Medicine and Animal Sciences. 
Tables 10 to 12 also provide insight into the overall research funding strengths of the State of Iowa. No 
departments or institutions other than Iowa State University and the University of Iowa received more 
than 10 federal R&D awards in the FY 1997 to FY 2003 period. 
CORE COMPETENCY RESEARCH AREAS SUGGESTED BY ISI CITATIONS DATA 
ISI provides specific insight regarding the volume of publications produced by departments and the 
influence, in terms of citations, that each department’s work is having within its field. Battelle used the 
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ISI data, in addition to extramural funding data, Starlight™ analysis, and in-depth interviews, to provide 
an overview of where institutional strengths in science and technology may lie. 
Battelle accessed the ISI data for 1997 through 2001. In determining areas of strength within the 
biosciences, the focus was on bioscience and related fields where the institution has published at least 50 
papers that meet either or both of the following ISI indices parameters: 
• The relative impact of the published papers should be 1.25 or higher, where 1.0 equals the average 
impact of a U.S. paper in the field. “Relative Impact” represents the institution’s citation impact in the 
field (number of citations its papers receive in a field divided by its total number of papers) divided 
by average national impact of a paper in that field. A number above 1.0 can be read as a percentage, 
i.e., 1.25 equates to a 25 percent higher-than-average impact, while a 0.9 impact is 10 percent lower 
than average. 
• The publication quotient or citation quotient of 2.0 or higher indicates a concentration of effort in the 
area within the institution. The ratio measures the degree of concentration in a field within an institu-
tion versus the U.S. average. A ratio of 1.0 equals the national average, while greater than 1.0 
indicates a higher concentration in Iowa versus the nation. 
ISI data were only available for Iowa State University, The University of Iowa and the Ames Laboratory. 
Table 13 illustrates the areas of strength suggested by the ISI data within bioscience fields in Iowa: 
 
Table 13: Overall Iowa Bioscience Publication Strengths. 
The ISI data indicate that Iowa is generating significant impact relative to the U.S. as a whole in terms of 
R&D in 
• Clinical Immunology and Infectious Diseases (1.71 relative impact) 
• Agriculture and Agronomy (1.50) 
• Anesthesia and Intensive Care (1.42) 
• Otolaryngology (1.29) 
• Entomology/Pest Control (1.27). 
Also of note is Ophthalmology in which Iowa achieves a relative impact of 1.2.  
Field  Citations  Publications 
Citation 
Quotient
Publication 
Quotient
Relative 
Impact to US
Agricultural Chemistry 555 185 2.85 2.79 0.94
Agriculture/Agronomy 929 387 5.80 3.56 1.50
Anesthesia & Intensive Care 638 119 1.20 0.77 1.42
Biotechnology & Applied Microbiology 602 106 1.63 1.61 0.93
Clinical Immunology & Infectious Diseases 3,481 308 3.15 1.70 1.71
Dentistry/Oral Surgery & Medicine 721 263 3.29 2.76 1.09
Entomology/Pest Control 365 140 1.58 1.14 1.27
Food Science/Nutrition 654 209 1.66 1.59 0.95
Microbiology 6,750 718 2.03 1.79 1.04
Ophthalmology 721 176 2.14 1.64 1.20
Otolaryngology 571 187 2.85 2.04 1.29
Veterinary Medicine/Animal Health 801 308 2.17 1.79 1.12
Top Fields in Publications, FY 1997-2001
(Citation or Publication Quotient Greater than 2.0 or Relative Impact Greater than 1.25)
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The Agriculture and Agronomy field also has strong citations and publications quotients (at 5.8 and 3.56 
respectively). Also of note for high citations and publication quotients are Agricultural Chemistry, 
Clinical Immunology and Infectious Diseases, Dentistry, Oral Surgery and Medicine, Microbiology, 
Ophthalmology, Otolaryngology and Veterinary Medicine/Animal Health. 
Because of the comparative differences in bioscience focus of The University of Iowa (primarily human 
biomedical focused) and Iowa State University (primarily plant and animal bioscience focused), the ISI 
citations data were separately analyzed for each. Table 14 illustrates the results for the University of Iowa, 
while Table 15 shows Iowa State University. (Research fields that are part of the overall state strengths 
shown in Table 13 are represented in orange in Tables 14 and 15.) These results clearly illustrate the 
different focus areas of both universities, with each having their respective and separate strength areas 
that contribute to Iowa’s quite broad expertise in human, animal and plant bioscience.  
 
Table 14: Bioscience Publication Strengths of the University of Iowa. 
Note: Field names in orange are fields that are part of a combined statewide strength. 
 
Table 15: Bioscience Publication Strengths of Iowa State University. 
Note: Field names in orange are fields that are part of a combined statewide strength 
 
Field  Citations  Publications 
Citation 
Quotient
Publication 
Quotient
Relative 
Impact to US
Anesthesia & Intensive Care 638 118 1.44 1.10 1.44
Clinical Immunology & Infectious Diseases 3,383 297 3.68 2.36 1.72
Clinical Psychology & Psychiatry 1,266 162 2.01 1.85 1.20
Dentistry/Oral Surgery & Medicine 718 262 3.93 3.97 1.09
Environment/Ecology 735 153 0.52 0.44 1.31
Immunology 5,733 342 1.41 1.15 1.36
Microbiology 5,776 545 2.09 1.96 1.18
Oncogenesis & Cancer Research 2,526 190 0.93 0.79 1.30
Oncology 2,120 170 1.11 0.97 1.27
Ophthalmology 720 175 2.57 2.36 1.20
Otolaryngology 571 187 3.42 2.94 1.29
Research/Lab Med. & Med. Tech. 1,604 163 1.31 1.15 1.26
Top Fields in Publications for University of Iowa, FY 1997-2001
(Citation or Publication Quotient Greater than 2.0 or Relative Impact Greater than 1.25)
Field  Citations  Publications 
Citation 
Quotient
Publication 
Quotient
Relative 
Impact to US
Agricultural Chemistry 362 128 11.53 6.62 0.88
Agriculture/Agronomy 899 379 34.85 11.94 1.48
Animal & Plant Sciences 848 143 6.14 4.11 0.76
Animal Sciences 550 262 6.47 3.97 0.83
Biology 648 124 4.04 2.47 0.83
Biotechnology & Applied Microbiology 255 56 4.29 2.92 0.75
Entomology/Pest Control 349 131 9.39 3.67 1.30
Environment/Ecology 910 336 3.33 2.29 0.74
Food Science/Nutrition 546 187 8.58 4.89 0.89
Plant Sciences 1,519 366 7.13 4.24 0.85
Veterinary Medicine/Animal Health 629 289 10.57 5.74 0.93
Top Fields in Publications for Iowa State University, FY 1997-2001
(Citation or Publication Quotient Greater than 2.0 or Relative Impact Greater than 1.25)
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One research area of particular note is the Environment/Ecology field (highlighted in gray in both 
Table 14 and Table 15). Interestingly, this field is considered a strength for each of the two universities 
separately—The University of Iowa for relative impact (1.31) and Iowa State University for citation 
quotient and publication quotient (3.33 and 2.29 respectively), yet it fails to meet the publications and 
citations strength criteria for the state as a whole. 
Battelle’s ISI citations analysis highlights several factors relating to the biosciences in Iowa: 
• There is significant institutional depth in a broad range of bioscience, biomedical and related 
disciplines. Both Iowa State University and The University of Iowa contribute to this depth. 
• Iowa has strengths in the three primary components of bioscience—human medicine, veterinary 
medicine and animal health, and plant sciences/agricultural science. 
• The University of Iowa is particularly strong and productive in Clinical Immunology and Infectious 
Diseases, Immunology, Otolaryngology, Ophthalmology, Anesthesia and Intensive Care, and Clinical 
Psychology and Psychiatry. 
• Iowa State University has demonstrated impact in Agriculture/Agronomy and Entomology and Pest 
Control. The University also has a strong concentration in Agricultural Chemistry, Animal and Plant 
Sciences, Veterinary Medicine and Animal Health, Food Sciences, and Nutrition. 
RESEARCH CORE COMPETENCY AREAS SUGGESTED BY STARLIGHT™ CLUSTER 
ANALYSIS 
Battelle, through its research at the Pacific Northwest National Laboratory (PNNL), has developed 
proprietary pattern recognition and clustering software that provides unique insight into research strength 
areas. The clustering tool, known as Starlight™, uses pattern recognition algorithms to cluster research 
fields into grouped strength areas. Starlight™ is valuable because it allows free association of words and 
phrases, rather than forcing clustering on preselected key words—thus, there is no a priori bias to the 
clusters identified.  
Battelle has performed the Iowa Starlight™ analysis on both patent and research abstract data. This 
provides perspective on key Iowa strength areas from a corporate and academic patent perspective, in 
addition to investigating research grant themes. The performance of the clustering analysis involves the 
following steps depicted in Figure14: 
Step 1—Content Development: Developing a data set with sufficient descriptive content, such as patent 
abstracts or grant abstracts. Starlight™ cannot work with only titles or single sentence descriptions. 
Step 2—Pattern Recognition: The analysis generates clusters where patents or grant activity have 
apparent relationships and produces a series of words to describe and link these cluster areas. 
Step 3—Interpretation and Grouping by Expert 
Review: the identification of key themes and 
groupings that result for Starlight™ require an 
experienced research analyst to interpret and explain 
the types of technologies and specific activities that 
are represented in the cluster items. 
Step 1:
Content 
Development
Step 2:
Pattern 
Recognition 
Results
Step 3: 
Interpretation 
by Expert 
Review
Method for Using Starlight Cluster Analysis
Figure 14. 
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The Iowa grants analysis dataset contained detailed abstract information for 1,880 grants, including grant 
data from the following agencies for FY 1997 through to Nov. 2003: 
• NIH—1,416 grants 
• USDA—319 grants  
• NSF—145 grants (only bio/agriculture-oriented grants) 
The majority of the grants were issued to the state universities: 
• The University of Iowa—1,302 (69 percent) 
• Iowa State University—432 (23 percent) 
• All other entities—146 (8 percent) 
Starlight™ output is provided to the analyst in both graphical and spreadsheet table formats. This allows 
for visualization of key cluster areas and deeper investigation of the actual grants or patent information 
contained within each apparent cluster. Figures 15 and 16 illustrate the resulting graphic for grants 
activity, with grants included from NIH, NSF and USDA federal funding sources. 
 
Figure 15: Starlight™ Research Clusters—Grant Data by Agency. 
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Figure 16: Starlight™ Research Clusters—Grant Data by Universities. 
 
The grants cluster analysis indicates that R&D strengths are present most notably within the two largest 
state universities, Iowa State University and The University of Iowa. Key federal grant funded research 
cluster areas are identified in Table 16. 
 
Table 16: Details of Starlight™ Meta Clusters of Federal Research Grant Strengths. 
IOWA Grants Data Colored 
by Key Universities
IOWA State
Univ of IOWA
All Other
Genetics
Disease/Infection Studies
Vascular
Analytics
Soil/Crop/Water 
Analysis
Neural Studies
Miscellaneous
Cell/Molecular 
Studies
Meta Cluster Title
 # of Ind. 
Cluster 
 # of 
Grants # of Grants by Institution # of Grants by Agency
Cell/Molecular Studies 7 510 UI = 370, ISU = 112, 
ARS/NADC = 6, Other = 22
NIH = 404, NSF = 64,
USDA = 42
Crop/Soil Analysis 1 49 ISU = 36, ARS/NADC = 7,
UI = 1, Other = 5
USDA = 47, NIH = 1,
NSF = 1
Disease/Infection Studies 2 96 ISU = 48, UI = 32,
ARS/NADC = 14, 
Other = 2
USDA = 50, NIH = 45,
NSF = 1
Genetics 4 259 UI = 177, ISU = 72,
ARS/USDA = 2, Other = 8
NIH = 174, NSF = 46,
USDA = 39
Neural Studies 1 51 UI = 50, ISU = 1 NIH = 50, USDA = 1
Vascular Analytics 4 225 UI = 186, ISU = 18,
ARS/NADC = 9, MUM = 7,
Drake U = 2, Other = 3
NIH = 200, USDA = 23,
NSF = 2
Miscellaneous Non-Descript Cluster 1 473 UI = 288, ISU = 136,
ARS/NADC = 13, MUM = 2,
Drake U = 2, Other = 32
NIH = 326, USDA= 117,
NSF = 30
Grant Clusters
 Iowa Bioscience Path for Development 
 
 
44 
Battelle also investigated patent data for the State of Iowa to examine the key areas of R&D that are 
resulting in potentially commercializable intellectual property. Patents were collected by Inventor State of 
Iowa with a total of 5,129 patents clustered in the Starlight™ analysis (Figure 17). 
 
Figure 17: Starlight™ Clusters—Patent Data by Universities and Other Patent Holders. 
 
Patent data show that the seed/agriculture and engineering sectors have been most productive in the 
generation of patents in Iowa. It is also evident that the great majority of patents generated in the state are 
coming from non-academic IP generation sources—companies such as Pioneer in seed development and 
John Deere in agricultural equipment and associated engineering disciplines. Iowa State University is 
noticeably active in the materials science and plant breeding/genetics areas, while The University of Iowa 
is evident in the biotechnology cluster around the descriptors “cell, nucleotide and nucleus.”  
The Starlight™ analysis is notable in that it shows a disconnect between some of the primary research 
grant focus areas and those areas generating patents. Within the biosciences in Iowa, only a comparatively 
small number of patent clusters emerge from the analysis; namely, corn and soybean plant breeding, 
genetics, and cell, nucleotide and protein biotechnology. Areas of distinct focus in the research arena, 
such as animal sciences, diseases and infection studies, neural studies and vascular analytics, for example, 
have not yet resulted in substantial intellectual property generation in Iowa. It should be noted, however, 
that on a national basis the private sector holds 97 percent of all patents (a logical situation given the 
importance of progress and innovation to the private sector). Iowa State University, in particular, demon-
strates strong performance in intellectual property generation, with a recent ranking in Nature of 4th 
nationally in biotech related IP. 
Soybean Breeding
and Genetics
Corn Breeding
and Genetics
IOWA State
Univ of IOWA
All Other
Biotechnology
Electronics
Hydraulics and
Pneumatics
Materials
Science
Ag Equipment
Engineering
Utility Patents Collected 
by Inventor State
Jan. 1997 – Nov. 2003
Source:  USPTO
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CORE COMPETENCY RESEARCH AREAS SUGGESTED BY REPUTATION 
Examining publications or research grants (either through funding levels or context, as in the case of 
Starlight™ analyses) provides a perspective for establishing a state’s or university’s core competencies. 
However, given that some unique strengths also may exist without a strong direct tie to research 
publications or funding mechanisms it is important to look beyond these types of analyses to determine 
such strengths. One method is to use third-party-based reputation analyses, such as the U.S. News & 
World Report’s Graduate School Rankings and Best Hospitals Rankings.20 These rankings, while 
typically geared more toward the general public, often help establish areas of strength in the less research 
intensive areas. 
Table 17 details the rankings of Iowa institutions that appeared in published reputation rankings (most 
recent, typically 2002). The agricultural strength of Iowa State University is shown through a rank of 10th 
in agricultural engineering and 17th in veterinary medicine. Many of the University of Iowa’s medical 
school and health discipline strengths are detailed. Through this analysis some specific non-research 
intensive strengths appear, including physician assistant (2nd), nursing (8th), and primary care (9th). 
Additionally, the University of Iowa’s overall strength in otolaryngology is demonstrated by combined 
strengths in audiology (1st) and speech-language pathology (1st). 
 
Table 17: Iowa Bioscience-Related Academic Reputation. 
 
                                                   
20
 U.S. News &  World Report methodology for identifying “America’s Best Hospitals” was devised in 1993 by the National 
Opinion Research Center at the University of Chicago, which carries it out and refines it each year. The U.S. News Index 
accounts for reputation cited by a random sample of board-certified physicians in each specialty area over the past three years 
as well as data from an annual survey of hospitals by the American Hospital Association, generally covering extensiveness of 
services. 
Field Institution Rank
Peer Assessment Score
(out of 5 - if applicable)
Biological Sciences University of Iowa 45 3.4
Engineering - Agricultural Engineering (2003) Iowa State University 10 N/A
Health Disciplines - Audiology University of Iowa 1 4.5
University of Northern Iowa 58 2.6
Health Disciplines - Clinical Psychology University of Iowa 12 3.9
Health Disciplines - Health Services Admin. University of Iowa 11 3.4
Health Disciplines - Nursing University of Iowa 8 4.2
Health Disciplines - Nursing: Anesthesia University of Iowa 25 3.2
Health Disciplines - Nursing Specialties: Nursing Service Admin. University of Iowa 1 N/A
Health Disciplines - Nursing Specialties: Nurse Practitioner-Pediatric University of Iowa 11 N/A
Health Disciplines - Nursing Specialties: Nurse Practitioner-
Gerontological/Geriatric 
University of Iowa 2 N/A
Health Disciplines - Physical Therapy University of Iowa 3 3.8
Des Moines University (Osteopathic Medical Center) 74 2.5
Health Disciplines - Physician Assistant University of Iowa 2 4.1
Des Moines University (Osteopathic Medical Center) 48 2.7
Health Disciplines - Public Health University of Iowa 18 2.5
Health Disciplines - Rehabilitation Counseling University of Iowa 3 4
Drake University 48 2.6
Health Disciplines - Speech-Language Pathology University of Iowa 1 4.7
University of Northern Iowa 51 3
Health Disciplines - Veterinary Medicine Iowa State University 17 2.8
Medical Schools - Primary Care University of Iowa (Roy J. & Lucille A. Carver) 9 3.5
Family Medicine University of Iowa (Roy J. & Lucille A. Carver) 11 N/A
Internal Medicine University of Iowa (Roy J. & Lucille A. Carver) 18 N/A
Rural Medicine University of Iowa (Roy J. & Lucille A. Carver) 4 N/A
Medical Schools - Research University of Iowa (Roy J. & Lucille A. Carver) 24 3.7
Iowa’s Institutions US News & World Report Graduate Ranking and Peer Assessment Score
Note: Bold represents a major category.  Indented Field is a Sub discipline of a larger category.
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Table 18 details the rankings of Iowa hospital and clinical care institutions. 
 
Table 18: Iowa Bioscience-Related Hospital/Clinical Care Reputation. 
 
Again the strength of the University of Iowa’s research and care in otolaryngology is demonstrated by the 
hospital receiving a rank of 3rd. Other top 10 strengths include eyes/ophthalmology (6th) and 
orthopaedics (8th). 
SUMMARY OF CORE COMPETENCY AREAS SUGGESTED BY QUANTITATIVE 
ANALYSIS 
The quantitative data sources (grants data, ISI citations data and cluster analysis data) provide 
considerable insight into the R&D strengths of Iowa in the biosciences and related fields. Contained 
within these data are broad themes that serve as “direction finders” to the state’s bioscience core 
competencies (both broadly based and human medicine/health specific).  
Among the broadly based R&D core focus areas are 
Plant Breeding and Genetics—Significant programs in soybean and corn/maize breeding and genetics 
in conjunction with other plant genetics and sequencing expertise. 
Biotechnology and Applied Microbiology—Broad areas, with applications in cellular and molecular 
studies associated with plants, animals, and human medicine. 
Immunology and Infectious Disease—Substantial programs in human, animal, and plant based disease 
studies, disease prevention, and treatment. 
There are other areas of expertise in the state suggested by the quantitative data sources. These include 
• Agricultural Equipment Engineering (mostly conducted in commercial R&D settings, with some 
support at state universities) 
• Food Safety and Nutrition 
• Materials Science 
• Agricultural Chemicals 
• Entomology and Pest Control 
• Veterinary Medicine and Animal Health. 
Field Institution Rank
U.S. News 
Index
Reputational 
Score
Ear, Nose, And Throat University of Iowa Hospitals and Clinics 3 70.0 31.3%
Eyes/Opthalmology University of Iowa Hospitals and Clinics 6 - 22.9%
Gynecology University of Iowa Hospitals and Clinics 50 31.4 1.3%
Hormonal Disorders University of Iowa Hospitals and Clinics 29 29.3 1.8%
Neurology And Neurosurgery Mercy Medical Center 48 28.9 0.0%
Orthopedics University of Iowa Hospitals and Clinics 8 39.6 10.3%
Psychiatry University of Iowa Hospitals and Clinics 14 7.2%
Respiratory Disorders University of Iowa Hospitals and Clinics 25 29.9 2.8%
Rheumatology University of Iowa Hospitals and Clinics 48 33.3 1.6%
Urology University of Iowa Hospitals and Clinics 21 32.4 4.4%
Iowa Hospitals US News & World Report Ranking and Reputational Score
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Table 19 details each of the broadly based core focus areas and expertise areas suggested by the 
quantitative data. 
 
Table 19: Broadly Based Core Focus Areas Suggested by Quantitative Data. 
Federal Research Grants 
Starlight Cluster 
Analysis Core Focus 
Areas 
NIH NSF USDA 
Publication 
& Citation 
Strength  
(ISI Data) Grants Patents 
Academic 
Reputation 
(U.S. News & 
World Report 
Rankings) 
Plant Breeding 
and Genetics        
Biotechnology 
and Applied 
Microbiology 
       
Immunology 
and Infectious 
Disease 
       
Agricultural 
Equipment 
Engineering 
       
Food Safety 
and Nutrition        
Materials 
Science        
Agricultural 
Chemicals        
Entomology 
and Pest 
Control 
       
Veterinary 
Medicine and 
Animal Health 
       
 
Among the human medicine/health-specific research and clinical strengths, the core focus areas include 
Cancer, Oncology and Oncogenesis—Led by The University of Iowa’s Holden Comprehensive Cancer 
Center. 
Cardiovascular research and vascular analytics—The University of Iowa’s Cardiovascular Center has 
received more than $325 million in extramural support since its founding in 1971. 
Otolaryngology—A world renowned research program and clinical practice at The University of Iowa 
ranked 3rd in the nation by U.S. News & World Report. 
Ophthalmology—The 6th ranked program in the country by U.S. News & World Report. 
Neurosciences—Expertise maintained at both Iowa State University and The University of Iowa, and 
high quality research and clinical practice at The University of Iowa in neurology and neurosurgery. 
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Public Health and Preventative Medicine—Ranked 18th in the nation at The University of Iowa by 
U.S. News & World Report, and 15th in NIH funding. 
There also are other areas of human health/medical expertise in the state suggested by the quantitative 
data sources. These include 
• Anesthesiology 
• Audiology 
• Nursing 
• Orthopaedics 
• Pediatrics 
• Radiology and radiation diagnostics 
Table 20 details each of the human medicine/health-related core focus areas and expertise areas suggested 
by the quantitative data. 
 
Table 20: Human Medicine/Health Core Focus Areas Suggested by Quantitative Data. 
Federal Research 
Grants 
Starlight 
Cluster 
Analysis Core Focus 
Areas 
NIH NSF USDA 
Publication 
& Citation 
Strength  
(ISI Data) Grants 
Academic 
Reputation 
(U.S. News & 
World 
Report 
Rankings) 
Best 
Hospitals  
(U.S. News & 
World Report 
2003 
Rankings) 
Anesthesiology        
Audiology        
Biostatistics        
Cardiovascular        
Neurosciences, 
Neurology & 
Neurosurgery 
       
Nursing 
       
Oncology 
       
Ophthalmology 
       
Orthopaedics        
Otolaryngology        
Pediatrics        
Public Health & 
Preventative 
Medicine 
       
Radiology & 
Radiation 
Diagnostics 
       
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The core focus areas resulting from the quantitative analysis are used to direct the focus of field-work 
interviews for additional investigation, and identify core competencies and technology platforms. 
The following section details Battelle’s findings from the qualitative interview research conducted with 
Iowa bioscience institutions. Both the quantitative and qualitative findings are evaluated by Battelle 
experts to determine core technology platforms upon which bioscience development may be built. The 
technology platforms are discussed in detail beginning on page 83 of this document. 
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Qualitative Assessment of the Iowa Bioscience Base: 
Interview and Fieldwork Findings 
The analysis of grant, publishing, and patent data sets a context for understanding where Iowa’s core 
competencies in bioscience research are focused. To further investigate these fields and deepen our 
understanding of the core bioscience focus areas in Iowa, extensive interviews were conducted with 
university administrators, faculty, scientists, clinicians, industry executives, and development agencies in 
the state. These interviews are essential in developing an understanding of how the data on publications 
and grant awards translate into on-the-ground focus areas in Iowa. 
In total, face-to-face interviews individually or in small group sessions were conducted with more than 
225 individuals. These included interviews with more than 200 academic scientists and faculty at Iowa 
State University, The University of Iowa, and the University of Northern Iowa, together with over 25 
interviews conducted with commercial bioscience-related companies and associated industry promotion 
and economic development groups. 
The interviews, for the most part, confirmed the areas of specialization in Iowa identified in the 
quantitative analysis. They also, however, highlighted several new and emerging areas of R&D focus and 
some key theme areas that were not readily apparent within the quantitative datasets. One challenge in 
using quantitative data is the rapid rate of change in scientific enterprise. Peer review systems—whether 
used for federal grant awards, citation analysis, or in reputation rankings—tend to lag emerging new 
fields of inquiry, recognizing younger and new scientific talent. One objective of the qualitative inter-
views was to capture emerging areas, faculty, and fields of inquiry at each of the three universities.  
The analysis synthesized the core content of the fieldwork interviews and highlighted key areas of 
strength and focus. Both these qualitative interviews and the quantitative research are of substantial 
importance in determining core competencies—they go hand-in-hand to facilitate identification of 
• Where Iowa is heading in terms of building upon and leveraging its core bioscience strengths, and in 
terms of developing and enhancing new and emerging areas of bioscience focus 
• What the current pipeline of bioscience R&D activity is within academic research institutions in the 
state 
• Which areas of bioscience are generating patents and intellectual property that can lead to commercial 
opportunities for Iowa. 
The field interviews provide information relevant to each of these question categories, but they are most 
important in providing an in-depth understanding of current and emerging R&D strengths and 
opportunities. 
Based on the interviews, findings are organized into three key levels: 
Established Strengths in which Iowa has considerable strength through at least two of the following: 
• A significant number of well-funded researchers, scientists and/or clinician scientists working in 
basic, applied, or clinical research. 
• Recognized clinical expertise. 
• Applied science R&D assisting critically important current and/or emerging commercial sectors. 
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• A number of commercial enterprises with R&D or production facilities working on the delivery of 
products or services. 
Strong and Growing focus areas in which Iowa has demonstrated strengths that are more focused on one 
dimension or which have lower levels of research activity, clinical expertise, or commercial enterprises, 
or have a more niche focus of activity. In many instances, these include focus areas that are required to 
support other areas of strength, or to form platforms for economic development from the biosciences. As 
such, these are highly important strengths to continue building. 
Emerging and Notable are smaller or embryonic programs that show significant potential for bioscience 
development in the State of Iowa. 
Based on these general parameters, the team identified the focus areas summarized in Figure 18. 
 
Figure 18: Focus Areas Based on Qualitative Assessment. 
Bioinformatics and genomics are strongly positioned in Iowa at both the University of Iowa and Iowa 
State. However, genomics and post-genomic sciences are the basic pillar upon which much bioscience 
progress will be made. Other states are investing heavily in initiatives to enhance their genomics, 
proteomics, metabolomics, and bioinformatics infrastructure and bolster their position in these critically 
important fields. While this field is a key strength in the state and was classified as “strong and growing” 
in Iowa, it is an area of great competition and growth and momentum must be maintained. 
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In the modern biosciences, seldom does an area of focus stand on its own. Rather, biosciences should be 
viewed as a system of interrelated disciplines and areas of study that support and assist in the advance-
ment of one another. For this reason, the NIH and similar organizations are focusing increasing grant-
making attention on multidisciplinary institutes, centers, and research teams. Figure 19 illustrates some of 
the interrelationships and supporting links that exist between established, building, and emerging strength 
areas in Iowa bioscience. These and other links are explored in detail in the analyses that follow regarding 
technology platforms and opportunities. 
 
Figure 19: Interrelationships Among Iowa’s Interview-Identified Bioscience Strength Areas. 
The links between strength areas are critical to the emergence of bioscience core competencies in Iowa. 
As in any system, a change in one of the parameters (strength areas) is likely to affect the operation of 
others. For example, an enhanced center for the support of drug development with associated pilot 
facilities likely would increase the attention of various medical and veterinary disciplines on drug 
discovery activities. Equally, such an enhancement could spur biosystems engineering work on bio-
processing activities for drugs or lead to an increased nanotechnology focus on drug delivery. Each of 
these strength areas is discussed below, and the reader should bear in mind the linkages and 
interrelationships that may exist. 
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ESTABLISHED STRENGTH AREAS 
Each of these qualitatively identified areas of strength and competency are examined in further detail in 
Tables 21 through 50. In each table, Battelle provides: 
• A definition of the field or specialty area 
• Details regarding the strengths in Iowa identified by interviewees 
• Supporting quantitative statistics (where available) 
• The name of the primary engaged institutions in Iowa. 
 
Table 21:  Iowa Established Strength Areas: Plant Breeding and Genetics 
Plant Breeding and Genetics 
Field Definition Acquiring fundamental knowledge in plant sciences and using it to develop enhanced crop cultivars and new 
economic uses for Iowa crops. 
Interview Identified 
Strengths 
• Iowa State University has a substantial history and track record in the development of new plant 
cultivars in key cash crops such as corn and soybean. 
• The ISU Plant Sciences Institute is operating to “generate knowledge and develop practices for the 
creation of valuable traits in crops important to Iowa using the power of genomics and bioinformatics.” 
Multiple centers operate under the umbrella of the Institute, including: 
o Center for Designer Crops (molecular research) 
o Center for Plant Genomics (understanding plant genes and whole plant genome discovery) 
o Center for Plant Transformation and Gene Expression (transgenics) 
o Baker Center for Plant Breeding (enhancing cultivars via breeding methods and 
germplasm enhancements) 
o Center for Crops Utilization Research (new uses for Midwestern crops) 
o Center for Designing Foods to Improve Human Nutrition (functional foods, nutraceuticals, 
etc.) 
o Center for Plant Responses to Environmental Stresses (stress research and tolerance 
enhancement) 
o Baker Center for Bioinformatics and Biological Statistics (genomic data analysis and 
support) 
o Seed Science Center. 
• ISU is focusing its substantial resources in plant biosciences to push forward multiple R&D platforms 
for the state, including: 
o Enhancing the nutritional (and economic) value of plants in animal and human diets 
o Creating a plant biofactories/biopharmaceutical production industry for Iowa 
o Unlocking the potential of plant genomics and transgenics 
o Generating applications for crops in biorenewable resource projects 
o Protecting crops from natural and man-made threats. 
• The Plant Sciences Institute comprises over 220 faculty affiliates across 32 departments in 7 ISU 
colleges. 
• 45,000 sq.ft. Carver Co-Lab opened to facilitate interaction between University and industry scientists 
in plant sciences. 
Supporting 
Statistics 
• Almost $24 million in external research funding generated in 2001 by affiliated faculty –$17.2 million 
from federal agencies. 
• Over 400 graduate students working on plant sciences at Iowa State University. 
• Genetics cluster at Iowa State University confirmed by Starlight™ analysis. 
• ISU 177 federal grants in genetics. 
Key Institutions • Iowa State University 
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Table 22: Iowa Established Strength Areas:  Cancer (Oncology) 
Cancer (Oncology) 
Field Definition The study or science dealing with the physical, chemical, and biologic properties and features of tumors 
including causation, pathogenesis, and treatment. 
Interview Identified 
Strengths 
• Holden Cancer Center at The University of Iowa is an NCI-designated Comprehensive Cancer 
Center. 
• Key expertise in Lymphoma (SPORE21), Head and Neck Cancer, and Urologic Cancers (prostate and 
bladder). Additional focus areas in GI malignancies, orthopedic tumors, and breast cancer. 
• Research areas designated as a focus by the Cancer Center include: 
o Cancer Epidemiology (running the Iowa Cancer Registry, a SEER22 program) 
o Cancer Immunology and Immunotherapy  
o Cell Signaling and Developmental Pharmacology  
o Free Radical/Oxidative cancer events (pioneers in this field) 
o Cancer Genomics 
o Molecular and Tumor Virology  
o Molecular Mechanisms of Metastasis  
o Prostate Cancer Research  
o Tumor Imaging  
• Strong core resources in: 
o Biostatistics  
o Central Microscopy 
o Clinical Trials Support  
o DNA Core  
o Free Radical Research  
o Flow Cytometry  
o Gene Transfer Vectors  
o Large Scale Digital Cell Analysis  
o Small Animal Imaging  
o Tissue Culture Hybridoma  
o Tissue Procurement  
o Health informatics. 
• Work in a number of translational areas, including for example: small molecule and potential drug 
candidate research and development, cancer imaging, and gene therapy. 
• Clinical trials infrastructure in place. 
• Good and expanding resources in radiation oncology. 
Supporting 
Statistics 
• 153 cancer researchers and clinicians in 37 departments and six colleges at The University of Iowa 
• 170 published papers between 1997-2001 in Oncology with a relative impact of 1.27, and 190 papers 
in Oncogenesis and Cancer Research with relative impact of 1.3. 
• 56 NIH-NCI grant awards in 2003. 
• Cluster confirmed by Battelle Starlight™ analysis. 
Key Institutions • The University of Iowa 
                                                   
21
 SPORE = Specialized Programs of Research Excellence (a NIH designation). 
22
 SEER = Surveillance, Epidemiology, and End Results (a program of the National Cancer Institute). 
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Table 23: Iowa Established Strength Areas: Cardiovascular 
Cardiovascular 
Field Definition The branch of medicine dealing with the heart and blood vessels. Also includes the cardio-pulmonary field 
examining the heart and lungs as a system. 
Interview Identified 
Strengths 
• The Cardiovascular Center at The University of Iowa has a significant track record in science dating 
back to the early 1970s and has performed pioneering work on arteriosclerosis, lipids and cholesterol. 
The Center has brought in $350 million in grant funding to Iowa since its formation in 1974. 
• Current research expertise in: 
o Resuscitation including wave forms and reduction of free radical injury 
o Vascular structure and function, including work on free radicals involved in signaling and 
injury, inflammation, and the innate immune system of the vascular wall 
o Thrombotic mechanisms contributing to cardiovascular disease and stroke 
o Inherited diseases of the heart muscle 
o Neural pathway effects on hypertension 
o Neurobiology of cardiovascular regulation 
o Basic causes of hypertension 
o Cardioelectrophysiology including studies of atrial defibrillation and arrhythmia 
management 
o Pediatric cardiovascular diseases (genetic links) 
o Fatty acids, lipoproteins and hypertension. 
• Recognized for research in neuro control, lipids, imaging, free radicals, vector physiology, and ion 
channels. 
• Opportunity to move research program into a more applied and translational focus (drug discovery, 
targeted drugs, gene tests, etc.), but need resources and an organized center to do this. 
Supporting 
Statistics 
• The University of Iowa’s cardiology and cardiovascular research includes 180 scientists, from various 
departments and colleges across campus. The Cardiovascular Division of the Department of Internal 
Medicine has over 30 faculty, with more than half heavily engaged in research. 
• Major program project grants/SCOR’s23 from NIH 
• Four interdisciplinary training programs supporting 15 predoctoral and multiple postdoctoral trainees. 
• 635 papers published in Cardiovascular and Hematology research and Cardiovascular and 
Respiratory research between 1997 and2001. Relative impact of 1.19 in Cardiovascular and 
Respiratory. 
• Cluster confirmed by Battelle Starlight™ analysis. 
Key Institutions • The University of Iowa 
                                                   
23
 SCOR = Specialized Center of Research (a NIH designation). 
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Table 24: Iowa Established Strength Areas: Animal Breeding and Genetics 
Animal Breeding and Genetics 
Field Definition The development of animals with optimized characteristics for use by humans. Includes the genetic improvement 
of livestock and other animal species  
Interview Identified 
Strengths 
• In terms of livestock and comparative genomics ISU considered to be in the top 3 in the world. 
• In terms of livestock animal breeding, ISU is generally regarded as one of the top (if not the top) 
institutions in the world. 
• ISU has the top animal genetics and genomics group in the U.S. and is considered a world leader in 
porcine, bovine and avian genomics. ISU has internationally recognized strengths in microbial 
genomics and infectious disease. 
• Very strong in animal science and meat science. 
• New Center for Integrated Animal Genomics goes considerably beyond livestock and is broad in 
terms of bioinformatics capabilities and work on companion animals. Used the term “integrated” to 
denote work on livestock, companion animals and across into microbial. 
• Deep expertise in pigs (because of importance to Iowa agricultural sector). This shows great promise 
for human linkages, since the pig is a very useful human model. 
• 50 faculty within the Center for Integrated Animal Genomics. 
• The Center provides a forum to bring together people from across the ISU campus to advance animal 
genomics, microbial genomics, comparative genomics and bioinformatics—ultimately with the goal to 
enhance the health of animals and people. 
• Within animal genomics ISU has considerable depth in quantitative genomics, and good strengths 
also in molecular. 
• Directly working as major contributors on the chicken and pig genome projects. 
• Deep resources and facilities for basic science and applied research. Good support in 
instrumentation, genomics cores, proteomics, confocal and electron microscopy.  
• Specific goals in the Center for Integrated Animal Genomics: 
o Genetic improvement of livestock species  
o Improved food safety and reduction in the use of antibiotics  
o Development of vaccines and anti-microbial agents  
o Development of designer animals for specialized animal products to improve human health  
o Deduction of possible bioterrorism threats through the food chain  
o Economic development of the animal genomics industry in Iowa. 
• The University of Iowa is also active in animal transgenics and operates a state-of-the-art transgenic 
animal (mice) facility. 
Supporting 
Statistics 
• 262 papers published in Animal Sciences between 1997-2001 with citation quotient of 6.5. 
• Genetics cluster at ISU confirmed by Starlight™ analysis. 
Key Institutions • Iowa State University 
• The University of Iowa 
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Table 25: Iowa Established Strength Areas: Crop Protection (Pests, Diseases, and Stress) 
Crop Protection (Pests, Diseases, and Stress) 
Field Definition Approaches to the protection of economic crops from damage and economic losses caused by plant diseases, 
pests, and environmental stresses. 
Interview Identified 
Strengths 
• Strong in field crop entomology, with additional strengths in medical entomology and disease 
prevention. Main entomology focus is on insecticide development, with little work being done in 
molecular engineering. 
• Taking approach of integrated pest management to reduce and optimize the use of pesticides, 
fungicides, and insecticides. 
• The Center for Plant Responses to Environmental Stresses (CPRES) performs fundamental research 
on how plants detect and respond to biotic and abiotic stresses in their environment. Biotic stress 
research studies the molecular mechanisms used by viruses, bacteria, fungi, and nematodes to incite 
disease and by plants to resist infection. Research on abiotic stresses includes molecular 
mechanisms by which plants resist unfavorable conditions such as drought, flooding, chilling, excess 
salts, toxic metals, and pollutants. 
• Plant Health and Protection is offered as an interdepartmental major administered by the departments 
of Plant Pathology, Entomology, Agronomy, Horticulture, and Forestry. The program emphasizes a 
holistic approach to plant health maintenance encompassing soil fertility and plant nutrition, genetics 
and plant breeding, cultural practices, and protection from pests such as insects, weeds, and the 
microorganisms that cause plant diseases. 
• 16 full-time faculty in the Department of Plant Pathology. 
• Research focus areas in corn and soybean diseases, plant viral diseases, fungi, host-parasite 
interactions, quantitative pest management, soybean cyst nematodes, seed infections, and the 
emergence of new plant diseases. 
Supporting 
Statistics 
• ISI citations data for Iowa State University show the following levels of paper publication between 
1997-2001: Agricultural Chemistry (128 papers), Agriculture/Agronomy (379), Entomology and Pest 
Control (131) and Plant Sciences (366). 
• Iowa State University’s focus on crops confirmed by Battelle Starlight™ analysis. 
Key Institutions • Iowa State University 
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Table 26: Iowa Established Strength Areas: Infectious Diseases 
Infectious Diseases 
Field Definition Includes acquired diseases caused by infectious agents such as viruses, bacteria, myco-bacteria and prions. 
Interview Identified 
Strengths 
• Focus of research within the College of Veterinary Medicine at ISU, with research in: 
o Traditional production animal diseases 
o Foreign and exotic animal diseases 
o Preharvest food borne diseases 
o Antimicrobial resistance 
o Zoonotic diseases (West Nile Virus and Nipah) 
o Immunology and inflammatory diseases 
• Strong focus of research at The University of Iowa from both a clinical infectious diseases standpoint 
and via microbiology. 
• Deep and expanding expertise in human respiratory diseases and respiratory pathogens. $3.3 million 
per year NIH contract in the field (funded for seven years at the University of Iowa). Examining 
pathogenic mechanisms in common human respiratory diseases such as pneumonia. Also studying 
how human cells respond to pathogens in the airway. 
• University of Iowa also working on CMV (cytomegalovirus), inflammation and enteric pathogens (such 
as salmonella and shigella). Expertise in viral pathogenesis and viral regulation of genes. 
• University of Iowa virologists and virologists within Iowa State University (primarily the College of Vet 
Medicine) cooperate well—with University of Iowa contributing strengths in mammalian virology. 
• Vaccine and vaccine delivery systems research at The University of Iowa.  
• Strong inflammation program at The University of Iowa housed in 11,000 sq.ft. of new lab space at 
Oakdale campus. Work in microbial pathogenesis, and on the development of immunosuppressive 
and immunopromultory protein endotoxins. 
• University of Iowa expertise is mostly focused on viral and bacterial diseases—far less work on fungal 
and parasitic diseases. 
• Somewhat held back in infectious diseases research at The University of Iowa because of lack of 
BSL3 facilities. 
• The Center for Emerging Infectious Diseases, recently established in The University of Iowa College 
of Public Health, employs laboratory technologies, advanced epidemiological methods and clinical 
evaluations to better understand emerging infectious diseases. Pathogens under study include: 
human adenovirus, human metapneumovirus, influenza A, prions, SARS, West Nile Virus and 
Varizella-zoster virus. 
• At the University of Northern Iowa, researchers are investigating technologies for integrating 
bacteriophagy of anthrax and other pathogens, remote detection, and decontamination and 
therapeutics. 
Supporting 
Statistics 
• 12 faculty in Iowa State University College of Veterinary Medicine whose labs are focused on 
infectious diseases. 
Key Institutions • Iowa State University 
• The University of Iowa 
• University of Northern Iowa 
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Table 27: Iowa Established Strength Areas: Free Radical/Oxygen Biology 
Free Radical/Oxygen Biology 
Field Definition Free radical biology is the study of the interaction of free radicals within biological material. Free radicals are 
atoms or molecules with at least one unpaired electron, and are being found to be agents in a large number of 
diseases and pathological states. 
Interview Identified 
Strengths 
• The University of Iowa has, without a directed effort, become the top place in the world for attracting 
free radical researchers. Currently the University has more than 50 faculty involved in the study of 
free radicals. 
• Has the first ever PhD granting program in free radical biology (10 graduate students enrolled). 
• Other universities such as Alabama, Wisconsin, Oklahoma, and Emory have created and funded 
formal free radical centers. Iowa’s is not so supported and so risks losing its leadership advantage. 
• The University of Iowa has a broad platform in the field, incorporating study of free radicals by multiple 
scientists in: 
o Cancer 
o Cardiac disease and vascular disease 
o Hypertension 
o Diabetes 
o Premature birth 
o Inflammation and infectious diseases 
o Aging 
o Neurodegenerative diseases 
o Bone disease 
o Lou Gehrig’s disease. 
• Because of advanced state of The University of Iowa’s research in the field, they are beginning to 
move into translational work and are submitting a SPORE on head and neck cancer and free radicals. 
• One Iowa project is moving into clinical trials based on Vitamin E anti-oxidant affects after aneurisms. 
• This is a relatively new field of study that uses good basic science to lead to pragmatic clinical results. 
The University of Iowa has a lead that may warrant preserving with funding of a formal center with 
associated facilities and support. 
Supporting 
Statistics 
• 27 current NIH grants in which the study of free-radicals is a major cited component. 
• Concentration confirmed by Battelle Starlight™ analysis. 
Key Institutions • The University of Iowa 
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Table 28: Iowa Established Strength Areas: Orthopaedics 
Orthopaedics 
Field Definition Orthopaedics is the medical specialty devoted to the diagnosis, treatment, rehabilitation, and prevention of 
injuries and diseases of the body’s musculoskeletal system. 
Interview Identified 
Strengths 
• University of Iowa orthopaedics operates the Biomechanics Laboratory where major areas of 
investigation include total joint arthroplasty (hip, ankle, knee), osteonecrosis of the hip, high-energy 
fracture comminution, fracture fixation, cell culture mechanostimulus, joint kinematics, and articular 
contact stresses as they relate to joint degeneration. 
• The Ignacio V. Ponseti Biochemistry and Cell Biology Laboratory at The University of Iowa conducts 
basic and applied biological research investigating the normal structure and function of the 
musculoskeletal system. Other areas of investigation include normal skeletal growth and development, 
tissue regeneration, tissue aging and cell-matrix interactions. Current areas of investigation include the 
molecular biology of intervertebral disc development, aging of articular cartilage, osteoarthritis, 
spondylo-epiphyseal dysplasias, chondrocyte-matrix interactions, response of chondrocytes to cartilage 
matrix proteins and age-related changes in chondrocyte function.  
• Research and development work is taking place in total wrist replacement. 
• The University of Iowa maintains a SCOR in arthritis 
• Biomechanical engineering work for orthopaedic devices and total joint replacements (e.g. total hip). 
• Major clinical practice in orthopaedics and orthopaedic surgery. 
• Multiple industry relationships with Zimmer, Smith and Nephew, DePuy and Genzyme Biosurgery. 
• Working collaboratively with Iowa State University on bi-ped animal model for arthritis (using the Emu). 
• Interdisciplinary center at the University of Northern Iowa (RERC), in combination with a prosthesis 
company, working to develop a new prosthesis and/or orthotic for resting diseased or wounded 
extremities. 
Supporting 
Statistics 
• Department of Orthopaedics and Rehabilitation at The University of Iowa ranked in the top 10 by U.S. 
News. Ranked 8th in orthopaedic surgery. 
• 28 MD’s and 9 PhD research staff 
• 170 papers published between 1997-2001, with citations quotient of 1.3 
• 3rd in the U.S. in NIH funding (behind Case and Yale) 
Key Institutions • The University of Iowa 
• Iowa State University 
• University of Northern Iowa 
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Table 29: Iowa Established Strength Areas: Ophthalmology 
Ophthalmology 
Field Definition Ophthalmology is the medical specialty relating to the treatment of diseases and disorders of the eye 
Interview Identified 
Strengths 
• Major research programs at The University of Iowa in: 
o Eye pathology (F. C. Blodi Eye Pathology Laboratory) 
o Ocular Melanoma 
o Glaucoma, with an emphasis on the potential adverse effects of Beta-Blockers 
o Macular degeneration  
o Molecular ophthalmology 
• In macular degeneration, The University of Iowa operates The Center for Macular Degeneration with 14 
faculty working in the field. It has been one of the leaders in the diagnosis, treatment, and research of 
macular degeneration for over 20 years, and now is studying macular degeneration at the cellular and 
molecular levels. Have identified the locations of genes that cause three different types of hereditary 
macular degeneration and have discovered over 100 specific macular-disease-causing mutations. In 
addition, The University of Iowa has investigated the disease at the cell and tissue level and have 
identified important molecules and biological processes involved in the development of macular 
degeneration. 
• In molecular ophthalmology have made major contributions through discoveries related to 
o Macular Degeneration  
o Retinitis Pigmentosa  
o Glaucoma  
o Hereditary Obesity - Bardet Biedl Syndrome  
o Corneal Dystrophy  
o Vitreoretinopathy  
o Uveitis - ADNIV  
o Optic Neuropathy  
Discoveries facilitated by the Molecular Ophthalmology Laboratory (MOL) 
• Also operate the Carver Laboratory for Molecular Diagnosis which is dedicated to providing non-profit 
genetic testing for rare eye diseases. Most of the diseases studied are so rare that commercial tests 
would be unlikely to be viable. 
Supporting 
Statistics 
• The University of Iowa ranked 6th in the nation in ophthalmology by U.S. News 
• 14 clinicians rated in Best Doctors in America 
• 13 NIH grants through the NIH National Eye Institute. 
• 175 published papers between 1997-2001, with relative impact of 1.2 and citation quotient of 2.6 
Key Institutions • The University of Iowa 
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Table 30: Iowa Established Strength Areas: Otolaryngology 
Otolaryngology 
Field Definition Otolaryngology is the branch of medicine concerned with the diagnosis and treatment of disorders and diseases 
of the ears, nose and throat (ENT). 
Interview Identified 
Strengths 
• The University of Iowa Department of Otolaryngology-Head and Neck Surgery is one of the most 
comprehensive ENT programs in the world. 
• Considerable strengths at The University of Iowa in: 
o Cochlear implants—where Iowa is a leader in clinical research and development 
o Genetics/etiology of hearing loss 
o Head and neck cancer 
o Speech pathology 
o Engineering for ENT needs, including assistive devices 
• Multiple research areas, with resources focused through: 
o Auditory Physiology Research Lab—conducting basic and applied research to better 
understand how the cochlea and auditory nerve function, as well as how cochlear implants 
function 
o Cleft Palate-Craniofacial Research—Iowa has a long history in cleft palate research and 
clinical treatment 
o Head and Neck Oncology Research—works with disorders of the head and neck within the 
anatomic limits determined by the structures between the dura and the pleura. Work 
includes the oral cavity, the larynx and pharynx, the nose and sinuses, the thyroid and 
parathyroid glands, the lymphatics, muscle and bone of the head and neck. 
o Iowa Cochlear Implant Research Center—have implanted over 150 children and over 250 
adults with every type of cochlear implant available in the U.S. and have a substantial 
database following some of these patients for as long as 12 years. 
o Molecular Otolaryngology Research Lab—The lab offers genetic testing at the DNA level 
for several types of inherited hearing impairment. This is one of the few laboratories in the 
nation to make this service available to families. 
• Strong relationships with industry in the development and testing of devices, especially auditory and 
speech devices. 
Supporting 
Statistics 
• The University of Iowa ranked second in ENT by U.S. News. 
• 187 papers between 1997-2001, with a relative impact of 1.29 and citations quotient of 3.4 
• 21 faculty 
• 26 grants from the NIH National Institute for Deafness and Other Communication Disorders (NIDCD) 
Key Institutions • The University of Iowa 
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Table 31: Iowa Established Strength Areas: Pulmonology/Lung Diseases 
Pulmonology/Lung Diseases 
Field Definition Pulmonology is the medical practice pertaining to the lungs and respiratory system. 
Interview Identified 
Strengths 
• The University of Iowa is considered to be the equal of National Jewish in Colorado in terms of status, 
and has three times the amount of epithelial biologists. Main difference is the basic science emphasis 
of Iowa, versus the industry collaborations that National Jewish and UNC Chapel Hill enjoy. 
• The University of Iowa has developed expertise in multiple environmental lung diseases. The 
agricultural working environment creates lots of dusts and allergens that promote respiratory 
disorders, such as asthma. 
• Iowa’s strengths in inflammation research directly link into environmental and other respiratory/lung 
disorders. 
• Performing fundamental immunologic research and vaccine based immunotherapies. 
• Major lung work being performed in: 
o Cancer 
o Asthma 
o Emphysema 
o Cystic Fibrosis 
o Inflammatory Lung Disease 
o Fibrotic Lung Disease 
o Pulmonary Hypertension. 
• Pulmonary division said to be one of the largest and most influential in the country. 
• Strengths in lung infectious diseases, immunology and genetics form a triad that is perhaps hard to 
duplicate elsewhere. 
• Have one of only a handful of clinical exposure facilities in the U.S. for delivering and assessing 
physiologic reactions. 
• Receive many calls from drug companies interested in working with them on drug delivery via the 
lungs. 
• Pulmonary rehabilitation is also a focus area. 
Supporting 
Statistics 
• 29 faculty working within Internal Medicine on pulmonary diseases and disorders. 
• 256 papers published in Cardiovascular and Respiratory Systems with a 1.19 relative impact, plus 
107 papers in Environmental Medicine and Public Health with a 1.17 relative impact. 
• 25 current NIH grants related to the lung and respiratory systems. 
• Cluster confirmed by Battelle Starlight™ analysis. 
Key Institutions • The University of Iowa 
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Table 32: Iowa Established Strength Areas: Digestive Diseases and Disorders (Gastroenterology) 
Digestive Diseases and Disorders (Gastroenterology) 
Field Definition Gastroenterology is the field of medicine concerned with the function and disorders of the digestive system. 
Interview Identified 
Strengths 
• Leading research thrust at The University of Iowa is on the development of immune modulators. 
• Research has led to a breakthrough discovery that is relevant to a wide variety of autoimmune 
disorders, not just GI disorders (e.g. asthma, arthritis, lupus, dermatitis, inflammatory bowel disease, 
Crohn’s disease). This immune research is led by an immunoparasiteologist and has generated a 
patent on the use of all helminths (a worm) and derivatives from them for the treatment of human 
diseases. Likely to result in a new path of immune disorder treatment producing helminth egg 
therapies or drugs based on genetic/biochemical characteristics of the worm. Link between The 
University of Iowa and Iowa State University because host animal for producing the helminths is pigs. 
Double blind studies showing great effectiveness from this parasite introduction and treatment. 
• Also strong in GI device work including tools for advanced endoscopy, drainage stents (wedge stents 
for draining malignant strictures), operating instruments and cauterizing guide wire devices. 
• Expertise in neuro gastroenterology, primarily leading to clinical research developing investigative 
techniques for pain in the gut. Also probes and training devices for people with anal-rectal dysfunction 
and extreme constipation. 
• Program in pediatric gastroenterology. 
• Multiple recent publications in the American Journal of Gastroenterology and other journals. 
• Somewhat held back in total research volume by heavy clinical demands placed on 
gastroenterologists since this discipline tends to be a significant revenue generator for 
hospitals/practice plans. 
Supporting 
Statistics 
• 19 faculty in the division at The University of Iowa. Comparatively large and would place them in the 
Top 20 in terms of rank. (Largest player is Mayo Clinic with 70)  
• 10+ major NIH grant awards 
• 69 papers in Gastroenterology between 1997-2001 
Key Institutions • The University of Iowa 
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Table 33: Iowa Established Strength Areas: Neurosciences 
Neurosciences 
Field Definition The discipline concerned with the development, structure, function, chemistry, pharmacology, clinical assessment, 
and pathology of the nervous system. 
Interview 
Identified 
Strengths 
• A major research focus within the College of Veterinary Medicine at Iowa State University. Focus areas 
include: Parkinson’s disease (especially environmental factors); Alzheimer’s disease; Eye Disorders 
(with an emphasis on the retina); Pain, and Prion Diseases. 
• University of Iowa researchers are leaders in brain imaging and neurosciences, muscular dystrophy, and 
Huntington’s disease. 
• Focus within the Department of Biological Sciences at The University of Iowa with 8 faculty concentrating 
in neurobiology. 
• The neurosciences program at The University of Iowa has strengths in molecular and cellular 
neuroscience, developmental and systems neuroscience and cognitive and behavioral neurosciences. 
• Within Neurology at The University of Iowa, research is being conducted in: 
o Alzheimer’s Disease  
o Autonomic Dysfunction (including Neurobiology of Cardiovascular Regulation)  
o Cognitive Neuroscience of Human Emotion and Behavior  
o Epilepsy  
o Experimental Neuroanatomy  
o Human Factors Studies (including Driving Safety)  
o Movement Disorders (including Parkinson's Disease and Huntington’s Disease)  
o Neurochemistry and Neurobiology  
o Neurodegenerative Diseases  
o Neuroergonomics  
o Neuromuscular Diseases (including Amyotrophic Lateral Sclerosis and Peripheral 
Neuropathy)  
o Sleep disorders  
o Stroke 
o Visual Function  
• Neuro expertise within The University of Iowa extends across into neurosurgery. Iowa neurosurgeons 
have developed state-of-the-art magnetic guided neurosurgery systems. 
Supporting 
Statistics 
• Iowa State University College of Veterinary Medicine has 7 major principal investigators funded in 
neuroscience. Have multiple RO1’s from the NIH. 
• 43 faculty and fellows within University of Iowa department of neurology, 8 in neurosciences within the 
College of Biological Sciences and 7 faculty in the Division of Neurosurgery (within the Department of 
Surgery) 
• The University of Iowa has 56 NIH grants through the NIH National Institute for Neurological Disorders 
and Stroke (NINDS)—53 grants from the National Institute for Mental Health (many with major 
neurological research content). 
• Neural studies confirmed as a distinct cluster in Iowa by Battelle Starlight™ analysis. 
Key Institutions • The University of Iowa 
• Iowa State University 
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STRONG AND GROWING 
Table 34: Iowa Strong and Growing Areas: Bioinformatics and Genomics 
Bioinformatics and Genomics 
Field Definition Bioinformatics involves the application of computer technology to the management of biological information. 
Specifically, it is the science of developing computer databases and algorithms to facilitate and expedite 
biological research, particularly in genomics. Genomics is the study of genes and their function. 
Interview Identified 
Strengths 
Note: Bioinformatics and Genomics are very strong at both Iowa State University and the University of Iowa. 
They are, however, listed in the “strong and growing” category because of their extreme importance to 
bioscience R&D and future clinical practice. Other states are investing heavily in these fields, and because of 
this, continued growth in these fields in Iowa is highly important and forms the basis for advancement of multiple 
recommended bioscience platforms. 
• Iowa State University has multiple centers working in bioinformatics and genomics, especially as they 
relate to plants and animals. These centers include: 
o Center for Plant Genomics 
o Center for Plant Transformation and Gene Expression 
o Baker Center for Bioinformatics and Biological Statistics 
• Iowa State’s bioinformatics and biostatistics program has research initiatives taking place in 
bioinformatics and biostatistics (10 PI’s); systems biology (5 PI’s), functional and structural genomics 
(20 personnel), genome evolution (5-6 personnel), and macromolecular structure and function (15-20 
personnel).  
• The Center for Plant Genomics  provides technical support for research projects that require high-
throughput data collection and analysis (such as large-scale EST sequencing, mRNA and protein 
profiling, and genetic & physical mapping). The Center also partners to develop, adapt and/or 
evaluate novel technologies for genomics and proteomics research through its Microarray and 
Proteomics facilities.  
• The Center for Plant Transformation and Gene Expression is a pragmatic institution working to 
develop efficient methods for producing transgenic plants that will be safe for human health and the 
environment, and to develop gene expression technologies to ensure that transgenes are stably 
expressed in the desired parts of plants and under the correct conditions. 
• The University of Iowa also has considerable strength in bioinformatics and genomics, both from a 
basic science level and into active support of major clinical research programs in cancer, cystic 
fibrosis, macular degeneration, rare inherited disorders, cardiovascular disease and other fields. 
• The University of Iowa cemented its growth in bioinformatics with the formal establishment of the 
Center for Bioinformatics and Computational Biology (CBCB). The CBCB encompasses 26 funded 
PI’s and supports 9 full-time computational scientists. External funding is derived from both public and 
private sources and totaled $17.6 million as of December 2003. The Center has 16 labs from 17 
departments and 5 colleges. 
• The University of Iowa’s  research  initiatives are focused on: 
o Gene therapy 
o Disease gene understanding and therapeutic targeting 
o Genomic and transcriptional resource generation 
o Animal models of disease 
o Bioinformatics - providing the information science techniques necessary to integrate data 
from research in genomics, molecular evolution and macromolecular structure/function 
relationships to provide understanding of biological systems. 
o Functional and Structural Genomics ( also includes collaborations with ISU faculty involved 
in genomics initiatives with plants, animals and microbes).  
o Genome Evolution - with expertise in molecular evolution with emphasis on whole genome 
analyses and on understanding patterns and processes of change that occur among 
genes and genomes over time. (Includes collaboration with ISU faculty). 
o Macromolecular Structure and Function  
o Computational Biology  
o Metabolic and Developmental Networking  
o Mathematical Biology and Biological Statistics  
• Joint bioinformatics workshop held by Iowa State and The University of Iowa to showcase respective 
strengths and encourage collaboration. 
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Bioinformatics and Genomics 
 
• Expertise at both universities in whole genome sequencing, including active participation in the 
human genome project. 
Supporting 
Statistics 
• Cluster concentration in Iowa confirmed by Battelle Starlight™ analysis. 
• ISI citations analysis shows a significant volume of papers from both Iowa State (160 papers in 
Molecular Biology and Genetics and 36 in Cell and Developmental Biology) and The University of 
Iowa (373 papers in Molecular Biology and Genetics and 172 in Cell and Developmental Biology) 
• 70 plus bioinformatics related faculty at Iowa State. 
Key Institutions • Iowa State University 
• The University of Iowa 
 
Table 35: Iowa Strong and Growing Areas: BioEconomy 
BioEconomy 
Field Definition The BioEconomy is an economy where the basic building blocks for industry and the raw materials for energy 
are derived from plant-based (renewable) sources. 
Interview Identified 
Strengths 
• Major push at Iowa State University and a concerted strategic effort to make a significant impact on 
the Iowa economy. One of the formal ISU Presidential Initiatives. 
• Focus on industrial applications of bio-resources (mainly plant materials) including: Chemicals, Fuels, 
Fibers, and Energy. 
• BioEconomy operations are organized around “platforms” that bring people from diverse disciplines to 
focus on pragmatic problems and opportunities. Platforms include: 
o Lignocellulosic feedstock development—using grasses and tree fiber crops to produce 
high quality fibers that can be used in biocomposite materials such as fibermat and 
fiberboard. 
o Syngas fermentation—working with crops and other plant materials to break them down 
into gas and then synthesize from gas phase into liquids. Main thrust on the production of 
polyesters and hydrogen (5+ year horizon) 
o Vegetable lipids—mostly involves chemistry and chemical engineering moving double 
bonds in fatty acids. Results can be as diverse as increased food shelf life through to 
polymerization for making plastics. 
o Expression of recombinant proteins—requires a bioprocessing facility and involves using 
plants (such as corn) to produce recombinant proteins for industrial and pharmaceutical 
applications. 
o Metabolic engineering of new fermentation products—Idea here is to identify biocatalysts 
to improve fermentation technology (trying to improve fermentation yields and broaden the 
organic acid and alcohol products of fermentation). 
o Biofuels—such as the production of ethanol from corn or biodiesel from soybeans. 
• Key resources in Iowa include the BECON facility for biomass energy conversion (with DOE Energy 
of the Future program), Plant Sciences Institute coordinating scientific research, Center for Plant 
Genomics, Center for Crops Utilization Research, Center for Plant Transformation, Ag Biosystems 
Engineering, IPRT Center for Catalysis, Chemical Engineering, Institute for Combinatorial Discovery, 
etc. 
• Companies already formed in Iowa related to BioEconomy, which constitutes a growing cluster. 
• The University of Iowa is also actively involved and operating the Center for Catalysis and 
Bioprocessing—50 faculty associated with this well equipped pilot scale facility. 18 staff, Good 
Laboratory Practice (GLP) structure and 16,000 sq.ft. of space. 
• The ABIL center at the University of Northern Iowa has been performing leading edge work in bio-
based lubricants since its establishment in 1990. The UNI program has recently been awarded 
funding from the USDA to move towards a national center for ag-based product testing and advocacy. 
Spin-off company, Environmental Lubricants Manufacturing, now commercializing products 
successfully. 
• The University of Northern Iowa’s RRTTC Center is assisting those who to desire to use recycled or 
biomass-based materials for manufactured products. 
• Ames DOE Lab focused on materials sciences and may be leveraged into more of a biomaterials 
focus. 
Supporting 
Statistics 
• Cluster specialization confirmed by Battelle Starlight™ analysis on Iowa patents. 
• ISI data confirms some of the important strengths, including Materials Science and Engineering with 
239 papers at Iowa State University, 37 at The University of Iowa and 124 from Ames Lab. Intensity 
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BioEconomy 
also in Organic Chemistry and Polymer Science (229 ISU, 125 U of I and 42 from Ames Lab). 
Key Institutions • Iowa State University & Ames Lab 
• The University of Iowa 
• University of Northern Iowa 
 
Table 36: Iowa Strong and Growing Areas: Statistics and Epidemiology 
Statistics and Epidemiology 
Field Definition Statistics is a branch of applied mathematics concerned with the collection and interpretation of quantitative data 
and the use of probability theory to estimate population parameters. Epidemiology is the scientific study of 
diseases; includes analyzing the occurrence and distribution of diseases and the factors that govern their 
spread. 
Interview Identified 
Strengths 
• National strengths at The University of Iowa in cancer epidemiology and neurological disease 
epidemiology. Cancer work is greatly facilitated by strong cancer registry with good funding and a 
high capture rate. 
• The University of Iowa has NIH funding in the field. 
• Epidemiology centered within the Department of Public Health at The University of Iowa looking at the 
epidemiology of chronic diseases such as:  
o cancer  
o cardiovascular disease  
o mental illness  
o diseases caused by the environment. 
• Epidemiology at The University of Iowa cooperative within the university and also across into close 
working relationship with the College of Veterinary Medicine at Iowa State University. 
• Strengths in zoonotic diseases and their relationship to food animal worker and slaughter/meat 
processing environments. 
• Strong applied work with industry and other researchers in vaccine trials. Working with CDC in 
monitoring adeno viruses in the immunocompromised patient. 
• Good support from mathematics in terms of modeling and complex models for infectious diseases. 
• Iowa State University recognized as having one of the strongest statistics programs in the U.S.. 
• Iowa State operates the Statistical Laboratory—a research and service institute developing and 
applying statistical methodology to support research throughout the University and beyond. 
• Iowa State statistics active with computational biology on the genetics side of statistics, and also with 
epidemiology and public health applications. 
• Strong mathematics base for quantitative support and modeling at The University of Iowa and Iowa 
State University. 
Supporting 
Statistics 
• University of Iowa Math and Stats with 274 papers and 1.14 relative impact, and Iowa State University 
with 217 papers and a 1.42 relative impact. 
Key Institutions • The University of Iowa 
• Iowa State University 
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Table 37: Iowa Strong and Growing Areas: Inflammatory Diseases and Mechanisms of Inflammation 
Inflammatory Diseases and Mechanisms of Inflammation 
Field Definition Inflammation is a fundamental response of virtually all multicellular organisms to infection and injury. Essential 
functions of the inflammatory response include detection and response to invading microbes and to cellular 
damage, control of microbial proliferation and of microbial material, and repair of tissue injury. 
Interview Identified 
Strengths 
• Inflammation is formally established as a research group at The University of Iowa and operates from 
11,000 sq. ft. of new space at the Oakdale campus. The University created the Inflammation Program 
as an interdisciplinary program comprised of independent investigators who share a common interest 
in understanding the cell and molecular biology of inflammation, its causes and consequences. The 
overall goal of this interactive group is to provide insights into cellular and molecular events of host 
defense within the context of inflammation. 
• Three major pushes related to inflammation: 
o Microbial pathogenesis 
o Arteriosclerosis (which has an inflammation component) 
o Malignant disease. 
• Investigators in the Inflammation Program are actively engaged in fundamental research on several 
cellular elements of the innate immune system, as well as soluble factors (e.g. cytokines, products of 
arachidonic and metabolism, and coagulation factors). 
• Designed to complement established programs in Immunology and Bacterial Pathogenesis. 
Supporting 
Statistics 
• ISI data show Immunology (no direct category for inflammation) having published 342 papers 
between 1997-2001 with a relative impact of 1.73. 
• There are 38 current NIH grants to The University of Iowa in which inflammation is a component of 
study. 
Key Institutions • The University of Iowa 
 
Table 38: Iowa Strong and Growing Areas: Food Science and Nutrition 
Food Science and Nutrition 
Field Definition Nutrition involves the study of the food and liquid requirements of humans or animals, consisting of the taking in 
and metabolism of food materials whereby tissue is built up and energy liberated. 
Interview Identified 
Strengths 
• Signature focus of Department of Food Science and Nutrition at ISU is in soy—working from breeding 
through to functional properties. 
• Working to understand the basic mechanisms by which soy imparts health benefits (such as lowered 
cholesterol, improved bone density, cancer prevention). 
• Iowa State University is operating a Botanical Center that is NIH funded for investigating 
medicinal/nutraceutical effects of herbs. Current focus on Echinacea and St. John’s Wort—working to 
identify bioactive components and novel compounds. $7 million in NIH funding for this research, with 
The University of Iowa also collaborating on the project (total of 20 labs engaged, 18 at ISU and 2 at 
The University of Iowa). Expect to bring soy in as an additional study plant. This is one of six NIH-
funded botanical supplement centers in the U.S. and the only one associated with a Food Science 
and Nutrition department. 
• Anticipate work with herbs will lead them on a path to anti-viral and immunity enhancement as a 
broad focus or theme. 
• Department at Iowa State University is also focused on functional food components, flavinoids, and 
folate nutrients. 
• Iowa State operating the Center for Designing Foods to Improve Nutrition, with a focus on improving 
the quality of food and developing food products that may help offset the obesity epidemic. 
Supporting 
Statistics 
• Iowa State University published 187 papers in food science and nutrition between 1997-2001with a 
citation quotient of 8.6.  
• The University of Iowa published 21 papers in the field. 
Key Institutions • Iowa State University 
• The University of Iowa 
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Table 39: Iowa Strong and Growing Areas: Biotechnology and Bioprocessing 
Biotechnology and Bioprocessing 
Field Definition Biotechnology involves the scientific manipulation of living organisms, especially at the molecular genetic level, 
to produce useful products. Gene splicing and use of recombinant DNA (rDNA) are major techniques used. More 
broadly it includes a set of biological techniques developed through basic research and now applied to research 
and product development. In particular, biotechnology refers to the use by industry of recombinant DNA, cell 
fusion, and new bioprocessing techniques. 
Interview Identified 
Strengths 
• Biotechnology and bioprocessing are a focus at both The University of Iowa and Iowa State 
University. 
• Iowa State operates a formal Office of Biotechnology to facilitate research and development in the 
field.  
• Iowa State is focusing biotech work in three broad areas: 
o Increasing the value of current agricultural raw materials through bioprocessing techniques 
o Increasing the efficiency, profitability, and sustainability of plant and animal production 
o Genetic modification of plants, animals, and microbes to produce more diverse products of 
greater economic value. 
• Iowa State University involved in statewide education initiatives to support biotechnology and raise 
public understanding. 
• Strong facilities in support of biotechnology research at Iowa State, including: 
o Animal Gene Transfer Facility 
o Microscopy facilities , including electron microscopy 
o Analytical services—providing resources for atomic absorption spectro-photometry, 
automated analysis, gas chromatography, carbon analysis. 
o Cell facility with flow cytometry and cell sorting. 
o Chemical Instrumentation facility with Magnetic resonance, mass spectrometry, x-ray 
diffraction, spectrophotometry and elemental analysis. 
o Confocal microscopy facility 
o DNA sequencing and synthesis facility 
o Fermentation facility 
o Hybridoma facility 
o Image analysis facility 
o Microanalytical instrumentation 
o Microarray facility 
o NMR Facility, with a 500MHz NMR spectrometer 
o Plant transformation facility 
o Protein facility conducting amino acid analysis, peptide synthesis, protein/peptide 
sequencing, HPLC, mass spectrometry, electroblotting and proteomics 
o Proteomics facility 
o Soybean molecular marker facility. 
• Bioprocessing and its relation to biotechnology is also a major focus of the Center for Biocatalysis and 
Bioprocessing—this center has a 20 year operating history and is one of very few places in academia 
equipped with large-scale biotechnology piloting facilities, GLP lab operations, and BL2 facilities for 
large scale work. 
• The University of Iowa Center for Biocatalysis and Bioprocessing is primarily focused on: biocatalyst 
fundamental properties, bioremediation, bioprocessing, new biocatalyst discovery, novel biocatalyst 
applications, biosensing technology, and reactive agent development. 
• Iowa State University in the late planning stages for a bioprocessing facility at their research park. 
Supporting 
Statistics 
• ISU has over 283 “biotechnologists” from 26 departments in five colleges. University of Iowa Center 
for Biocatalysis and Bioprocessing has 59 faculty members and 300 researchers. 
• The University of Iowa published 48 papers between 1997-2001 in Biotechnology and Applied 
Microbiology with a relative impact of 2.13, while Iowa State published 56 papers with a 1.34 relative 
impact. 
Key Institutions • Iowa State University 
• The University of Iowa 
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Table 40: Iowa Strong and Growing Areas: Biosystems Engineering 
Biosystems Engineering 
Field Definition Biosystems Engineering includes the study and development of engineering solutions to agricultural, 
environmental, and related problems and needs. It is closely related to the traditional discipline of Agricultural 
Engineering. 
Interview Identified 
Strengths 
• Biosystems Engineering thrust is in multiple areas at Iowa State University: 
o Environmental and natural resource engineering, examining complete hydrology and soil 
water landscape system and biosystems approaches to decontamination and 
sustainability. Use lakes, wetlands, etc. as bioreactors to naturally use biomicrobes to 
clean up chemicals. 
o Antibiotics and pharmaceuticals—working on biosystems engineering approaches to 
removal of growth hormones, antibiotics, etc. that enter the ecology. Most of the grants 
from USDA. 
o Homeland security, monitoring and environmental genomics. 
o Advanced machine systems—tractors, combines, chemical applications, tankers, clean up 
of manure handling systems, etc. Work for meat packing industry in automation. Also work 
to look at systems for farm safety (how should they be secured and monitored). John 
Deere concerned that machines are properly cleanable and contamination removable. 
Need to build in biosafety to machines. 
o Livestock industry—big facility design issues, efficiency, animal welfare, smell control etc. 
Observation of animal stress factors—heat, humidity, air circulation—plus the effects on 
the health of the livestock industry’s workforce. 
o Food safety and food engineering—getting more and more into bioengineering. Storage of 
grains (air circulation), transportation, grain handling and grain quality assurance. Working 
with sensors to test fat, carbohydrate, protein content etc. in a rapid way (ISU developed 
the first of these instruments). Plus new issues of bioterrorism and contamination of the 
food chain. 
• At The University of Iowa related engineering work is taking place within the well established Optical 
Science and Technology Center. Expertise is particularly strong in infrared monitoring devices and 
oxygen sensor devices. 
Supporting 
Statistics 
• 26 faculty: 8 in environmental biosystems, 4 in machine systems, 7 on animal environmental 
engineering, 5 in food and process engineering, and 1 attached to the BioEconomy Initiative. 
• $4.8 million in annual research expenditures. 
• State commercial focus in agricultural machinery and processing equipment confirmed by Battelle 
Starlight™ analysis of patents. 
Key Institutions • Iowa State University 
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Table 41: Iowa Strong and Growing Areas: Health Informatics/Nursing 
Health Informatics/Nursing 
Field Definition Health informatics is an evolving scientific discipline that deals with the collection, storage, retrieval, 
communication and optimal use of health related data, information and knowledge. The discipline uses the 
methods and technologies of the information sciences for the purposes of problem solving and decision-making. 
Interview Identified 
Strengths 
• The College of Nursing at The University of Iowa is using health informatics as a core tool in several 
projects. Studies have examined outcomes and quality of care and developed normative rating scales 
for care. Considerable focus on care of the elderly—a direct issue for Iowa which has an older 
population than most states. 
• Health informatics in the College of Nursing draws on database management skills, research design, 
statistical analysis, and knowledge of the patient population. 
• The College of Nursing operates a research dissemination core that is in its 11th year of funding and 
provides knowledge to practitioners on the care of older adults to help improve care delivery (30,000 
protocols disseminated by this program). 
• The University of Iowa has the only P30 from the NIH in gerontology nursing. 
• Operates a genetics track in master’s and doctoral programs, including genotyping and phenotyping 
work. 
• Operates an interdisciplinary program in health informatics. Has built capacity in knowledge 
representation (building text representations of patient interaction, clinical effectiveness coding 
systems). Is developing protocols and scoring systems for nursing quality management that are being 
developed into software by an outside vendor (with University of Iowa retaining the property rights). 
• Believes it has the opportunity to have more than 60+ organizations feeding data into it for processing 
and analysis—it could serve as a central clearinghouse and electronic processing center for clinical 
outcomes data. This could form the core of a data warehouse system it could sell, plus be a tool to 
link medical and nursing research. It believes it is the only place in the country with a nursing (as 
opposed to medical) outcomes focus. 
Supporting 
Statistics 
• Currently ranks 10th in NIH funding with $5 million annually. 
• Also has highest volume of T32 nursing training grants in the country (focused on gerontology, 
genetics, outcomes measurement and effectiveness). 
• 16 current NIH grants from National Institute for Nursing Research. 
• ISI data show University of Iowa with 64 papers in Healthcare Science and Services between 1997-
2001. 
Key Institutions • The University of Iowa 
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Table 42: Iowa Strong and Growing Areas: Gene Therapy 
Gene Therapy 
Field Definition Gene Therapy is a group of approaches to preventing and/or treating disease by replacing, removing or 
introducing genes or otherwise manipulating genetic material. Genes may be introduced by direct injection or 
using a viral vector to deliver genes into cells. 
Interview Identified 
Strengths 
• The Iowa Center for Gene Therapy, established in the fall of 1998 through joint funding by 
NIH/NIDDK and the Cystic Fibrosis (CF) Foundation, is one of three such centers in the United 
States. The purpose was to create an organized center at the University of Iowa for promoting 
research and training on gene therapy approaches for treating CF and other serious inherited 
diseases. 
• The Gene Therapy Center supports four research core facilities: the Vector Core, the Animal Models 
Core, the Cell Morphology Core, and the Cells and Tissue Core.  
• Due to an increasing need for CF lung tissue in basic research, the University of Iowa formed a 
Midwest Regional CF Lung Tissue Acquisition Program as part of this Center for Gene Therapy of CF 
and Other Genetic Diseases at the university. The goal of this consortium is to create a frozen 
repository of viable primary cells and lung tissue specimens for basic research. 
• The University of Iowa has a long-standing history as a leader in the field of CF research and applied 
gene therapies for this disorder. The University of Iowa has several funded CF research programs, 
including a Research Development Program (RDP) funded by the CF Foundation, a CF Scientific 
Center of Research (SCOR) funded by NHLBI, and a Gene Therapy for CF program project grant 
(PPG) funded by the NIH. 
• Developing some good strengths in animal modeling (including the cloning CF ferrets). 
• CF total of 10 main lead researchers. Broad funding. All of them are generating patents and 
intellectual property (IP). 
• Developing strong expertise in biofilms as a result of CF work. 
Supporting 
Statistics 
• The Gene Transfer Vector Core was established with approximately $1.1 million provided by the 
College of Medicine and the Carver Trust. The Transgenic Animal Facility, built in 1992 at a cost of 
$2.4 million, is at the Oakdale Research Park. Total CF funding at $8 million to $12 million annually. 
• 26 NIH grants related to gene therapy and cystic fibrosis. 
• Cluster confirmed by Battelle Starlight™ analysis. 
Key Institutions • The University of Iowa 
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EMERGING AND NOTABLE 
Table 43: Iowa Emerging and Notable Areas: Imaging and Sensor Devices 
Imaging and Sensor Devices 
Field Definition Imaging is the capture, storage, manipulation, and display of visual information or data, which in the biosciences 
may be achieved through a variety of means such as microscopy, x-rays, PET scans, fluoroscopy, magnetic 
resonance images, etc. Sensors can include a variety of chemical, biological or electronic means for detecting 
the state or change in a biosystems (e.g. temperature change, presence of invading microorganisms, increased 
biofluid flow, heart arrhythmia, etc.)  
Interview Identified 
Strengths 
• Both The University of Iowa and Iowa State University have strengths in imaging and sensor R&D 
and the application of these technologies. 
• The University of Iowa College of Engineering Imaging Group (CEIG), for example, provides a 
collaborative environment for medical image processing, analysis, research, and education. 
Contributing departments include Electrical and Computer Engineering, Biomedical Engineering, and 
Radiology  
• The University of Iowa College of Medicine has particular imaging strengths in advanced 
physiological imaging, down to the sub-millimeter level. The College is also taking a leading role in 
the development of volumetric imaging tools and techniques. Particular emphasis is being placed on 
imaging for cardiovascular and pulmonary applications through the Center for Advanced Imaging 
Research. 
• The University of Iowa is home to some of the leading experts on medical image processing, analysis, 
and machine vision. 
• The Department of Agricultural and Biosystems engineering at Iowa State University is placing an 
emphasis on research in biosystems engineering through the use of biosensors, image analysis, and 
biological systems modeling. 
• Both Iowa State University and The University of Iowa are also leaders in the application of imaging to 
the creation of virtual reality environments for use in training and research.  
• Biosensors are also a focus of research in the Iowa State University entomology department, whose 
recent emphasis involves development of miniature biosensors for detection and location of sources 
of compounds of importance to defense and precision agriculture. 
• Iowa State University is also taking a leading role in the development of environmental monitoring 
sensors and systems, and developing biosensor applications for food safety monitoring and 
biosecurity. 
Supporting 
Statistics 
• Cluster of more than 25 faculty and research scientists engaged in The University of Iowa’s Center for 
Advanced Imaging Research. 
• Multiple awards from government agencies in biosciences engineering and related disciplines. 
Key Institutions • The University of Iowa 
• Iowa State University 
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Table 44: Iowa Emerging and Notable Areas: Metabolomics 
Metabolomics 
Field Definition Metabolomics uses genomics to understand metabolism—the network of chemical reactions organisms use to 
maintain life.  
Interview Identified 
Strengths 
• Iowa State University has been equipping a $1 million lab for metabolomics funded by the W. M. Keck 
Foundation. Termed the Metabolomics Research Laboratory, it will facilitate the study of metabolites to 
provide clearer understanding of the function of genes. 
• At Iowa State the focus of metabolomics initially will be on plants. Work is taking place on starch 
metabolism, genes that direct seed oil production, and analysis of the herbs Echinacea and St. John’s 
Wort. The work in metabolomics at Iowa State is central to the University’s Center for Designer Crops, 
a component of the Plant Sciences Institute. 
• Metabolomics research will be fundamental to many of the goals of Iowa State in terms of adding value 
to plant crops. The science may lead to enhanced oils, plant morphology changes, color manipulation, 
functional foods, and other desirable characteristics. 
• Strength at Iowa State is ability to link from model systems (Arabidopsis) across into crops and the 
know-how of growing the crops. They then take genomics and focus it on the understanding of 
metabolism. Rapid identification of lipids and other metabolite classes will be useful in a variety of 
applications, such as plant and animal breeding, the characterization of transgenic crops, and basic 
research. 
• At The University of Iowa metabolomics will also be an outgrowth of genetics and proteomics research. 
Metabolomics brings a different and complementary perspective to biomedical research and 
therapeutic development. Metabolites are measurable, directly responsible for health, and changeable 
through intervention. By definition, the concentrations of metabolites are the direct reflection of 
metabolism, and by measuring changes in metabolite concentrations, the full range of biochemical 
effects induced by a therapeutic intervention can be determined. 
• In a clinical setting, metabolomics can be used to diagnose or predict disease, stratify patient 
populations by their specific metabolism, or to determine the safety or efficacy of a therapeutic 
intervention. Metabolomics is useful in most aspects of biomedical research, and it is likely to evolve 
into an essential component of the drug discovery and development process. 
Supporting 
Statistics 
• Iowa State has 14 faculty specializing  in designer crops, a manager of the metabolomics lab, and an 
assistant for the center. Roughly $1-2 million range of grant funding. 
Key Institutions • Iowa State University 
• The University of Iowa 
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Table 45: Iowa Emerging and Notable Areas: Biofluidics 
Biofluidics 
Field Definition Biofluidics involves the modeling of biological fluids, such as arterial haemodynamics or respiratory systems. It is 
being facilitated by advances in high performance computing. 
Interview Identified 
Strengths 
• The University of Iowa may be well positioned to progress science in biofluidics. Expertise in lung 
imaging and modeling, and expertise in the cardiovascular system, both have direct relevance to 
biofluidics—and biofluidics models may be useful in the analysis of infections, diseased tissue 
locating, post-surgery prognosis modeling, artificial organ and tissue development, and detection of 
cardiovascular abnormalities (such as aneurisms). 
• Strong computational modeling expertise, coupled with medical imaging expertise, is critical to 
progress, and both exist at The University of Iowa. 
Supporting 
Statistics 
• No data 
 
Key Institutions • The University of Iowa 
 
 
Table 46: Iowa Emerging and Notable Areas: Biofilms 
Biofilms 
Field Definition Also known as “microbial mats,” biofilms consist of layered groups or communities of microbial populations. 
Biofilms are produced by microorganisms and consist of a sticky rigid structure of polysaccharides and other 
organic contaminants. This slime layer is anchored firmly to a surface and provides a protective environment in 
which microorganisms grow. 
Interview Identified 
Strengths 
• The University of Iowa is taking a leading role in the new field of biofilms and claims to have become 
the center for medical biofilms research. Much of the work is taking place within the Cystic Fibrosis 
Center, but it is broader than just CF (although it is a model biofilm disease). Work is fundamental and 
the next ten years will see molecular level work, gene correlation to antibiotic resistance and then a 
move into clinical applications. Lots of patents being generated. Some small pharmaceutical and large 
biotech companies are starting to become players in biofilms disease and treatment. 
• Physicians prescribe antibiotics to treat bacterial infections; however, such treatment is generally 
ineffective if bacteria cluster in biofilm colonies. Now the Iowa scientific community is focusing attention 
on developing therapeutic agents to combat biofilm infections. 
• University of Iowa researchers have identified a subset of genes in a bacterium that behave differently 
when the organism exists as a biofilm. These findings may lead to an understanding of the genetic 
causes of increased antibiotic resistance in biofilms. By examining the list of genes that were 
differentially activated or repressed in biofilms, the researchers have found other genes that have also 
been linked to the ability of non-biofilm cells to withstand lower concentrations of antibiotics. 
Supporting 
Statistics 
• 5 main NIH grants identified with the term “biofilms” in them at The University of Iowa. 
Key Institutions • The University of Iowa 
 
 Iowa Bioscience Path for Development 
 
 
78 
Table 47: Iowa Emerging and Notable Areas: Nanotechnology 
Nanotechnology 
Field Definition Nanoscience is the study of the principles of molecules and structures with at least one dimension between 1 
and 100 nanometers (one nanometer is one billionth of a meter). Nanotechnology is the application of the unique 
properties of such objects to materials, devices and biological systems. 
Interview Identified 
Strengths 
• Nanotechnology appears to be a growing field at both The University of Iowa and at Iowa State 
University 
• The Optical Science and Technology Center at The University of Iowa is working on novel optical 
components to gather bio information via imaging, both noninvasive and invasive. Working with 
personnel in cancer, and able to work at the single molecule level. 
• 15+ groups on The University of Iowa campus would consider themselves working in 
Nanotechnology. 
• Joint work with University of Colorado in photopolymerization. Work is in nano-structures/ordered-
structures using photo polymerization.  
• Researchers at The University of Iowa are conducting research to see how plants handle nano-sized 
particles and what would be some of the risks attached. Biomimicry is one of their basic science 
investigative areas. Plus remediation aspects of technology - working on environmental aspects of 
nanotechnology. 
• At Iowa State University, scientists in materials sciences and within chemistry are active in 
nanotechnology. Work within chemistry has focused on mesoporous spheres as catalysis promoters 
(mesoporous silica bioreactors), non-invasive cell identification tools, drug delivery tools and as 
artificial gene therapy vectors. 
• The Iowa State University Materials Science and Engineering Program has a focus in nanomaterials 
and nanotechnology. 
• Iowa State University Research Park now home to a nanotechnology company, Bioforce 
Nanosciences, which is a developer of ultra-miniaturized nanoarray technologies for solid-phase, 
high-throughput biomolecular analysis. 
• The Mechanical Engineering Department at Iowa State University has a world-class laboratory that 
provides facilities for experimentation to investigate the fundamental and feasibility concepts of laser 
advanced manufacturing, microelectromechanical systems (MEMS), and nanotechnology. 
• Materials scientists at Ames Laboratory are performing experiments to characterize materials, 
modeling the systems at the atomic level using some of the world’s fastest supercomputers, and 
developing theoretical models to explain these properties. 
• IPRT at Iowa State features the new Microanalytical Instrumentation Center, with clean room facilities 
designed to facilitate nanotechnology research. Facility is unique in being designed for use by 
chemists in developing nano-scale instrumentation. 
Supporting 
Statistics 
• No data 
 
Key Institutions • The University of Iowa 
• Iowa State University 
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Table 48: Iowa Emerging and Notable Areas: Biosecurity 
Biosecurity 
Field Definition Biosecurity encompasses work to ensure that ecologies sustaining either people or animals are maintained. 
Biosafety encompasses the science of prevention of large-scale loss of biological integrity, focusing both on 
ecology and human health.  
Interview Identified 
Strengths 
• Iowa has multidimensional strengths in biosafety and biosecurity that have not yet been pulled into a 
formal program, institute, or center. However, Federal support for a biosecurity initiative has come in 
the form of a planning grant. 
• Iowa State University has specific strengths in biosecurity as it relates to agrosecurity, food and 
animal safety and infectious disease threats. The University also has expertise in water, soil and other 
ecosystem sustainability and security fields. 
• Iowa State has organized food security and public health security under the Center for Food Security 
and Public Health with the mission of increasing national preparedness for accidental or intentional 
introduction of disease agents that threaten food production or public health. 
• The University of Iowa has a strong program in infectious diseases, with an emphasis on respiratory 
diseases and zoonotic diseases. This is an interest shared with Animal Sciences and the College of 
Veterinary Medicine at Iowa State University. 
• Good virology expertise at The University of Iowa and Iowa State. 
• Lack of BL3 facilities limiting progress somewhat. 
• Opportunity for an integrated approach to biosecurity between Iowa institutions including: humans, 
animals, food, agricultural production and processing, engineering, and ecological/environmental 
monitoring and protection. 
• Collaborations being developed with other Midwestern universities in a consortium approach to 
biotechnology (University of Kansas and Wichita State University, for example). 
• Iowa State University is operating the Biosafety Initiative for Genetically Modified Products  using 
science based risk/benefit analysis. 
Supporting 
Statistics 
• No data 
Key Institutions • Iowa State University 
• The University of Iowa 
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Table 49: Iowa Emerging and Notable Areas: Drug Development 
Drug Development 
Field Definition Drug development (as opposed to drug discovery) involves the various procedures, formulation, trials, and 
studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and 
marketing. 
Interview Identified 
Strengths 
• The Center for Advanced Drug Development (CADD) at The University of Iowa is ten years old and 
mostly performing analytical development, pre-formulation and stability research. The Center provides 
a fee-for-service operation to researchers and corporations. It performs 350 batches of 
pharmaceutical dosage forms a year, and can do more than one project per day. 85% of projects are 
for clinical trials for humans, while the rest are development and stability batches. CADD has 6,500 
sq.ft. and 17 people. 
• The Division of Pharmaceutical Services occupies the whole ground floor of the College of Pharmacy 
at The University of Iowa. It began as a manufacturing department for the pharmacy of the university 
hospitals, and was upgraded to comply with GMP specifications to help faculty with accessing grants 
from the federal government. Now the institution has a considerable track record in contract work for 
pharmaceutical companies (extremely unusual for an academic institution). 
• 85-90% of the Division of Pharmaceutical Services’ work is with smaller pharmaceutical companies 
and start up pharma companies who cannot afford to set up their own small GMP facilities. Conducts 
formulation and analytical development—and mostly manufacture for Phase I and II in all forms 
(except soft gelatin capsules, aerosols and transdermals). Have 24,000 sq.ft. and 56 staff members.  
• Kentucky has a similar pharmaceutical services operation but it is smaller; Maryland’s is newer but 
more limited; and Purdue is just starting one. Linking into a cGMP biologics facility will make Iowa 
unique. 
• Iowa State University is in the late planning stages for the development of a biotechnology processing 
facility for protein production and purification at their Research Park in Ames. 
• Drug formulation is also a distinguishing feature of The University of Iowa’s expertise in 
pharmaceutics. Many new drug products will not necessarily involve new chemical entities (drug 
discovery). Modified compound formulations may be designed to more effectively balance 
conveniences, efficacy, and toxicity using improved delivery techniques. 
Supporting 
Statistics 
• No Data 
Key Institutions • The University of Iowa 
• Iowa State University 
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Table 50: Iowa Emerging and Notable Areas: Materials Science (Applications to Bioscience) 
Materials Science (Applications to Bioscience) 
Field Definition Materials Science includes those parts of chemistry, physics, geology, and even biology that deal with the 
physical properties of materials. It is usually considered an applied science, in which the properties under study 
have some industrial purpose. Biomaterials are any substance (other than drugs) or combination of substances 
synthetic or natural in origin, which can be used for any period of time, as a whole or as a part of a system which 
treats, augments, or replaces any tissue, organ, or function of the body. 
Interview Identified 
Strengths 
• The Department of Biomedical Engineering at The University of Iowa has a concentration in 
biomaterials, especially implant biomaterials. 
• Work in Biomedical Engineering’s Biomaterials Laboratory involves the modification of ultra high 
molecular weight polyethylene (UHMWPE)  to be chemically adhered to the polymethylmethacrylate 
bone cement for better fixation of implants made of UHMWPE such as the acetabular cup of the hip 
and tibial plateau of the knee joint. Another area of research is the use of thermal seeds to heat 
prostate tissues. The development of PdCo alloy seeds and testing of the seeds in various conditions 
have moved into the clinical trial stage. 
• Developing expertise in biofilms may be directly relevant to future biomaterials and biocompatibility 
issues. There is also work in tissue engineering at The University of Iowa. 
• At Iowa State University there is a very strong tradition of materials science tied to the work of the 
Ames Laboratory. Work on campus in biomaterials is progressing, with examples including the 
synthesis and design of new biopolymeric materials for protein stabilization, tissue engineering, and 
controlled and targeted delivery of DNA, drugs, and genetically engineered proteins and peptides. 
• Iowa State’s expertise in materials science, chemistry and chemical engineering is being applied to 
the BioEconomy initiatives in addition to biotechnology. Polymers, biocomposite materials, adhesives, 
and other materials are being developed and tested by Iowa State. 
• Opportunity may exist to leverage the reputation and expertise of the Ames Lab into further research 
tied to biomaterials and to the BioEconomy initiatives in the state. 
Supporting 
Statistics 
• No data 
Key Institutions • Iowa State University and Ames Laboratory 
• The University of Iowa 
 
SUMMARY 
The above tables provide significant insight into the bioscience core competencies and specific areas of 
focus in Iowa. Conclusions regarding these competencies and strengths are incorporated, together with 
the findings of the quantitative analysis, to develop and refine “technology platforms” upon which a 
bioscience economy may be built in Iowa. The specific recommended platforms, and the research core 
competencies to leverage in building them, are discussed in detail in the next section. 
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Iowa Paths to Biosciences Development: Leveraging Core Research 
Competencies and Technology Platforms  
The purpose for gaining an understanding of Iowa’s research core competencies is not only to identify the 
key research strengths and drivers for biosciences. To ensure economic impact the key technology plat-
forms must be identified that move this research toward commercialization around products, processes, 
and market-driven niches. Core competencies identification also helps focus on the state’s specific 
possibilities for becoming a bioscience growth center around major niches and opportunities. Of 
particular importance is the ability of a state to have specific areas for near-term (within the next two to 
five years) development that takes advantage of core research strengths that will contribute to economic 
growth. It is these near-term areas for development that identify how the state can be a thriving center for 
the biosciences and can provide the foundation for further, more longer-term investments needed to 
establish broader core competencies for growth in the longer term. 
Given the close linkages of research and industry development in the biosciences and the extensive 
reliance on research for new bioscience products, it is helpful to focus on areas of primary research for 
near-term development. But research alone is insufficient to ensure bioscience development. The most 
likely areas for bioscience development can be found where research intersects with a state’s industry 
base, competitive advantages, and market opportunities. 
The criteria for selecting near-term opportunities for technology development include areas in which there 
are 
• Existing research focus strengths 
• Bases of commercial activity emerging or established within the state, or a genuine opportunity to 
create a base in the near future 
• Distinct opportunities to leverage Iowa’s comparative advantages to create competitive marketplace 
advantages 
• Significant product market potential 
• Links to, or reinforcements of, other bioscience strengths and core research competencies, thereby 
helping to enhance other fields as it expands. 
Based on these criteria, the following technology development platforms are identified for near-term 
development, focus, and investment in Iowa: 
  BioEconomy Platform 
  Integrated Drug Discovery, Development, Piloting, and Production Platform 
  Advanced Food Products Platform 
  Integrated Post-Genomic Medicine Platform 
  Animal Systems Platform 
  Integrated Biosecurity Platform. 
These six platforms represent the base from which a significant R&D, business base, and bioscience 
economy may be built. They each specifically draw upon Iowa’s institutional expertise in multiple fields, 
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since it is multidisciplinary research that is increasingly gaining importance in driving new study areas, 
technologies, and commercializable innovations and discoveries. The assembly of multidisciplinary 
platforms is likely to increase the opportunity for winning federal agency grant awards. It is also a 
specific match to the type of cross disciplinary institute structure being formally adopted by Iowa State 
University and more informally used within The University of Iowa. 
In addition to the main platforms, Battelle also identified several additional areas of opportunity that 
represent longer-term or less broad bioscience sector development potentials. The identified areas consist 
of relatively compact groups of people working in leading edge fields, new formative centers just recently 
pulled together, or established areas of expertise in which investment in infrastructure and/or personnel 
are required to sustain or accelerate development momentum. These additional opportunity areas include 
  Host-Parasite Biology and Systems 
  Instrumentation, Devices and Sensors 
  Formation of a Cardiovascular Research Institute 
  Formation of a Free Radical Research Institute. 
Each of the main bioscience platforms and opportunity areas noted above are linked to multiple centers of 
bioscience excellence and related disciplines within Iowa’s academic R&D institutions. Figure 20 sum-
marizes the competency areas identified through quantitative research (the column of disciplines on the 
left) and those identified through the in-depth qualitative interviews (the column of disciplines on the 
right). The center column depicts the main technology platforms and opportunity areas that can result 
from the integration of these qualitative and quantitative strengths. 
Figure 21 shows how Iowa’s bioscience research strengths, determined and validated through both 
quantitative and qualitative analyses, lead to the recommended six specific technology platforms. Each of 
these six platforms, as well as the four emerging opportunity areas, are described in the following narra-
tives. Each narrative includes a figure designed to show the specific linkages between the quantitatively 
based and qualitatively based core competency disciplines and recommended platforms and opportunity 
areas. The figures graphically illustrate the way in which these platforms are reinforced by the R&D 
talent across a wide range of strength disciplines in Iowa. 
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Figure 20: Quantitative and Qualitative Core Competencies and Resulting Biosciences Technology Platforms. 
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 Figure 21: Iowa’s Validated Research Strengths Leading to Recommended Platforms. 
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The use of biorenewables has received considerable attention in Europe where the European Community-
sponsored “Interactive European Network for Industrial Crops and Their Applications” (IENICA) has 
undertaken significant analysis of potential markets for biorenewables. IENICA segments the potential 
market into five main areas: 
• Oils 
• Fibers 
• Carbohydrates (sugars, starches, glycogen) 
• Specialty Products 
• Proteins. 
IENICA’s research concludes that the first three of these (oils, fibers and carbohydrates) will have the 
greatest potential impact on agriculture because they will require large production land acreage. 
Independent of fuel production (such as ethanol and biodiesel), IENICA predicts that the main oil market 
opportunities will be in 
• Bio-lubricants 
• Bio-printing inks 
• Bio-solvents 
• Linoleum 
• Surfactants 
• Polymers 
• Paints and Surface Coatings. 
In terms of fiber applications, the Europeans predict opportunities in 
• Matting based products (filters, growth media, textiles) 
• Biocomposites (such as materials for use in vehicle manufacturing) 
• Insulation products 
• Wood-based panel substitution with annual constituents (such as straw) 
• Paper and pulp manufacturing. 
Non-food carbohydrates markets, especially those for starches, represent approximately 50 percent of 
total starch use in the European Community. These non-food uses are primarily in 
• Paper and cardboard manufacturing 
• Plastics and detergents 
• Fermentation and technical uses 
• Specialty areas including water purification, cosmetics, toiletries, pharmaceuticals, paints, and 
agrochemicals. 
Proteins are predicted to have major applications (outside of food) in packaging and labeling industries, 
pharmaceutical and chemical production, adhesives, and cosmetics. 
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It is therefore evident that considerable opportunities exist for the commercial exploitation of 
biorenewables. Much of the future for these products depends on the development of processing 
technologies that will generate products at a price competitive to alternative (usually petroleum based) 
production pathways. 
As noted previously, Iowa has, through the Industries of the Future program, already identified the 
BioEconomy as a component of the future world economy in which Iowa can gain an early and 
sustainable leadership position. Iowa State University research, sponsored by the U.S. Department of 
Energy, Iowa Department of Natural Resources, and the Iowa Energy Center, resulted in the Fall of 2002 
publication entitled “Biobased Products and Bioenergy Vision and Roadmap for Iowa.” The Roadmap 
provides a vision statement for Iowa’s potential position in the BioEconomy stating that by 2020: 
Iowa leads the nation in developing the BioEconomy. Growth of the BioEconomy had led to an 
unprecedented period of sustained economic growth in the state and has allowed Iowa to develop 
abundant amenities and a quality of life rated among the highest in the United States. Iowa 
biorefineries24 enjoy widespread support from Iowans because they consistently 
• Produce superior products 
• Capture significant value for all segments of bioproduct value chains 
• Provide high rates of return to investors 
• Attract local and outside capital 
• Provide exciting, challenging and lucrative jobs 
• Improve environmental conditions and ecological diversity. 
The Iowa State University report for Industries of the Future specifically outlines the science and 
technology focus areas that need to be addressed to assure advancement of the BioEconomy and Iowa’s 
leadership position within it. The science and technical focus areas include 
• Plant Science—improving processing functionality; expression of desirable characteristics; plant 
vigor; durability of feedstocks; manure characteristics; uniformity of raw material; pest resistance; 
optimized yields; environmental impact; and genomics, bioinformatics, and metabolomics 
capabilities. 
• Production—improving understanding of the impact of crop residue removal; developing best 
management practices; expanding planting and harvest windows; developing cost effective methods 
of harvesting, transporting, and storing biomass; adoption of appropriate farm policies; and 
developing a marketing system for crop residues and specialty crops. 
• Processing—improving plant component separation; conversion processes; management and 
financing systems that reduce feedstock costs; quality and availability of feedstock; and developing 
decentralized preprocessing technologies. 
• End Use—designing biorefineries that enhance functionality/performance of local biomass resources; 
exploiting specific markets for local/regional biobased products; adopting policies that encourage 
domestic consumption of biobased products; establishing certification programs that verify biobased 
content and product performance.  
                                                   
24
 The Iowa State University report defines biorefineries as “integrated processing plants that yield numerous products.” 
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Focus products of the Iowa BioEconomy are anticipated to include 
• Industrial Chemicals 
• Ethanol 
• Enzymes 
• Biodiesel 
• Hydrogen 
• Carbohydrate-based chirals 
• Building materials such as fiber board, ceiling tiles, etc. 
While there are considerable scientific, technical and market hurdles to overcome, efforts are already 
underway for Iowa to implement this platform, with its advocates noting it has the opportunity to become 
a major contributor to the state’s economic health. Indeed, the BioEconomy in Iowa is not some long-
term dream; it is already becoming a reality as R&D advances in the state result in new companies being 
formed in the field. Iowa is already home to a growing biorefineries industry. 
Figure 22 illustrates the key linkages between quantitative and qualitative core competency disciplines 
and the BioEconomy platform. This figure shows the importance of many core research areas to the 
success of this platform and the widespread expertise that will be needed to position Iowa to succeed in 
this arena.  
Iowa State University is certainly central to the state’s initiatives in the BioEconomy. The University has 
put in place a structure of institutes and R&D centers that positions it well as the leader in driving 
the science and technology of the BioEconomy forward. The following components of Iowa State 
University are key elements in BioEconomy technology platform development: 
The Plant Sciences Institute—an umbrella organization comprising nine research centers and three task 
forces. Each of these centers and task forces has a role to play in the BioEconomy—but chief among them 
are six centers that in combination provide a vertically integrated chain of discovery, research and 
development: 
• Laurence H. Baker Center for Bioinformatics and Biological Statistics—developing methods, 
programs, and algorithms for acquiring genomic data and analyzing it for use by plant scientists. 
• Center for Plant Genomics—developing and using genomic technologies to provide the genetic 
understanding of plant resources that will form the underpinning of control over plant growth, 
development, and inherent characteristics. 
• Center for Plant Transformation and Gene Expression—working to develop methods to 
efficiently insert and transfer genes in order to efficiently generate transgenic plants and assure their 
safety. 
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Figure 22: Quantitative and Qualitative Core Competencies and Resulting BioEconomy. 
• Center for Designer Crops—working to understand and control the plant production of metabolites 
that produce useful applications (such as starch, oils or drug compounds). 
• Center for Plant Responses to Environmental Stresses—working to help modify plants to 
withstand wider ranges of biotic and abiotic stress. 
• Raymond F. Baker Center for Plant Breeding—integrating breeding techniques and germplasm 
enhancements to develop plant cultivars to meet the expression needs and plant characteristics as 
BioEconomy feedstocks. 
The above centers provide a pathway of basic and applied science from fundamental genomic discoveries 
through to the exploitation of these discoveries expressed through new, optimized plant cultivars. Thus, 
there exists at Iowa State a basic fabric of interrelated research centers providing an applied and highly 
focused research and development engine for the BioEconomy. The work of the R&D scientists is further 
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supported by additional centers and research institutes at Iowa State that can take the science output and 
direct it for optimal use in developing the BioEconomy. Examples of such pragmatic centers and 
supporting programs at Iowa State include 
• Center for Crops Utilization Research—facilitating basic and applied mission-oriented research to 
find new uses for Midwestern crops and identify uses for potential crops (both food and non-food 
uses). The Center operates a Crop Products Pilot Plant including: 
o Wet pilot plant facilities 
o Dry pilot plant facilities 
o A hazardous solvents pilot plant 
o Fermentation facility 
o Sensor evaluation laboratory 
o Process development laboratory 
o Analytical services laboratory 
o Technology transfer pilot plant. 
• Center for Catalysis—working on the catalytic chemistry of converting green feedstock’s into 
BioEconomy products such as plastics and lubricants. 
• Center for Sustainable Environmental Technologies—developing and demonstrating sustainable 
energy and environmental technologies, including the study of biomass-derived chemicals, fuel, and 
power. The Center has resources to specifically assist in the evaluation and scale-up of sustainable 
technologies, including 
o Fermentation reactor 
o Biomass gasifier, using biomass resources to generate heat and power 
o Virtual pilot plant (through ISU’s Virtual Reality Application Center) 
o Biomass Energy Conversion Facility (BECON), a 12,000 sq. ft. research facility 
dedicated to pilot-scale testing of biomass-energy technologies. 
These centers are interdisciplinary in their research and staffing and benefit not only from Iowa State’s 
strong position in genomics and plant biosciences, but also the University’s departmental strengths in 
chemistry, biochemistry, chemical engineering, and biosystems engineering. The same pathway of basic 
through applied BioEconomy products also works at Iowa State for developing advanced food and 
nutrition products. 
The integrated approach to BioEconomy, Biotechnology, and Food Products R&D in Iowa is 
illustrated in Figure 23. It is evident that Iowa State University has put in place a structure well-
suited for moving from basic science research to pragmatic commercializable products (assuming 
that the system is adequately funded, staffed, equipped, and organized). 
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Figure 23: Integrated Approach to BioEconomy, Biotechnology, and Food Products R&D in Iowa. 
 
Within this basic structure of BioEconomy development in Iowa, both The University of Iowa and the 
University of Northern Iowa have contributions to make and expertise that should be engaged and 
integrated. The University of Iowa has considerable strengths in the biological sciences, bioinformatics, 
genomics, and proteomics. It also has the Center for Biocatalysis and Bioprocessing with skills and 
facilities directly relevant to the BioEconomy and biotech technology development paths, in addition to 
medical and health scientists with applicable skills to food science and nutrition. The Center for 
Biocatalysis and Bioprocessing at The University of Iowa is a unique facility and provides expertise 
relevant to both BioEconomy opportunities (in chemical catalysts and associated chemistry fields) and 
biotechnology opportunities (given established knowledge of, and facilities for, cGMP processes and 
practices). 
Likewise, the University of Northern Iowa is making important contributions related to the BioEconomy. 
This is especially notable in the area of bio-based lubricants, where UNI operates the ABIL (Ag-Based 
Industrial Lubricants) research program. ABIL has more than a decade of operating experience in 
research and development of hydraulic and other industrial lubricants from soybean and other vegetable 
oils. The program receives support from state, federal, and private industrial partners. ABIL serves as a 
microcosm of the type of progress that may result in Iowa through BioEconomy research, development, 
and investment. Since its founding, ABIL discoveries have led to a portfolio of products commercialized 
by private industry, including 
• Multi Grade Hydraulic Fluid 
• Industrial Hydraulic Fluid 
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• Food-Grade Hydraulic Fluid 
• Fifth Wheel Grease  
• Chain Bar Oil 
• Rail Curve Grease  
• Food Grade Grease  
• Cotton Picker Spindle Grease  
• Viscosity Modifier/Property Enhancer  
• Optimized Soybean Base Oils. 
INTEGRATED DRUG DISCOVERY, DEVELOPMENT, PILOTING, AND PRODUCTION 
PLATFORM 
Iowa has established piloting and production facilities within an academic research setting—The 
University of Iowa—that may form the basis of an integrated suite of piloting and production services for 
academia and industry. There is an opportunity to make this a more widely known and used technology 
platform as it represents a unique resource for bringing new drug discoveries from testing to market. 
Currently, there is a worldwide shortage of GMP quality facilities for the production of mid-scale 
volumes of drugs and biological preparations—the volumes required for clinical trials and for the 
production of orphan drugs. While there are contract commercial entities that service this market, there is 
likely to be an expanding shortage of facilities based on the large pipeline of compounds, drugs, and 
biologics starting to move into clinical trials. 
The University of Iowa’s Center for Advanced Drug Development (CADD) and the GMP production 
facilities of the Division of Pharmaceutical Services are fairly unique facilities in academe. Together 
these resources provide a substantive resource for drug development and production that is primarily used 
on a contract basis by small pharmaceutical and biotechnology companies located outside Iowa. 
At the other end of the drugs pipeline, The University of Iowa has considerable breadth and depth in basic 
sciences research in a variety of medical disciplines. Work in cardiac and vascular systems, cancer, 
gastroenterology, neurology, and pulmonology, for example, could lead to discoveries of biological 
mechanisms that would be suited to drug screens. 
The University of Iowa may be able to form an integrated pipeline of R&D for new drugs and biologics. 
It has the basic science, drug development, GMP production, and clinical trials structure required to 
conduct complete in-house projects. This would increase the likelihood of pharmaceutical and 
biotechnology companies forming and staying in the state. One key element of an integrated pipeline, 
however, is missing —The University of Iowa lacks a drug discovery facility.  
By establishing a Drug Discovery Center, The University of Iowa would be equipped with a continuous 
model structure for facilitating the movement of basic science discoveries from the bench to the bedside. 
In combination with the University’s identified strengths in genomics, and emerging strengths in 
proteomics and metabolomics, Iowa has almost all of the key required elements in place. 
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This is an area considered by The University of Iowa to be ripe for integration and collaboration across 
several departments and colleges, including chemistry, biochemistry, pharmacology, and medicinal and 
natural products chemistry. Figure 24 lays out this drug pipeline concept and shows how filling the gap 
with a drug discovery center leads to a more fully integrated model. 
 
Figure 24: Concept for Integrated Drug Discovery, Development, Piloting, and Trials Pipeline. 
 
An integrated model on this scale would be very expensive and difficult for competing academic 
institutions to set up. Having direct commercial experience in drug development services and in GMP 
production, as Iowa has, would be a great challenge for another institution to duplicate. It takes years of 
experience and training to achieve the credentials to be licensed by the FDA for GMP production, and a 
multiyear track record of uninterrupted success in GMP production in order to be trusted by external 
commercial biotechnology and pharmaceutical companies with their production: The University of Iowa 
has already achieved this. 
The concept for establishing a Drug Discovery Center at The University of Iowa has been proposed by 
the Department of Pharmacy members Gerald Gebhart, Ph.D., and Johannes Hell, Ph.D.25 The Battelle 
field project team met with the Pharmacy staff to discuss the concept, the development of which is 
expected to require three primary components: 
1. Personnel—Initially estimated at three full-time positions including one full-time position for a 
faculty member who would direct the Center, with oversight by a steering committee (ideally 
composed of both University of Iowa and industry representatives). 
                                                   
25
 Letter to Dr. Jean Robillard (Dean of the University of Iowa College of Medicine) from Gerald F. Gebhart, Ph.D. 
(Professor and Chair, University of Iowa Department of Pharmacology) and Johannes W. Hell, Ph.D. (Associate 
Professor, University of Iowa Department of Pharmacology). October 12, 2003. 
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The Pharmaceutical Service Division at The University of Iowa 
is a Food and Drug Administration-registered pharmaceutical 
manufacturing facility, occupying approximately 24,000 square 
feet on the ground floor of The University of Iowa College of 
Pharmacy building. The division manufactures, under contract, 
clinical supplies of most types of pharmaceutical dosage forms 
for clinical testing. These dosage forms include sterile 
injectable solutions, emulsions, and suspensions; sterile 
lyophilized (freeze-dried) preparations; tablets (film-coated and 
uncoated) and capsules; topicals (ointment, creams, gels); and 
oral liquids (solutions, suspensions, emulsions). The division is 
also licensed with the DEA and can manufacture dosage forms 
containing schedule I-V actives. Pharmaceutical Service 
typically serves over 65 client organizations per year. CADD 
performs a wide range of assays to obtain data for pre-
approved active pharmaceutical ingredients, new molecular 
entities, drug products, and excipients. The Center for Biocatalysis and Bioprocessing (CBB) at The 
University of Iowa has a 20-year track record in combining 
scientific faculty with modern facilities to research and develop 
new technologies for chemical, pharmaceutical, nutritional, and 
agrochemical industries. The CBB consists of 59 faculty 
members and more than 300 researchers, including graduate 
and undergraduate students, postdoctoral scientists, 
technicians, and visiting faculty and industrial scientists. 
Principal areas of CBB study include biocatalyst fundamental 
properties, bioremediation, bioprocessing, new biocatalyst 
discovery, novel biocatalyst applications, biosensing 
technology, and reactive agent development. During FY2003, 
the CBB laboratory collaborated with more than 60 industrial 
companies and institutions and more than 90% of the CBB 
laboratory’s contract income is from the private sector. Some 
examples of industry collaborations include production of 
vaccines, antibiotics, anticancer drugs, polymers, BL2-LS 
pathogens (used to develop diagnostics and vaccines), 
biochemicals, enzymes, pharmaceutical intermediates, and 
derivatives of bioactive compounds. 
2. Instrumentation—for performance of high throughput screens. 
3. Compound Libraries—including a classic chemical library of 50,000 to 500,000 compounds, 
peptide libraries to be custom-made by the Center, and biological libraries to be pioneered by the 
Center. 
As Professors Gebhart and Hell note: 
Basic research as performed in many laboratories at The University of Iowa continuously 
uncovers new biological mechanisms that would offer themselves for drug screens (e.g. discovery 
of a new ion channel), but does not take advantage of such novel scientific insight. The Center 
(for Drug Discovery) would catalyze the desirable bench-to-bedside approach by facilitating 
drug discovery and by bringing together basic and clinical researchers. It also holds the promise 
to generate income for UI through patents in the future and to foster the establishment of bi-
otechnology-oriented companies in Iowa, thereby improving the infrastructure and economy in 
our state. It would be a long-term investment with far-reaching benefits. 
The development of a Drug Discovery Center at 
The University of Iowa is a clear and logical step 
in completing a thorough and difficult-to-replicate 
suite of services designed to develop basic science 
discoveries into new drugs, biologics, and 
therapeutics.  
 Iowa State University has important elements of the 
drug pipeline that should be integrated into the 
platform. Iowa State can provide a similar basic 
science through testing and production pathway on 
the veterinary medicine side, and has considerable 
expertise in combinatorial chemistry, which may be 
integrated into the drug discovery system. The Iowa 
State University College of Veterinary Medicine’s 
work on companion animal medicine may prove to be a 
means to achieve early trials and market introductions 
of drugs on a timeline shorter than that required for 
human medicines.  
Iowa State University also has plans to develop a 
biologics facility on their research park—a facility 
focused on protein recovery and purification. Such a 
facility would complement the facilities at The 
University of Iowa and provide a resource for 
production of products for use in biotechnology, 
pharmaceuticals and nutraceuticals. It would also 
provide a resource for protein extraction related to 
potential BioEconomy applications.  
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Figure 25 illustrates the key linkages between quantitative and qualitative core competency disciplines 
and the drug discovery, development, piloting, and production platform. 
 
Figure 25: Quantitative and Qualitative Core Competencies and Resulting Integrated Drug Discovery, 
Development, Piloting, and Production Platform.  
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ADVANCED FOOD PRODUCTS PLATFORM 
Many of the same scientific disciplines and skills that will power the BioEconomy initiatives will also be 
broadly applicable to developing advanced food products. Such products may include: 
• Functional Foods—The Institute of Medicine defines functional foods as “any food or food 
ingredient that may provide a health benefit beyond the traditional nutrients it contains.” Functional 
foods can be either plant- or animal-based. 
• Nutraceuticals—The definition given by the Iowa State University Extension is that a nutraceutical 
is “any substance that may be considered a food or part of a food and provides medical or health 
benefits, including the prevention or treatment of disease.” 
• Phytochemicals—Nutritionists use the term phytochemical when referring to naturally occurring 
components of plants that have physiological effects on humans. Such physiological effects might 
include enhanced immune system activity, chemoprevention, and reduced cholesterol. 
As shown in Figure 26, the same vertically integrated system of scientific R&D that will contribute to 
Iowa’s leadership in the BioEconomy has a food path that could lead to an advanced foods economy in 
the state. 
 
Figure 26: Potential Path for Advanced Food Economy in Iowa. 
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Iowa State University and The University of Iowa have much to contribute to advanced foods develop-
ment. Already the two universities, in collaboration, have attracted a $6 million, 5-year NIH grant to 
study and isolate active chemicals in the commonly used herbs Echinacea and St. John’s Wort. This work 
represents a significant step in phytochemical discovery, an area of research that others within Iowa State 
have been actively engaged in—such as work to uncover the antiviral properties of “hypericin,” a 
phytochemical present in St. John’s Wort. 
At its core, work in advanced food products addresses one of the economic development missions in the 
state—that of generating products that have added value. Work to identify, isolate, and prove the health 
and nutrition benefits of various plant and animal components may lead to 
• Transgenic corn or soy expressing enhanced levels of beneficial nutrients, vitamins and 
phytochemicals (as with Golden Rice). Such crops will have increased value in world commodity 
markets. 
• Traditional crops expressing beneficial nutrients, vitamins, and phytochemicals that are then 
separated from the crop to produce processed supplements and nutraceuticals. 
• New crops, produce, herbs, fruits, and animal varieties for production by Iowa farmers that will have 
advanced food characteristics and the ability to command a premium price. 
• A base of nutraceutical and chemical extraction R&D and production companies leveraging the 
expertise or Iowa universities in various related disciplines. 
• Food processing technologies and companies using advanced techniques that maintain the functional 
and beneficial qualities in advanced plant and animal products. 
The work to identify active chemicals and compounds in foods may also generate a logical link into the 
drug discovery and development pipeline discussed previously. Identifying and analyzing a chemical in 
St. John’s Wort that has anti-depressive qualities, for example, may lead to the development of a more 
traditional pharmaceutical product, rather than simply consumption of the herb. Thus, the advanced foods 
initiative may be an additional branch pipeline for discoveries related to pharmaceuticals and biologics. 
Much of the work related to beneficial chemicals in advanced foods will have logical links into the 
strongest areas of medical research at The University of Iowa. Examples might include 
• Cancer Research—with the discovery of immunopromultory or immunosuppressive chemicals, 
chemoprevention agents, etc. 
• Cardiovascular Research—with development of low saturation oils, cholesterol reducing chemicals, 
nutrients that reduce blood pressure, etc. 
• Free Radical Research—where vitamins have already been identified at The University of Iowa that 
have highly positive activity during oxidative events, helping to reduce free radical damage. 
• Neurological Research—with the potential discovery of chemicals and nutrients having a positive 
effect on neurodegenerative diseases. 
Much of the expertise is in place at both Iowa State University and The University of Iowa to make 
significant progress in advanced food research and applications possible. Iowa State operates a substantial 
Food Science and Human Nutrition program and has the basic science bases largely covered in terms of 
genomics, proteomics, metabolomics, chemistry, and biochemistry. The University also has the required 
strengths in gene expression (and insertion) and plant and animal breeding to advance initiatives in the 
field. 
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Iowa State University may also make important contributions in advanced food initiatives through the 
Institute for Food Safety and Security, helping to assure the safety of genetically modified or otherwise 
modified food products resulting from advanced food initiatives. 
Figure 27 illustrates the key linkages between quantitative and qualitative core competency disciplines 
and the advanced food products platform. 
 
Figure 27: Quantitative and Qualitative Core Competencies and Resulting Advanced Food Products 
Platform. 
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INTEGRATED POST-GENOMIC MEDICINE PLATFORM 
The importance to medicine of the decoding of the human genome, and indeed the future of humanity, is 
hard to overstate. DNA underlies every aspect of human health, both in terms of function and dysfunc-
tion. In many respects, the genomic revolution is moving the practice of medicine from a mix of art and 
science into a purely quantitative scientific realm. 
While there is still a vast landscape of medical discovery ahead of the world’s scientists, the decoding of 
the genome has been the first step into that new landscape. Obtaining a detailed picture of how genes 
function, how they express proteins, and how they interact with environmental factors ultimately will 
change the way in which disorders are diagnosed, treated, and prevented. This will bring forth revolu-
tionary changes in clinical and public health practices and have a profound effect on health care, one of 
the largest components of the U.S. and individual states’ economies. 
While the decoding of the human genome represents a tremendous scientific accomplishment, it is 
perhaps most significant as a starting point for new discoveries that will take place in comparatively new 
life science fields, such as functional genomics, proteomics, pharmacogenetics, human genomic 
epidemiology, and bioinformatics. The genome provides something akin to a national highway map—it 
points scientists in general directions, but new and deeper investigations are required to fill in the city, 
neighborhood, and street-level detail. It is at this detailed local level that functional genomics and 
proteomics come into play, but these have to be further supported by strong epidemiological and patient 
outcomes data. 
In the future, it is likely that many of the most significant medical discoveries and advances will be made 
at those institutions that are able to combine clinical disease or disorder expertise, together with large-
scale epidemiology and outcomes databases related to the diseases or disorders, and which have strong 
genetic research capabilities to look for genes related to the disease or disorder epidemiology being 
observed (see Figure 28). 
 
Figure 28: Integrated Post-Genomic Medicine. 
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The rise in importance of bioinformatics, biostatistics, and health informatics is being advanced by the 
data-driven nature of quantitative post-genomic bioscience. In 21st century medical research, it is likely 
that those institutions that control the largest and most comprehensive datasets will have a comparative 
advantage in making important discoveries. In a knowledge economy, data is king, and Iowa has some 
advantages already evident. 
The University of Iowa has the main components needed to provide solutions in post-genomic medicine. 
It has 
• Access to a comparatively stable population base in Iowa, where patient records have substantive 
longevity and the potential to be maintained into the future 
• The ability to track patient disease or disorder morbidity through time 
• A strong clinical practice providing health care to patients with a broad variety of diseases and 
disorders 
• The ability to examine patients for genomic characteristics that appear to be related to disease 
susceptibility, progression, outcomes or resistance. 
At the University of Iowa, clinical research, pathology, gene expression, and epidemiologic and outcomes 
data can be brought together to rapidly advance post-genomic medicine and associated discoveries. 
Ophthalmology is one area at the University of Iowa in which the concept of an integrated post-genomic 
medicine platform could be advanced fairly rapidly. Iowa’s ophthalmologists have, for decades, stored 
photographs in a database of each patient seen. This rich data resource of eye pathology data, in 
combination with a very stable population base, can enable disease epidemiology and outcomes to be 
studied. Data mining directs ophthalmologists and geneticists to examine specific patients for genes that 
may be related to the development, progression, or non-progression of a given eye disease. Advances 
using such an integrated system have already been made at The University of Iowa in glaucoma and 
macular degeneration. Recognition of Iowa’s leadership in the field has helped expand the dataset, as 
ophthalmology programs around the world have started to share samples with Iowa. Iowa now has 40,000 
human samples from nearly all countries in the world, with 700 of the samples demonstrating the rarest of 
eye diseases. 
Once genes are identified, researchers can move into animal models to express the gene. Then scientists 
are able to look at pathophysiology, plus start work on prevention. Ophthalmology researchers have 
stratified macular degeneration phenotypically, discovering that it actually represents multiple diseases. 
The macular degeneration team has begun to discover causative genes. Next steps could incorporate work 
on drugs to slow progression of the disease together with population genetic testing. Such a basic 
structure for gene discovery and pathophysiology studies would naturally extend into drug 
discovery initiatives, linked to the drug discovery/development technology platform  previously 
discussed. 
This integrated approach of “clinical practice  data gathering   data mining   gene discovery” may be 
applied in Iowa in a number of medical areas. For example, the longitudinal Muscatine cardiovascular 
study has a large dataset associated with it, and the Cancer Center likewise has longitudinal data, tissue 
and runs the Iowa Cancer Registry—a component of the NCI’s Surveillance, Epidemiology, and End 
Results (SEER) program. Similar opportunities are presented in other strength fields at the University of 
Iowa, including otolaryngology, pulmonology, gastroenterology, and neurosciences.  
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The key to integrated post-genomic medicine platform development is generating data that 
combines clinical, pathology, and gene expression into one database system. University of Iowa 
researchers secured NCI funding for additional work on this challenge. Additional funding is needed 
for further physical infrastructure, resources, and faculty to advance database development and its clinical 
applications. This approach represents a basic platform concept which may be linked to multiple medical 
disciplines; it is also a platform best suited to an academic medical center operating with a stable patient 
base and having formal patient follow-up processes (i.e., The University of Iowa model). 
The success of such an integrated approach depends on population enrollment for longitudinal studies. 
The University of Iowa Hospitals would be well served by setting up a patient enrollment center in the 
University Hospital lobby, following the model already successfully employed by Washington University 
in St. Louis, Missouri. 
Figure 29 illustrates the key linkages between quantitative and qualitative core competency disciplines 
and the integrated post-genomic medicine platform. It shows that the vast majority of clinical discipline 
strengths in Iowa can fit into and contribute to this platform. 
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Figure 29: Quantitative and Qualitative Core Competencies and Resulting Integrated Post-Genomic 
Medicine Platform. 
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ANIMAL SYSTEMS PLATFORM 
Except in the economic use of manure by-products, BioEconomy opportunities largely have been 
discussed in terms of renewable resources from plant biomass. Focusing only on plant biotechnology 
and BioEconomy initiatives, however, misses another large scale aspect of the biosphere—animals.  
There are likely to be significant economic opportunities for Iowa related to animal biosciences, through 
developments such as the following: 
• Transgenic Animals—animals that carry a foreign gene that has been deliberately inserted into the 
animal’s genome. The foreign gene is constructed using recombinant DNA technology. In addition to 
a structural gene, the DNA usually includes other sequences to enable it to be incorporated into the 
DNA of the host and to be expressed correctly by the cells of the host. Transgenic animals present 
many opportunities: 
o Promoting meat quality, tenderness, fat content, rate of development, or other desirable 
characteristics in livestock 
o Preventing genetic diseases through genome manipulation 
o Imparting the ability to express foreign proteins through the milk, or other body fluids, of 
animals such as sheep, goats, or cows 
o Synthesizing proteins, including human proteins, in the white of eggs produced by 
transgenic chickens 
o Using transgenic animals in research, such as transgenic mice or pigs that can be used as 
model systems for human medicine experiments 
o Producing organs and tissue for xenotransplantation via animals such as pigs. 
• Chimeric animals—“new” animals created to have useful traits through the combination, or “fusing 
together,” of multiple species. The commonly cited example is the “Geep,” a goat-sheep chimera 
produced in the United Kingdom by fusing embryo cells from a goat and a sheep. 
• Animal Cloning—creating identical copies of an animal, potentially one with ideal commercial 
characteristics, thereby removing variability from the livestock system and enhancing its economics. 
To some, these concepts may read like science fiction—but for the most part they are already realities in 
limited forms. Some examples serve to highlight the possibilities: 
• Genzyme Transgenics created a transgenic goat carrying a gene that produces BR-96, a monoclonal 
antibody useful for the delivery of conjugated anti-cancer drugs. 
• PPL Therapeutics generated a cow whose milk contains alpha-lactalbumin, a human protein that 
provides essential amino-acids. 
• Scottish scientists have created the first cloned mammal, a sheep (the famous, and now deceased, 
“Dolly”). 
• Australian scientists produced sheep that grow 30 percent faster than “natural” varieties. 
• Animal genes have been transferred into plants to impart positive characteristics, such as the transfer 
of the “antifreeze gene” from an arctic flounder into tomatoes, to increase cold stress tolerance. 
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There should be little doubt that research will continue to advance in transgenics, chimerics, and cloning. 
These new arenas of science show promise for generating significant benefits, such as the introduction of 
completely predictable meat animal quality, inexpensive modes of protein and other chemical expression 
via animal pathways, and greatly increasing the availability of organs and tissue for transplantation 
purposes. These are areas of R&D with very large revenue generation probabilities, and they are the 
subject of much bioscience and biotechnology research. However, societal unknowns may factor into the 
ultimate potential of these fields. European boycotts of transgenics, bans on cloning and stem cell 
research, and potential ethical and moral issues in animal use and genome manipulation may substantially 
affect progress. 
There remain many challenging scientific and technical issues related to advanced animal systems. The 
research and development opportunities available to Iowa institutions are significant. Much work can be 
done in the following: 
• Gene discovery—genomics, proteomics and metabolomics 
• Gene transfer and expression 
• The passing of transgenes to animal progeny 
• Cloning of various animal species 
• Novel combinations of chimeric animals for beneficial use 
• The study of animal retrovirus risks in xenotransplantation 
• Immune system modulation for xenotransplantation 
• Commercial livestock production practices for transgenic animals 
• Transgene risk evaluation and biosafety. 
Iowa has many of the required skills within its Regent universities. Key components are in place: 
The Center for Integrated Animal Genomics (CIAG) at Iowa State University—a center developing 
and using techniques in computational, molecular, and cell biology to improve animal and human health. 
CIAG is building on Iowa State’s existing strengths in animal and microbial genetics, bioinformatics, 
animal sciences, biotechnology, veterinary medicine, and the life sciences. CIAG expresses its goal as “to 
enhance the breadth of animal research activities at Iowa State University, increase basic and translational 
research, and foster economic development and growth in Iowa’s biotechnology industries.” CIAG 
predicts that potential outcomes of their work could include 
• Genetic improvements of livestock species 
• Development of designer animals for specialized animal products and improving human health 
• Improvements in food safety and the reduced use of antibiotics 
• Development of safe and effective vaccines and anti-microbial agents 
• Reduction of possible biotechnology threats through the food chain 
• Increased harmony of animal agriculture with Iowa’s natural resources. 
The Center currently brings together over 40 faculty from three colleges at Iowa State University to 
conduct animal systems and animal agriculture research. 
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Animal Sciences Department—Recognized throughout the world and highly regarded for its work in 
meat science, pork, beef, and poultry. The meat industry ranks Iowa State University number two in meat 
science, number one in pork processing technology, and number two in beef processing. ISU’s meat 
laboratory is 30,000 sq.ft. with comprehensive slaughter and processing capabilities. 
Animal Gene Transfer Facility—The facility provides a variety of services to scientists who wish to use 
transgenic animals in their research. The facility maintains equipment necessary for creating transgenic 
animals via microinjection or blastocyst injection procedures. 
College of Veterinary Medicine—the oldest public college of medicine in the country and home to a 
variety of animal health programs and research initiatives. 
Iowa State University also is highly active in whole genome sequencing projects, with active participation 
in the pig, cow, and chicken genome projects. This research leadership provides Iowa scientists with early 
stage insight into genetic characteristics and properties of these important species. 
Expertise in animal models, systems, and transgenics also is maintained at the University of Iowa, which 
operates the Transgenic Animal Facility as a component of the College of Medicine. The transgenics 
facility provides centralized instrumentation and expertise in the generation, breeding, and analysis of 
transgenic animals in support of research. The main goal of the facility is to generate and subsequently 
identify transgenic mice requested by research investigators at both the University of Iowa and Iowa State 
University. The Transgenic Animal Facility also provides a service in the rederival of transgenic strains 
from other institutions. Further investment in animal facilities is anticipated at the University of Iowa 
with major space being allocated within the new Carver Biomedical Research Building. 
Figure 30 illustrates the key linkages between quantitative and qualitative core competency disciplines 
and the animal systems platform. 
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Figure 30: Quantitative and Qualitative Core Competencies and Resulting Animal Systems Platform. 
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INTEGRATED BIOSECURITY PLATFORM 
The federal government is taking the threat of bioterrorism and the need for enhanced biosecurity 
extremely seriously. The events of September 11th, 2001, awakened the nation to the extreme cunning 
and viciousness of international terrorists. The World Trade Center attack leaves no doubt that al-Queda 
or other terrorist networks likely would have no hesitation in using any weapon of mass destruction 
(WMD) that fell into their hands; indeed, the CIA warns that the al-Queda network has made obtaining 
WMD capability a very high priority.26 
The threat comes from multiple potential weapons, including nuclear bombs, radiologic bombs, 
chemicals, and biological weapons. The threat is also to multiple potential targets including humans, 
livestock, and agricultural resources. While the threat of a nuclear bomb or chemical weapon must be 
taken seriously, many terrorism experts note the technical difficulties involved in acquiring, developing, 
transporting, and detonating/dispersing such weapons27—whereas, an individual with smallpox in the 
contagious phase can deliver a “bioweapon” simply by visiting crowded areas. 
Bioterrorism thus presents a very real danger for the United States and the federal government is acting 
swiftly to fund programs that may act to counter the threat. The threat is posed by multiple potential 
diseases and biological agents including 
• Anthrax 
• Botulism 
• Plague 
• Smallpox 
• Tularemia 
• Viral Hemorrhagic Fevers (Ebola, Yellow Fever, Rift Valley Fever, etc.) 
Compounding the threat of these known disease agents is the potential that genetic engineering 
technologies could be used to 
• Enhance/expand the transmission (infection) characteristics of the infectious agent 
• Increase an infectious agent’s resistance to known antidotes or antibiotics 
• Bioengineer new infectious agents through recombinant DNA technology. 
As noted above, humans do not have to be the target for terrorists to cause the “terror” of substantial 
economic and social disruption. Hence there is also a concern that food sources, either livestock or crops, 
could be targeted. The outbreak of foot and mouth disease in the United Kingdom caused tremendous 
economic and social damage, as did the later outbreak in Canada. A similar outbreak in the U.S. ranching 
community could be devastating. More distant as a threat, but still a potential, is the fact that if genes can 
be introduced to food crops to produce pharmaceuticals, so might they be introduced to produce toxins. 
                                                   
26
 Bowman, Steve. “Weapons of Mass Destruction: The Terrorist Threat”. Congressional Research Service Report for Congress. 
March 7, 2002. 
27
 Bowden, Ibid. 
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Iowa has relevant strengths in human and veterinary medicine and plant sciences related to the detection, 
diagnosis, treatment, and prevention of both natural and man-made biosecurity threats. As biotechnology 
and the BioEconomy move forward, the increasing convergence and integration of bioresources will be 
central to the U.S. economy. Biorenewable resources are likely to underpin increasingly large sectors of 
the economy, including, for example 
• Food production and processing 
• Drugs and biologics for human and animal health 
• Chemicals from plant resources 
• Biocomposite materials 
• Energy resources. 
The biotech century, as it has been called, will see dramatic advances in both traditional and non-
traditional applications of biomass and biological materials. As the U.S. economy builds upon this new 
science base and reaps significant economic opportunities from it, bioresources will be realized as 
inherently fragile and more susceptible than other economic sectors to severe damage through accidental 
or deliberate contamination, transgene pollution and terrorist acts. In a bio-driven economy, biosecurity 
is not only an issue of human health, it also is an issue of economic and societal structural security. 
Iowa, with its expertise in human and animal infectious diseases plus plant diseases, may be well 
placed to take a leadership role in the development of an integrated and holistic biosecurity 
approach. Iowa’s initial application to the federal government for the formation of a Biosecurity 
initiative was integrated inherently in that it emphasized lung and enteric diseases—leading causes of 
illness and death in both humans and domestic animals and livestock. Several of the diseases in which 
Iowa has expertise are zoonotic; that is, they are able to transfer from animals to humans or vice versa. 
With strengths in human, animal, and plant health sciences, Iowa may be able to leverage work in one 
field into others. Examples include 
• Devices invented for detecting bacteria and other pathogens in a human environment may be applied 
to detecting pathogens that may harm or destabilize an industrial bioprocessing operation or a 
livestock operation. 
• Approaches to detecting and decontaminating pathogens or toxins introduced to water system 
reservoirs may be adapted to monitoring agricultural irrigation water or industrial process waters to 
prevent the introduction of alien substances. 
• Approaches to infectious disease treatment in animals may be applied more rapidly than they can be 
in human trials; once proven effective, they can be accelerated into human trials. 
• Approaches to preventing transgene migration and pollution in agricultural crops may be applied to 
ornamental plants as well as into food animal gene expression. 
• Work in the expression of chemicals through plant pathways can be extended into the rapid 
production of vaccines and drugs, as required, through plants, and delivery via advanced food 
products. 
Iowa may be successful in developing a smaller biosecurity initiative based on respiratory diseases, 
but this opportunity could be expanded into an Institute for Integrated Biosecurity that would 
tackle the large-scale system issues in biosecurity such as the food chain, water supply and use, 
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industrial bioprocessing, zoonotic disease emergence and transmission, etc. To the extent possible, all 
three Iowa Regent universities should be engaged in this initiative. An Institute, shared and operated 
among all three universities, might begin by concentrating on one of the systems, then apply its learning 
and methodologies to others. The likely result would be a broad suite of potentially commercializable 
discoveries in areas such as the following: 
• Monitoring devices and sensors 
• Detection instrumentation and diagnostic tests 
• Security and monitoring software 
• Models and protocols for incident response and containment 
• Production and processing equipment designed to prevent tampering, alert to tampering, or facilitate 
decontamination 
• Decontamination equipment and protective equipment 
• Microbes bioengineered to conduct decontamination or provide signaling/monitoring 
• Vaccines and other therapeutic approaches to bioattacks or disease outbreaks 
• Consulting services in facility and systems design for biosecurity. 
Iowa already is making progress on biosecurity initiatives and associated planning. The University of 
Iowa, Iowa State University, and collaborating universities in Kansas have received a National Institute of 
Allergies and Infectious Diseases (NIAID) planning grant for a biodefense center. There also is major 
NIH support at The University of Iowa for research related to respiratory pathogens—agents of great 
concern in both human and animal biosecurity. 
Iowa’s positioning for integrated biodefense may be further facilitated by the extremely close relationship 
between the state’s hygienic laboratory and the state university system. The University Hygienic 
Laboratory (UHL) is located on the campus of The University of Iowa with considerable collaborations 
and areas of cooperation between the two institutions. The laboratory is particularly well-suited to work in 
integrated biosecurity since it works with both diseases and environmental issues. 
Figure 31 illustrates the key linkages between quantitative and qualitative core competency disciplines 
and the integrated biosecurity platform. 
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Figure 31: Quantitative and Qualitative Core Competencies and Resulting Integrated Biosecurity Platform. 
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LONGER-TERM BIOSCIENCE POTENTIALS FOR IOWA 
Battelle identified a number of potential technology platforms that represent longer-term bioscience sector 
development potentials. The identified opportunity areas mainly consist of relatively compact groups of 
people working in leading-edge fields, new formative centers just recently pulled together, or established 
areas of expertise in which investment in infrastructure and/or personnel are required to sustain or 
accelerate development momentum.  
Longer-term potential technology platforms include 
• Host-Parasite Biology and Systems –Both The University of Iowa and Iowa State University have 
initiatives that examine host-parasite/host-microbe interactions. This area of science was highlighted 
in its importance by the helicobacter link to human ulcers, but at Iowa’s institutions even more basic 
and exciting discoveries are being made. Work at The University of Iowa, for example, is demon-
strating substantial immunologic health benefits imparted to humans by helminths (a form of 
worm)—work that is showing significant promise for therapeutic approaches to a wide range of 
autoimmune system disorders such as Crohn’s disease, inflammatory bowel disease, and asthma. 
Other fundamental discoveries have been made regarding symbiotic relationships between plants and 
bacteria. Bacteria are being found expressed in plant seed and play an important role in the absorption 
of plant nutrients. Fundamental discoveries, such as the above two examples, may lead to multiple 
new clinical therapies and commercial opportunities. The creation of a Host-Parasite Institute at The 
University of Iowa, with links into plant and animal biology at Iowa State University, may be area for 
future attention and focus.  
• Instrumentation, Sensors and Devices—Iowa’s universities contain multiple academic departments 
and centers engaged in the development of instrumentation, sensors, and devices. These range from 
the development of high throughput gene sequencing equipment, to non-invasive optical sensors and 
diagnostic instruments, environmental monitoring systems, and invasive medical instrumentation and 
systems. Several faculty inventors of devices expressed that a clear model for facilitating research, 
development, prototyping, testing and commercialization of instruments, sensors, and devices does 
not yet exist. An opportunity may exist to create a more formal structure to facilitate interactions and 
collaborative projects within and between Iowa institutions, with programs in engineering, optics, 
materials science, clinical diagnostics, imaging, and human and veterinary surgery.  
• Cardiovascular Research Institute—The University of Iowa has a considerable track record in 
advanced cardiovascular research. Since 1971, the “Cardiovascular Center” at The University of Iowa 
has obtained $324 million in external grant funding (an average of $10 million per year) and this 
funding has led to fundamental discoveries and contributions to cardiovascular science and clinical 
practice by Iowa cardiovascular scientists in areas such as neuro control, lipids, imaging, free 
radicals, vector physiology, and ion channels. Despite the contributions made by the cardiovascular 
team at Iowa, the Center has not received the level of formal funding support to match leading centers 
in other states. An opportunity exists to strengthen the assembled team and promote increased 
progress and interaction through the establishment of a formal Cardiovascular Research Institute, with 
dedicated research and practice space similar to the Comprehensive Cancer Center at The University 
of Iowa. The benefits of developing a research institute include preventing erosion of faculty skills; 
attracting NIH funding (which is increasingly being steered to major “institutes”); enhancing and 
integrating the clinical program to become more engaged in translational and applied medicine; and 
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providing the laboratory and clinical resources required to attract top quality faculty into weaker areas 
such as cardiac surgery and catheterization. Testimony for the attractiveness of the concept is 
provided by the recent Reynolds Foundation grants for cardiovascular centers, in which Iowa was a 
finalist against other top centers in the country, but, ultimately lost the project in the last round, when 
two out of four finalists were funded. 
• Free Radical Institute—The University of Iowa is a leader in research on the health impacts of free 
radicals (atoms or molecules with at least one unpaired electron). Even without a concerted institu-
tional mission, The University of Iowa has grown to become the leading world location for free 
radical researchers and biologists. Iowa now has the first Ph.D.-granting degree program in free 
radical biology, and is incorporating free radical research into a broad range of medical fields 
including cancer, cardiac disease and vascular disease, hypertension, diabetes, premature birth, 
inflammation and infectious diseases, aging, neurodegenerative diseases, bone disease, and Lou 
Gehrig’s disease. Free radicals research is a relatively new field of study that employs basic science to 
lead to pragmatic clinical results. Iowa’s lead in free radical research may warrant preserving it with 
funding of a formal center with associated facilities. Indeed, other states have begun to see the oppor-
tunities and have funded formal free radical research centers in Alabama, Wisconsin, Oklahoma, and 
Georgia. As with the Cardiovascular Institute concept, a Free Radical Institute would facilitate 
interaction between multiple groups of researchers, provide access to core facilities, and more firmly 
root the existing base of researchers in Iowa for the future. 
Illustrations of the linkages between quantitative and qualitative core competencies and the additional 
opportunity areas listed above are provided in Figures 32 through 35. 
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Figure 32: Quantitative and Qualitative Core Competencies and Resulting Host-Parasite Biology and Systems 
Opportunity. 
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Figure 33: Quantitative and Qualitative Core Competencies and Resulting Instrumentation, Devices, and 
Sensors Opportunity Area. 
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Figure 34: Quantitative and Qualitative Core Competencies and Resulting Cardiovascular Research Institute 
Opportunity Area. 
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Figure 35: Quantitative and Qualitative Core Competencies and Resulting Free Radical Research Institute 
Opportunity Area. 
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MARKET ANALYSIS  
The ultimate goal for the State of Iowa in supporting the development of bioscience platforms is 
economic development. R&D, in and of itself, is economic development in that millions of dollars flow 
into Iowa each year from federal and other external funding sources to support research. These dollars, in 
turn, create jobs and income for Iowans in, and related to, the R&D sector. The goal of technology-based 
economic development, however, is to move into an integrated model where local research feeds a local 
commercialization and production cluster, thereby capturing increased value-added economic gains for 
the state from its R&D work. It is important, therefore, that the development of platforms be made with 
an eye to markets and commercialization opportunities related to each platform.  
In this section, Battelle examines basic market forces and trends related to each of the key Iowa 
bioscience platforms. 
Market Trends in the BioEconomy 
The BioEconomy has been recognized by Iowa within its Iowa Industries of the Future program. The 
opportunity to convert agricultural crops and residues into biobased products and bioenergy presents 
entirely new value-added pathways for agriculture and industry in Iowa. Much of the opportunity for 
Iowa in the field has been detailed in the October 2002 report titled “Biobased Products and Bioenergy 
Vision and Roadmap for Iowa.”28 This report outlines potential markets for Iowa’s biomass resources and 
sets realistic goals for progress. The BIOWA Development Association, an association composed of 
representatives from agriculture, industry and academe, has been formed to support and promote the 
growth and development of Iowa’s Bioeconomy, an important step forward in generating progress in the 
sector. 
Iowa is wise to pursue the opportunities presented in the BioEconomy. The Office of the Chief Economist 
at the USDA notes that biobased products potentially can compete in some truly huge markets.29 For 
example, 
• Lubricant sales is a $5.1 billion market 
• Composite materials are a $14.6 billion market 
• Paints and coatings represent a $43 billion market 
• Plastics have a $77 billion market. 
As the USDA notes, if the agricultural sector could capture between 5 and 10 percent of each of these 
markets, it would mean major gains in farm income and rural development in the United States. The 
above markets, of course, represent only part of a far larger opportunity for biorenewable resources in 
fuels and energy applications.  
Power consumption has risen steadily in the United States during the past 50 years. According to the U.S. 
DOE, in 2001, the nation consumed 96.94 quadrillion Btu’s of energy (approximately 18 times more than 
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 Iowa State University. “Biobased Products and Bioenergy Vision and Roadmap for Iowa.”  October, 2002.  
Available online at: http://www.ciras.iastate.edu/iof/pdf/IABioVisionRoadmap.pdf. 
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 Conway, Roger. “The USDA’s Contribution to the President’s Bioproduct and Bioenergy Initiative.”  Office of 
Energy Policy and New Uses.  Office of the Chief Economist at the United States Department of Agriculture.  
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consumed in 1950).30 Energy consumption is projected to increase substantially by 2025, to 
136.48 quadrillion Btu’s. Consumption in 2003 was 98.08 quadrillion Btu’s, of which only 
5.98 quadrillion Btu’s came from renewable energy sources (including biomass, hydroelectric power, 
solar power, wind power, and other renewable sources such as landfill gases and municipal wastes). 
Clearly there is a great opportunity, and national imperative, to reduce reliance on imported energy 
sources, which in 2003, was 30.53 quadrillion Btu’s (over 25 quadrillion Btu’s comprising crude oil and 
petroleum products). 
Thirty-six percent of total energy consumption in the United States is used for manufacturing and other 
industrial purposes, 27 percent for operating the nation’s transportation system, 20 percent for powering 
homes, and 16 percent for general businesses. Of all the oil consumed in the world in 1999, the United 
States accounted for 25.5 percent, according to the DOE. The powerful U.S. economy depends 
disproportionately on energy consumption, with the United States consuming 
• 25.5 percent of world oil 
• 26.9 percent of world natural gas 
• 25.5 percent of world coal 
• 30.4 percent of world nuclear energy.  
The amount of power mined from fossil fuel sources in the United States is enormous, yet it is not enough 
to satisfy U.S. energy demand. For example, in 2000, Americans consumed 27.2 quadrillion more Btu’s 
of fossil fuels than the United States produced. Crude oil, used for gasoline, diesel fuel, and a host of 
other products, is the most common form of energy imported into this country. Moreover, while energy 
demand is increasing in the United States, it also is projected to grow significantly throughout the world. 
The DOE’s International Energy Outlook 2001 projects an increase in world energy consumption of 
59 percent by 2020 (with much of the increase in demand occurring in developing nations).31 
Eventually, the world’s fossil fuels will run out, but before that happens the demand and supply curves 
will cross and price increases will force alternative energy sources to become more prominent. When 
these events will happen is the subject of considerable economic debate, but it eventually will happen and 
those economies that can supply renewable energy resources and technologies will be well-positioned for 
economic growth. 
Freedonia Group foresees U.S. demand for fermentation chemicals to surpass $9 billion in 2007, with 
volume exceeding 30 billion pounds.32 In terms of value and volume, the bulk of fermentation products is 
composed of ethanol for fuel usage, with production driven by environmental regulation, tax incentives, 
and the future ban on MTBE. While fuel is expected to remain the largest market segment for chemical 
fermentation products, other areas of bio-fermentation are also expected to grow: 
• 1,3-propanediol (PDO) is an emerging new fermentation product for plastics and fibers 
• Demand for Erythritol, a fermentation chemical used as an artificial sweetener in foods and beverage, 
is also expected to grow 
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 U.S. Department of Energy. “Energy Consumption by Sector and Source.”  Available online at: 
http://www.eia.doe.gov/oiaf/aeo/pdf/aeotab_2.pdf. 
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 Energy Information Administration (EIA). “Annual Energy Outlook 2001.” DOE/EIA-0383(2001) (Washington, 
DC, December 2000). 
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 Freedonia Group.  “Fermentation Chemicals to 2007 - Market Size, Market Share, Demand Forecast and Sales.”  
Study #: 1662.  May, 2003. 
 Iowa Bioscience Path for Development 
 
 
120 
• Fermentation-based lactic acid (a primary feedstock) production is expected to grow with the rise in 
demand for polylactic acid-based biopolymer manufacturing 
• Plastics and fibers are also predicted to experience double digit rapid growth through 2007 
• Polylactic acid polymers reached the market in 2002, and POD polymers are forecasted to reach 
commercialization by 2007 
• Natural polymer demand in the United States will grow by 6.4 percent annually through 2005.  
According to the United Nations, the impact of the BioEconomy will increase in forthcoming years, 
spreading from the farm to the manufacturing sector.33 Many of the products we currently touch, wear, 
and see are already produced, in one way or another, using biotechnology-derived reagents. The 
development of genetic engineering and recombinant DNA technology will lead to higher levels of 
productivity and economic viability. 
The benefits of assuming leadership in the BioEconomy may be substantial for Iowa. According to the 
Institute for Decision Making at the University of Northern Iowa, a cluster of 10 biorefineries in the state 
would create 22,000 jobs, have an $11.6 billion economic impact, and generate $367 million in taxes.34 
These statistics are reinforced by the conclusions of BioEconomy Partners in New York, who found that 
one bioeconomy development initiative in California created more than 13,000 jobs, commercialized 250 
new products, and led to the start-up of 45 new companies within a 5-year period.35  
Market Trends in Advanced Food Products (Functional Foods and Nutriceuticals) 
According to Decision Resources Market Research, by almost every measure, the markets for functional 
foods (defined as disease-fighting, whole or processed food products) and nutraceuticals (defined as 
bioactive ingredients and dietary supplements) are flourishing.36 National Health Interview surveys show 
that retail sales of dietary supplements in the United States exceeded $10 billion in 1996, and consump-
tion grew from 71 million users ten years ago to between 94 million and 130 million users by the close of 
the century.37 Functional foods are far outpacing growth in the total food market; with nutritionally 
improved products accounting for 78 percent of total growth in more than 35 major food categories, 
according to Decision Resources Market Research. 
Fry Foods International estimates the total market for functional foods in Japan, the United States, and 
Europe at approximately $38 billion.38 Growth over the next five years has been estimated conservatively 
at 15 percent annually, while some predict the market will double. Functional foods is currently the 
largest growth area in the food industry. 
The U.S. market for functional foods is still developing and also is evolving in a different way from 
Europe and Asia. Of particular interest are products that may improve the functioning of the immune 
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Biotechnology in Developing Countries.”  Ad Hoc Expert Group Meeting.  Palais de Nations, Geneva.  November, 
2001. 
34
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system, reduce cancer risks, or help prevent cardiovascular disease and lower cholesterol. Consumer 
interest has been growing in botanical or herbal fortified beverages, including green-tea-based beverages. 
Sales of vitamin and mineral fortified juices (primarily vitamins E and calcium) also have grown. Addi-
tionally, soybean products, including soy milk, have increased in popularity, due to perceived health 
benefits. Sales of fiber- and vitamin-fortified food products, such as cereals, have grown, particularly 
those with reduced fat content. The U.S. market for dairy products containing probiotics has not grown or 
expanded as in other parts of the world. Broadly interpreted, the U.S. market for functional foods is 
currently estimated at $15 billion. 
Similar figures are put forth by Sloan Trends and Solutions in Food Technology.39 They identified the 
world market for functional foods as $47.6 billion (having grown from $30 billion in 1995). The U.S. 
component of the functional foods market is estimated at $18.25 billion. The largest product subsector in 
functional foods is beverages, followed by breads/grains, prepared foods, dairy, snacks, and condiments. 
Sloan Trends and Solutions identified the following top trends in functional foods: 
1. Increasing nutrient and specialty foods fortification 
2. Marketing for specific physical conditions 
3. Lifestyle enhancing products, as in energy, immunity, and mental performance 
4. Crossover products from sports nutrition 
5. Children’s health 
6. Marketing toward gender, age, and ethnicity 
7. Weight reduction, satiety, and appetite suppression 
8. Functional snacks 
9. Natural ingredients such as those containing essential fatty acids, herbals, and probiotics 
10. Nontraditional food markets, including eye health, oral health, and the medical foods market. 
One of the most innovative sectors in the rapidly growing functional foods market is the so-called 
“performance” functional foods that affect mood and mental and physical performance. An important 
issue in ensuring long-term growth in this sector is to consolidate research on the complex links between 
nutrition and functional ingredients such as herbs, mood and cognitive performance (an area in which 
both Iowa State University and The University of Iowa are researching). Scientists are finding inter-
actions between food, stress and mood, looking, for example, at the role of carbohydrates. Bioscience 
researchers are examining the impact of a number of nutrients and herbal ingredients on mood and 
cognitive performance, including herbs such as St. John’s wort and kava kava.  
The global nutraceutical market grew by 7 percent annually between 1999 and 2002, increasing from 
$38.2 billion to $46.7 billion. Between 2002 and 2007, researchers anticipate that the nutraceuticals 
market may increase an average of 9.9 percent annually, reaching $74.7 billion by 2007 (BCC March 
200340).  
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• Herbal and non-herbal extracts are expected to provide the strongest growth opportunities 
• Nutrients and functional food additives will generate above-average growth and sustain new product 
developments, expanding end-use applications. Soy and fiber compounds for liquid meal substitutes, 
energy drinks, sport beverages, and fortified foods will be among the fastest growing segments within 
the nutrients market. 
• Minerals and vitamins will generate slower growth in nutraceutical applications due to expected 
pricing competition. (Freedonia June 200241) 
The U.S. and European probiotics markets are expected to grow rapidly in coming years despite 
widespread consumer ignorance about what probiotics are and how they can benefit the human body, 
according to a Frost & Sullivan report.42 Probiotics are “friendly” bacteria that contribute to the health of 
the intestinal tract and, as such, link the advanced foods products platform and the host-parasite biology 
and systems sub-platform Battelle recommends. Frost & Sullivan estimate the U.S. market will reach 
$400 million by 2010 from a current level of $144 million. In the same period, European sales will more 
than triple, from $40 million to $138 million.  
Foods that are simply genetically modified (GM), rather than functional or nutraceutical, are already a 
staple in the American diet. According to RocSearch, 60 percent of all processed foods in U.S. grocery 
stores contain GM ingredients from corn, soy, or canola.43 In 2002, the GM food market was worth 
approximately $60 billion, according to Research and Consultancy Outsourcing Services.44 GM foods are 
forecasted to grow by 7 to 8 percent by 2010, versus 1 to 3 percent growth for conventional foods; but, 
this growth will very much depend on consumer acceptance. 
Market Trends in Animal Systems 
Under the Animal Systems platform, Battelle envisions opportunities for Iowa from multiple applications: 
• Marketable model animal systems and transgenic animal bioreactors 
• Cloning and transgenic animal production systems 
• Molecular farming—using livestock to produce medicines, nutraceuticals, and tissues for 
xenotransplantation purposes 
• Transgenic animals with enhanced production characteristics, such as increased meat or fiber yield. 
Transgenic animals, also called bioreactors, allow the effects of various factors on a gene’s function to be 
tested in a whole animal rather than merely in a test tube or cell. By inserting human DNA into an animal 
such as a mouse, medical researchers learn important information that may help them in their efforts to 
conquer human disease. 
According to Drug and Market Development, the use of transgenic animals in models of human disease 
has never been greater.45 In the United Kingdom, the use of transgenic animals increased by 27 percent in 
                                                   
41
 Freedonia Group.  “Fermentation Chemicals to 2007 - Market Size, Market Share, Demand Forecast and Sales.”  
Study #: 1662.  May, 2003. 
42
 Frost & Sullivan.  “Probiotics Manufacturers Battle Low Consumer Awareness; Raising Consumer Education is 
Priority.”  October, 2003. 
43
 RocSearch.  “Genetically Modified Food:  Markets, Issues and Implications.”  January, 2003. 
44
 Research and Consultancy Outsourcing Services.  http://www.rncos.com/research.htm. 
45
 Drug and Market Development Publishing.  “Transgenic Animals—Market Opportunities Now a Reality.”  
October, 1999. 
 Iowa Bioscience Path for Development 
 
 
123 
1998, representing 17 percent of all animal experiments, and leading to the first increase in total animal 
usage since 1976. Many diseases and disorders with a high level of unmet need can be treated success-
fully with drugs created from transgenic animals. The world market for recombinant proteins has been 
estimated at $12.8 billion in 1998, and the world market for antibodies exceeded $1 billion in 1998. 
Transgenic protein production offers significant economic and technological advantages over traditional 
methods of protein production; therefore, the market is highly likely to experience substantial growth. 
Advantages include reducing capital expenditures, lowered direct production cost per unit, and reducing 
the risk of transmission of human viruses and other adventitious agents (Drug and Market Development). 
For some drugs, a herd of 600 transgenic animals potentially could supply worldwide demand. Although 
laboratory manipulation of genes in animals, plants, and bacteria accounted for less than one percent of 
world supply of human therapeutic proteins in 1998, that one percent was valued at $12 billion, or 
50 percent of a then $24 billion global market for human proteins. 
As the number of transgenic and cloned transgenic animals increases, it is likely that the numbers of 
proteins that can be produced in animals also will increase as the cost of creating the initial founder 
animals decreases. The cloning of sheep, mice, goats and cows likely will allow companies to expand 
their production herds for transgenic therapeutics even faster, while reducing cost.  
Global demand continues to grow for human proteins and vaccines. These proteins serve numerous 
therapeutic purposes, such as treatments for cystic fibrosis, hemophilia, osteoporosis, arthritis, malaria, 
and HIV. Transgenic animals also can produce monoclonal antibodies (antibodies specifically targeted 
towards disease proteins) that are used in vaccine development. 
Transgenic animals are costly to produce and they have high value. The cost of making one transgenic 
animal ranges from $20,000 to $300,000, and only a small portion of attempts succeed in producing a 
transgenic animal. A Wisconsin firm that clones transgenic calves for human pharmaceutical production, 
however, estimated that one transgenic animal can produce, in its lifetime, $200 to $300 million worth of 
pharmaceuticals.46  
In addition to the enhancement of therapeutics, transgenic animals provide opportunity in other areas:  
• increased meat and dairy production  
• increased wool/fiber production  
• improved aquaculture production  
• increased availability of organs for transplantation. 
Public opinion and regulatory concerns are likely to impose initial limitations on the growth of the animal 
transgenics market. Many ethical issues are associated with genetically engineered foods and animals, 
with food safety being perhaps the most obvious area of potential impact from genetic engineering as it 
affects agricultural animals. In addition, xenotransplantation causes concern and uneasiness for many 
individuals and there are potential risks to the public from cross-over infections from animals to humans 
(zoonotic diseases). The history of science, however, is one in which the “genie is rarely returned to the 
bottle”—so rather than stopping bioscience progress through transgenics, public and regulatory concerns 
are more likely to simply slow progress. 
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Market Trends in Biosecurity 
The biosecurity threat comes from multiple potential weapons, including nuclear bombs, radiologic 
bombs, and chemical and biological weapons and diseases. Multiple potential targets are threatened, 
including humans, livestock, and agricultural resources. While the threat of a nuclear bomb or chemical 
weapon must be taken seriously, many terrorism experts note the technical difficulties involved in 
acquiring, developing, transporting, and detonating/dispersing such weapons—whereas an individual with 
smallpox in the contagious phase can deliver a “bio-weapon” simply by visiting crowded areas. Bio-
terrorism thus presents a very real danger for the United States and the federal government is acting 
swiftly to fund programs that may act to counter the threat. The threat is posed by multiple potential 
diseases and biological agents including the following: 
• Anthrax 
• Botulism 
• Plague 
• Smallpox 
• Tularemia 
• Viral Hemorrhagic Fevers (Ebola, Yellow Fever, Rift Valley Fever, etc.). 
Compounding the threat of these known disease agents is the potential that genetic engineering 
technologies could be used to 
• Enhance/expand the transmission (infection) characteristics of the infectious agent 
• Increase an infectious agent’s resistance to known antidotes or antibiotics 
• Bioengineer new infectious agents through recombinant DNA technology. 
As noted above, humans do not have to be the target for terrorists to cause substantial economic and 
social disruption. Hence there also is a concern that food sources, either livestock or crops, could be 
targeted. The outbreak of foot and mouth disease in the U.K. caused tremendous economic and social 
damage; a similar outbreak in the United States ranching community could be devastating. More distant 
as a threat, but still a potential, is the fact that if genes can be introduced to food crops to produce 
pharmaceuticals, so could genes be introduced to produce toxins.  
Because of the breadth of bioweapon threats, the federal government is funding multiple counter 
terrorism initiatives. States also are spending money preparing for biosecurity threats and incidents. 
Homeland security thus represents a rapidly expanding market for a host of technologies in detection, 
prevention, preparation, treatment, and decontamination. The total homeland security market is estimated 
by Richard K. Miller & Associates to approach $100 billion.47 The component of homeland security that 
comprises biosecurity initiatives is significant. Front Line Strategic Consulting estimates biodefense 
spending at $6 billion in 2003, and the NIH, CDC, DOD, and other federal agencies are budgeting several 
billion dollars for research and development programs.48 
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According to the Department of Homeland Security, since September 11, 2001, the Bush Administration 
has spent or budgeted $12.9 billion to prepare and protect the nation from a bioterror attack, including 
$5.2 billion in the Fiscal Year 2004 budget.49 This is 15 times the $305 million spent in Fiscal Year 2001. 
President Bush’s Fiscal Year 2005 budget request includes a $274 million Bio-Surveillance Program 
Initiative designed to protect the nation against bioterrorism and to strengthen the public health infra-
structure.50 The initiative will enhance ongoing surveillance programs in areas such as human health, 
hospital preparedness, state and local preparedness, vaccine research and procurement, animal health, 
food and agriculture safety, and environmental monitoring and integrate those efforts into one compre-
hensive system. The integration is an important point, since bio-attacks have implications across multiple 
interrelated systems (e.g., plant toxicity, water contamination, food animal contamination, and human 
infection in a connected system). 
Agrosecurity is an important component of the nation’s overall biosecurity. “Agrosecurity” is a term 
that was coined to address issues related to the vulnerability of the United States’ food and fiber system to 
acts of terrorism. Agrosecurity issues are focused on gaining a better understanding of the nature of 
potential threats to plant and animal production, marketing, and processing. In responding to these threats, 
the United States needs to continue developing resistant varieties of plants and animals, pesticides, as well 
as comprehensive educational programs. Iowa State University is a key component of biosecurity for the 
State of Iowa with scientists examining the growth, development, and transportation of plant and animal 
diseases and pathogens.  
The defense appropriations act, signed in January, provided an additional $328 million in USDA funding 
for homeland security.51 The USDA proposed $2.37 billion in the fiscal year 2003 budget to fight 
sabotage and protect the nation’s food supply from plant and animal disease, a $146 million increase in 
the budget. A $48 million increase was sought for animal health monitoring by the department’s Animal 
and Plant Health Inspection Service. An additional $19 million will go to support agricultural quarantine 
inspection programs, which will provide additional inspectors, canine teams, and high definition X-ray 
machines at high-risk ports of entry. 
Market Trends in Drug Discovery, Development, and Production 
In 2000, according to IMS Health, the worldwide pharmaceutical market was valued at $317 billion and 
projected to grow to $3 trillion by 2020.52 Capturing only a fraction of a percent of such a huge market 
can still amount to a major economic gain at a state level. 
Traditional drug production focuses on small molecule, chemical agents. This is a mature market in which 
pharmaceutical companies have excellent core competencies. Nevertheless, there is major restructuring 
underway based on the need by drug companies to reduce costs and become more efficient. Contract drug 
development services are growing strongly, involving clinical evaluations of drug safety, drug disposi-
tion, drug evaluation, and toxicology studies that reach above $4 billion, as well as contract manufactur-
ing efforts amounting to more than $12 billion. Among the contract services/outsourcing companies 
serving the pharmaceutical industry highlighted by Contract Pharma—the industry’s trade organization—
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were those located in San Antonio (TX), Albany (NY), Canada, Baltimore (MD) and Puerto Rico.53 The 
University of Iowa already is a well-established contract formulation and drug production provider. 
Other key market niches arising from traditional small-molecule chemical agent pharmaceuticals 
industries involve efforts to identify novel chemical agents. A particular source of novel chemical agents 
are natural product chemicals derived from plants. This market is expected to grow by more than 9 per-
cent annually and reach nearly $4.5 billion by 2008. Natural product chemicals not only are important for 
new pharmaceutical chemical agents, but also for herbal supplements and nutraceuticals, which bring 
health benefits through diet (see the advanced food products market assessment).  
Advances in biotechnology research has resulted in a growing number of new drug therapies produced by 
live, genetically modified microbial or animal cells, referred to as biologics. Genetic Engineering News 
(August 2002) reports that the current total pharmaceuticals market is $390 billion, of which biologics 
represents 7 percent.54 By 2006, the total pharmaceuticals market is expected to increase to $550 billion, 
of which biologics will account for $70 billion—implying a growth rate for biologics of 15 to 20 percent 
per annum. Moreover, approximately one-third of the entire new drug pipeline is composed of biologics. 
The manufacturing of biologics involves complex and expensive scale-up manufacturing processes and 
requires years of construction. The complexity and expense derives from the need to express the protein; 
purify cell lines; fill, label, and package; and maintain quality control over a very lengthy process. 
Currently the processing of biologics is much less efficient than that of traditional small-molecule agent 
drugs. Also, scaling up biologics production often requires significant process changes from earlier 
production of small quantities of the biologics used in research and development efforts. The capabilities 
at the University of Iowa in GMP biologics production, in addition to a major planned biologics 
production facility at Iowa State University, will give the state particular strength in this field. 
Freedonia predicts that U.S. demand for biologics will advance almost 12 percent annually to more than 
$56 billion in 2006.55 New product introductions evolving from advances in recombinant DNA and 
monoclonal antibodies will stimulate growth. Demand for applications in the treatment, prevention, and 
diagnosis of complex viral, malignant, and autoimmune disorders is expected to see the strongest gain as 
a result of the safety and performance shortcomings of available conventional products. Recombinant 
proteins are projected to remain the top-selling group of biologic products through 2006. Expanding 
knowledge and understanding of human genomics and proteomics likely will lead to a wealth of new 
disease targets as well as discovering in vivo substances with potential commercial value. Broad 
adaptation to protein production, coupled with safety and efficacy advantages over conventional 
preparations, will boost the range of therapeutic applications served by recombinant DNA technology. 
However, competition from small-molecule drugs developed through combinatorial chemistry and related 
methods will decelerate growth in overall demand for recombinant protein producers.  
Freedonia further predicts that sales of monoclonal antibody products will increase the most among all 
biologics through 2006, and that because of advances in recombinant proteins and monoclonal antibodies, 
                                                   
53
 Contract Pharma.  “Top Contract Service and Outsourcing Companies.”  
http://www.contractpharma.com/aug001.htm. 
54
 Genetic Engineering News.  “Biopharmaceutical Manufacturing.” August 1, 2002.  Available online at: 
http://www.genengnews.com/backissues/backissue.asp?issue_id=22&criterias=august,%202002. 
55
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November, 2002. 
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conventional biologics will provide below average growth opportunities.56 Conventional vaccines based 
on live and inactivated viruses may provide the best sales prospects, reflecting trends promoting greater 
preventive medicine activities. By contrast, competition from recombinant DNA and monoclonal 
antibody products will weaken the market potential of whole blood, plasma derivatives, and semisynthetic 
protein drugs.  
Hospitals, ambulatory health facilities, and pharmacies will likely comprise the largest markets for 
biologics as the treatment of complex diseases and disorders remains the leading application served by 
these products. 
Key industry analysts expect a serious mismatch between who controls capacity to produce biologic-
based pharmaceuticals and who needs the capacity. An analysis by USBancorp Piper Jaffray estimates 
that four biopharmaceutical companies—Amgen, Biogen, Boehringer-Ingelheim, and Genentech—will 
control more than half of the world’s biologics production by mid-decade.57 This leads USBancorp Piper 
Jaffray to conclude: “our analysis showing that there will be excess capacity does NOT imply that 
specific companies will not be left without production capacity for their products … the bulk of the 
manufacturing capacity will be a handful of companies, most of which are NOT contract manufacturers.” 
The August 2002 issue of Genetic Engineering reinforces the concern about access by quoting the Chief 
Manufacturing Officer of Applied Molecular Evolution based in San Diego: “There appears to be lots of 
capacity at larger companies, but production space is in short supply at smaller companies, where the 
action is and at contract manufacturers.”58 
Market Trends in Post-Genomic Medicine 
Increasingly, the tools of biotechnology are incorporating advanced computer-aided modeling, 
algorithms, statistical analysis, and pattern discovery to understand the structure and function of genes 
and proteins and to identify new potential targets of intervention for diseases. In addition, biotechnology 
is advancing the ability to design medications based on an individual’s genetic makeup rather than on 
educated guesses or trial and error. This genetic-enabled approach to medical care is technically referred 
to as pharmacogenetics or pharmacogenomics, and more popularly known as personalized or individual-
ized medicine. Frost and Sullivan, a leading market research firm, sees pharmacogenomics as having the 
potential to revolutionize gene-based diagnostics, helping that market grow by $3.5 billion by 2005.59 The 
combined revenues for pharmacogenetic services and gene-based diagnostics could reach nearly 
$6 billion.  
Reuters Business Insight performed recent research on the post-genomic medicine market and found that 
• Small-molecule drug discovery increasingly is being driven by functional proteomics and the focus 
has shifted to targeting intracellular gene regulating proteins and disrupting protein pathways. Early 
target validation has become a key priority and many different approaches are being explored.  
• Current approaches to increasing the efficiency of drug discovery include integrated use of 
technologies, especially chemical genomics, SNP scoring, rational drug design, early detection of 
drug toxicity, and bioinformatics.  
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• The dominance of small-molecule drugs in the marketplace will be challenged by promising 
emerging biotherapies, which include antisense therapies and gene therapies.  
• Theranostic tests, which predict drug response in individual patients, already are finding applications 
in many therapeutic areas, including infectious disease, cancer, and cardiovascular disease.60 
Reuters further notes that 
• Proteomics and other post-genomic technologies may revolutionize small molecule drug discovery.  
• The successful integration of post-genomic technologies will be essential for small-molecule drug 
discovery to reach its fullest potential.  
• Novel biotherapies could challenge the traditional dominance of small molecule drugs.  
• Predictive diagnostics hold the key to preventive medicine.  
• Closer linking of diagnostics and therapeutics will transform personalized medicine.61 
According to Fuji-Keisai Corporation, proteomics is projected to grow from a $565 million market in 
2001 to more than $3.3 billion in 2006.62 This represents an average annual growth rate of over 
40 percent. The fastest growing segment of the proteomics market is the protein chip segment that is 
expected to increase from $65.7 million in 2001 to more than $723 million in 2006. This represents an 
11-fold increase in market size in a six-year period and an average annual growth rate approaching 
62 percent. Demand for proteomics services is expected to be strong throughout this time period with an 
average annual growth rate of over 50 percent. The rate of growth in this market segment is expected to 
slow after 2004 when next generation proteomics platforms are introduced. The proteomics platform 
market segment will remain the largest with a growth from $311 million in 2001 to approximately 
$1.7 billion in 2006.  
Following the release of the first full draft of the human genome, the spotlight in biomedical research is 
shifting from genomics to proteomics as the key technology to transform information into pharmaceutical 
products. The need to improve the speed and efficiency of drug discovery is the primary driver of 
proteomics. Current step-wise screening and chemical optimization methods are both time-consuming 
(averaging 10 to 12 years from discovery to market) and expensive (estimated costs range from 
$500 million to $750 million). In addition, there is a high rate of failure in the clinical trials process due to 
toxicity or low efficacy of selected drug targets resulting in an increased interest in identification of 
biomarkers suitable to use in therapeutic planning and individualized medicine. It is hoped that both the 
rate of drug development and the rate of discovery of novel, informative biomarkers will dramatically 
improve using emerging proteomics platforms.  
Drug and Market Development notes that post-genomic medicine is being driven by new technologies 
and scientific insight that provide 
• Fundamental new ways to understand the molecular pathology of disease  
• Identification of genes associated with complex diseases for discovering new therapeutic targets  
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• Validation of genetic markers for predicting the risk of disease susceptibility, differential diagnosis, 
and monitoring therapeutic progress  
• Use of genetic markers to select optimal drugs and doses for individual patients and reduce individual 
therapeutic experimentation  
• Examination of natural genetic variation between and within populations and its impact on health and 
disease.63 
Other states and universities are taking note. The University of Minnesota and the Mayo Clinic recently 
announced a state-funded collaboration called the Minnesota Partnership for Biotechnology and Medical 
Genomics—a project designed to further enhance and leverage the more than $400 million already spent 
at the two institutions in genomics. Indeed, the Minnesota Partnership states that “medical genomic 
solutions will rank among the most important scientific breakthroughs in history.” Ohio and The Ohio 
State University are likewise placing an emphasis on post-genomic medicine and in defining the scope of 
the OSU Program in Pharmacogenomics they considered the following assumptions and predictions: 
• Numerous new drug targets (genes and their encoded proteins) will lead to a wave of drug discovery, 
exploiting the availability of genomic sequences of multiple organisms. Yet, the number of human 
genes that can serve as suitable drug targets for treating complex diseases is limited. Moreover, 
biological complexity is likely to limit therapeutic success when treating with drugs aimed at specific 
targets. Most of the major diseases and chronic illness of old age are complex multigenic disorders. 
Therefore, new drug discovery alone is insufficient to optimize future therapy. 
• Genetic variability among individuals will emerge as a major determinant of a patient’s response to 
drug therapy. Use of genetic information promotes individualized therapy, if applied together with 
conventional clinical data. 
• The outcome of drug therapy in an individual patient is likely to depend at least in part on genetic 
variations in multiple relevant genes. These include those that encode proteins in direct contact with 
the drug (transporters, metabolizing enzymes, receptors, and target enzymes), genes encoding 
proteins downstream in drug signaling pathways or metabolic cascades, and lastly, disease 
susceptibility genes. 
• Over the coming decade, we will learn about numerous variant genes predisposing an individual 
disease. Frequently, the same disease phenotype (e.g., hypertension) is associated with distinct 
genetic variant profiles as the underlying cause—each profile potentially requiring a different type of 
drug therapy. Moreover, recognition of disease susceptibility genes will permit early treatment or 
even prevention of disease, requiring novel but potentially much more effective therapeutic strategies. 
• Computational biology will permit the modeling of complex systems, eventually leading to prediction 
of drug effects in vivo. 
• Vast databases on biomedical, genetic, and clinical information will become broadly accessible, 
requiring an informatics approach for optimizing drug therapy. This information must be further 
digested so as to become accessible to health care practitioners and patients alike. 
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Tripp Umbach Healthcare Consulting, Inc. has examined the numerous paths by which post-genomic 
science may affect a revolution in medicine.64 The paths show the substantial market changes in medicine 
and healthcare delivery likely to result from genomics, proteomics, and associated sciences. Some of the 
most notable predictions are for 
• Pharmacogenomics—Drug treatments will be tailored to fit the precise genetic makeup of individual 
patients. In effect, this will start to shut down the “one size fits all” therapeutics. An individual’s 
enzyme function affects his or her response to drugs and drug dosage. Future advances will allow 
rapid testing of the patient’s genotype such that drug type and dosage can be customized to the 
individual. How important is this? Currently, more than 100,000 deaths, and more than 2.2 million 
serious complications, are caused by adverse reactions to medications. In addition, millions of people 
likely receive little benefit at all from their prescribed medications because the drug or its dosage does 
not fit their genotype. Pharmacogenomics will drastically increase the effectiveness of prescribed 
medication and greatly reduce hospitalizations caused by adverse drug reactions. 
• Drug Development—Most drugs today are based on about 500 molecular targets. Knowledge of the 
genes involved in diseases, disease pathways, and drug response sites may lead to the discovery of 
thousands of new targets. Hundreds of new drugs will emerge, aimed at specific sites in the body and 
at particular biochemical events leading to disease. Through enhanced targeting, these drugs will be 
more effective than today’s “general population” drugs, and they will cause fewer side effects. 
• Genetic Tests—Genetic tests already are in use and have been among the first applications of genetic 
discoveries. Tests can be used to diagnose disease, confirm diagnoses, provide prognostic information 
about the course of a disease, confirm the existence of a disease in asymptomatic individuals, and 
predict the risk of future disease in healthy individuals and their blood relatives. Several hundred 
genetic tests are already in clinical use and the introduction of new and more effective tests is 
expected to escalate rapidly. 
• Gene Therapy—Genes themselves may be used to treat disease or enhance genetic traits that can 
help fight or ward off disease. Through gene therapy, normal genes may be introduced to replace 
defective genes or to bolster normal functions, such as immunity. This field, therefore, has the 
potential to deliver effective therapies for genetic acquired diseases such as cancers and AIDS. While 
gene therapy is still a new and emergent field, in 2001, more than 500 clinical trials were already 
underway worldwide (with 78 percent based in the United States). 
The prospects for bioinformatics are inseparable from the prospects and market structure of biotech. 
Bioinformatics plays a key role in functionalities such as gathering, storing, classifying, analyzing, and 
distributing biological information derived from sequencing and functional analysis. It is the application 
of bioinformatics and informatics applications that leads to the potential to drive growth in the worldwide 
pharmaceuticals drug market from the $240 billion today to $3 trillion by 2020.  
It is clear that each of the major recommended Iowa platforms operate in sectors with large scale 
market opportunities. As the State moves forwards in its bioscience planning and strategy 
development, further market investigation should be performed. 
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SUMMARY OF IOWA’S BIOSCIENCE TECHNOLOGY PLATFORM OPPORTUNITIES 
Table 51 provides a summary of the six near-term, major technology platforms and the four longer-term/ 
niche emerging opportunity areas upon which to build Iowa’s bioscience base. As shown in Table 51, 
each of the six technology platforms and four emerging opportunity areas are derived from the state’s 
foundational strengths in basic research areas enhanced through specific enabling technologies and 
applied research. Each platform and opportunity area is then more fully defined and described through a 
brief summary of technology-based applications and examples of products that may stem from the 
research efforts. Finally, through the market analysis task, specific markets are linked to these platforms 
and opportunity areas—markets that are able to take advantage of these new products and spur the 
development of additional applications. 
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ar
s,
 fo
re
ca
st
s 
ha
ve
 b
ee
n
 to
ne
d 
do
wn
 (R
e
se
a
rc
h 
& 
Co
n
su
lta
n
cy
 O
ut
So
u
rc
in
g 
Sv
cs
, 
Fe
br
u
ar
y 
20
03
). 
•
 
In
 2
00
2 
G
M
 
fo
od
 
m
a
rk
e
t w
a
s 
w
o
rth
 a
pp
ro
xi
m
a
te
ly 
$6
0 b
illi
o
n
 (R
e
se
ar
ch
 &
 
Co
ns
ul
ta
n
cy
 O
ut
So
ur
ci
n
g 
Sv
cs
, F
e
br
u
a
ry
 2
00
3).
 
•
 
Th
e 
gl
o
ba
l n
u
tra
ce
u
tic
al
 
m
a
rk
et
 g
re
w 
a
t a
n 
a
nn
u
a
l r
a
te
 
o
f 7
%
 
be
tw
e
e
n
 1
99
9 
a
n
d 
20
02
 
in
cr
e
a
sin
g 
fro
m
 
$3
8.2
 bi
llio
n
 to
 
$4
6.7
 b
illi
o
n.
 
Be
tw
e
e
n
 2
00
2-
20
07
 
n
u
tra
ce
ut
ic
al
s 
a
re
 
pr
ed
ic
te
d 
to
 g
ro
w 
by
 a
n 
av
er
a
ge
 a
nn
u
al
 
ra
te
 o
f 9
.9
%
,
 
re
a
ch
in
g 
$7
4.7
 bi
llio
n
 
by
 2
00
7 
(B
CC
 M
a
rc
h 
20
03
). 
•
 
W
or
ld
wi
de
 d
em
a
n
d 
fo
r n
ut
ra
ce
ut
ic
al
 
ch
em
ic
a
ls
 w
ill 
in
cr
ea
se
 b
y 
6.
2 
%
 
a
n
n
ua
lly
 
re
a
ch
in
g 
$8
.
6 
bi
llio
n
 
by
 
20
06
.
 
•
 
Th
e 
fu
nc
tio
na
l f
oo
d 
m
a
rk
e
t i
n
 
th
e 
U.
S.
 
w
a
s 
va
lu
ed
 a
t $
18
.5
 b
illi
o
n
 in
 
20
02
 
(N
u
tri
tio
n
 B
u
si
n
e
ss
 
Jo
ur
n
al
 
Ap
ril
 
20
02
). 
•
 
M
u
lti
pl
e 
m
e
di
ca
l 
di
sc
ip
lin
e
s 
+
 
ge
no
m
ic
s 
•
 
G
en
et
ic
 
sc
re
e
n
in
g 
& 
ph
en
ot
yp
in
g 
 
•
 
Pr
o
te
om
ic
s 
•
 
Ti
ss
u
e
 b
an
ks
 
•
 
Pa
th
ol
og
y 
•
 
H
ea
lth
 
in
fo
rm
a
tic
s 
•
 
Ep
id
em
io
lo
gy
 
•
 
Bi
oi
n
fo
rm
a
tic
s 
an
d 
bi
o
st
a
tis
tic
s 
•
 
Tr
ia
ls
 
e
nr
ol
lm
e
n
t 
a
n
d 
m
a
n
a
ge
m
e
n
t 
•
 
Lo
ng
itu
di
n
al
 
fo
llo
w
-
u
p 
In
te
gr
at
ed
 
Po
st
-
G
en
o
m
ic
 
M
ed
ic
in
e 
•
 
Le
ad
in
g 
ce
n
te
rs
 
o
f e
xc
e
lle
n
ce
 in
 
m
u
lti
pl
e 
di
se
a
se
 
a
re
a
s 
(re
se
ar
ch
 
a
n
d 
cli
n
ic
al
 
pr
ac
tic
e
) 
•
 
M
a
rk
et
ab
le
 
in
fo
rm
a
tic
s 
da
ta
 
•
 
N
e
w
 
dr
ug
s,
 
bi
ol
og
ic
s,
 
th
er
ap
eu
tic
s,
 
va
cc
in
e
s,
 
e
tc
., 
pa
ss
in
g 
in
to
 
in
te
gr
at
ed
 
pi
pe
lin
e
.
 
•
 
Ph
ar
m
a
co
ge
no
m
ic
s 
m
a
rk
e
t a
nt
ic
ip
at
e
d 
to
 a
pp
ro
a
ch
 $3
.
5 
bi
llio
n
 b
y 
20
05
. 
Ph
ar
m
a
co
ge
ne
tic
 
se
rv
ic
e
s 
a
n
d 
ge
ne
-
ba
se
d 
di
a
gn
os
tic
s 
co
ul
d 
re
a
ch
 
$6
 bi
llio
n
. 
•
 
Fu
nc
tio
n
al
 
ge
no
m
ic
s 
m
a
rk
et
 w
a
s 
e
st
im
a
te
d 
to
 b
e 
wo
rth
 $9
40
 m
illi
o
n
 in
 
20
02
 
a
n
d 
pr
oje
ct
ed
 to
 
gr
ow
 
to
 $2
.2 
bi
llio
n
 b
y 
20
07
; w
ith
 a
n 
an
nu
al
 
gr
ow
th
 ra
te
 
o
f 
18
%
.
 
•
 
Pr
o
te
om
ic
s 
is
 
pr
o
jec
te
d 
to
 g
ro
w
 
fro
m
 
a
 $5
65
 m
illi
o
n
 m
a
rk
et
 in
 
20
01
 to
 o
ve
r 
$3
.3 
bil
lio
n
 in
 
20
06
. T
hi
s 
re
pr
e
se
n
ts
 a
n 
a
ve
ra
ge
 a
nn
ua
l r
a
te
 o
f g
ro
w
th
 o
f o
ve
r 
40
%
.
 
•
 
Ap
pl
ic
a
tio
n
 
o
f b
io
in
fo
rm
a
tic
s/
 in
fo
rm
a
tic
s 
a
pp
lic
a
tio
n
s 
ha
s 
th
e 
po
te
n
tia
l t
o 
dr
iv
e
 
gr
o
w
th
 in
 
th
e 
wo
rld
wi
de
 p
ha
rm
a
ce
u
tic
al
s 
dr
u
g 
m
a
rk
e
t f
ro
m
 
th
e 
$2
40
 bi
llio
n
 
to
da
y 
to
 $3
 
tri
llio
n
 b
y 
20
20
. T
he
 
fo
re
ca
st
 v
al
u
e 
fo
r t
he
 w
o
rld
wi
de
 in
fo
rm
a
tic
s 
m
a
rk
et
 in
 
th
e 
lif
e 
sc
ie
n
ce
 s
e
ct
or
 
is
 
be
tw
e
e
n
 $1
.
7 
an
d 
$7
 
bi
llio
n
 b
y 
20
07
.  
  
135 
Iowa Bioscience Path for Development 
Ba
si
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Re
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ch
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at
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Ap
pl
ic
at
io
n
s 
an
d 
Pr
o
du
ct
s 
M
ar
ke
ts
 
•
 
An
im
a
l 
bi
ol
og
y 
•
 
G
en
om
ic
s 
•
 
Tr
a
n
sg
en
ic
s 
•
 
An
im
a
l b
re
ed
in
g 
•
 
Bi
oi
n
fo
rm
a
tic
s 
an
d 
bi
o
st
a
tis
tic
s 
•
 
Vi
su
al
iz
a
tio
n
, 
m
o
de
lin
g,
 a
nd
 
im
a
gi
n
g 
An
im
al
 
Sy
st
em
s 
 
•
 
M
a
rk
et
ab
le
 
m
o
de
l a
n
im
a
l 
sy
st
em
s 
•
 
Tr
a
n
sg
en
ic
 
a
n
im
a
ls
 
•
 
M
a
rk
et
ab
le
 
sy
st
em
s 
a
n
d 
pr
ot
oc
ol
s 
•
 
Cl
o
ni
n
g 
a
n
d 
pr
od
uc
tio
n
 
te
ch
no
lo
gi
e
s 
•
 
M
a
n
y 
di
se
a
se
s 
a
n
d 
di
so
rd
er
s 
w
ith
 a
 h
ig
h 
le
ve
l o
f u
nm
e
t n
ee
d 
ca
n 
be
 
su
cc
e
ss
fu
lly
 
tre
at
ed
 w
ith
 th
e 
us
e 
o
f d
ru
gs
 
cr
ea
te
d 
fro
m
 
tra
ns
ge
ni
c 
a
ni
m
a
ls
. 
Th
e 
w
o
rld
 m
a
rk
e
t f
or
 
re
co
m
bi
n
an
t p
ro
te
in
s 
ha
s 
be
e
n
 e
st
im
a
te
d 
at
 $1
2.8
 bi
llio
n 
in
 
19
98
, a
nd
 th
e 
wo
rld
 m
a
rk
e
t f
or
 
a
nt
ib
od
ie
s 
w
a
s 
e
xp
ec
te
d 
to
 e
xc
e
e
d 
$1
 bi
llio
n
 in
 
19
98
.  
•
 
M
ic
ro
bi
ol
o
gy
 
•
 
Im
m
u
n
o
lo
gy
 a
n
d 
in
fe
ct
io
u
s 
di
se
a
se
s 
(hu
m
a
n
s,
 
a
n
im
a
ls
 
a
n
d 
pl
a
nt
s) 
•
 
H
ig
h-
le
ve
l 
bi
o
co
n
ta
in
m
e
n
t 
•
 
M
ic
ro
bi
al
 
pa
th
og
en
e
si
s 
•
 
M
ic
ro
bi
ol
o
gy
 
•
 
Vi
ro
lo
gy
 
•
 
To
xi
co
lo
gy
 
•
 
Se
n
so
rs
 a
n
d 
in
st
ru
m
e
n
ta
tio
n
  
•
 
Bi
o
pr
oc
e
ss
in
g 
•
 
En
vi
ro
n
m
e
n
ta
l 
sc
ie
n
ce
s 
•
 
R
is
k 
a
ss
e
ss
m
e
n
t 
Bi
o
se
cu
rit
y 
•
 
Va
cc
in
e
s 
•
 
D
ia
gn
o
st
ic
s 
•
 
D
ru
gs
 a
n
d 
th
er
ap
eu
tic
s 
•
 
Bi
o
de
co
n
ta
m
in
-
a
tio
n
 m
ic
ro
be
s 
•
 
En
vi
ro
n
m
e
n
ta
l 
m
o
n
ito
rin
g 
pr
od
uc
ts
 
•
 
Ac
co
rd
in
g 
to
 F
ro
nt
 L
in
e
 S
tra
te
gi
c 
Co
n
su
lti
n
g 
In
c.
, 
si
n
ce
 2
00
1 
bi
o
de
fe
ns
e 
fu
nd
in
g 
ha
s 
ris
e
n
 c
o
n
si
de
ra
bl
y.
 
Sp
en
di
n
g 
in
 
20
03
 w
a
s 
pr
o
jec
te
d 
at
 $6
 bi
llio
n.
 
Pr
o
po
se
d 
W
hi
te
 H
o
u
se
 2
00
4 
bu
dg
et
 c
al
ls
 fo
r 
a
 $5
.2 
bil
lio
n
 s
pe
nd
. 
•
 
Se
ve
ra
l b
illi
o
n
 d
ol
la
rs
 e
xp
ec
te
d 
to
 b
e 
sp
en
t b
y 
th
e 
N
IH
 
a
n
d 
DO
D
 
o
n
 r
e
se
a
rc
h 
in
to
 
de
te
ct
io
n
 
te
ch
no
lo
gi
e
s,
 im
pr
ov
ed
 v
ac
cin
es
,
 
a
n
d 
ne
w 
tre
at
m
e
n
ts
 fo
r v
ic
tim
s 
o
f b
io
lo
gi
ca
l w
a
rfa
re
 
(Fr
o
n
t L
in
e
 M
a
rc
h 
20
03
). 
•
 
D
e
m
a
n
d 
fo
r b
io
te
rr
or
is
m
 
e
qu
ip
m
e
n
t a
nd
 s
er
vic
e
s 
is
 
pr
oje
ct
ed
 to
 g
ro
w
 
by
 1
6%
 
a
n
n
u
al
ly
 th
ro
u
gh
 2
00
8,
 re
a
ch
in
g 
$1
0 b
illi
on
.
 
Va
cc
in
e
s 
a
re
 p
re
di
ct
e
d 
to
 b
e 
th
e 
fa
st
es
t g
ro
w
in
g 
se
gm
e
n
t, 
ris
in
g 
fro
m
 
54
%
 
a
n
n
u
a
lly
 
fro
m
 
$2
86
 m
illi
on
 in
 
20
03
 to
 
$2
.5 
bil
lio
n
 b
y 
20
08
. T
he
 s
e
co
n
d 
fa
st
es
t g
ro
w
in
g 
se
gm
e
n
t w
ill 
be
 b
io
de
te
ct
io
n 
e
qu
ip
m
e
n
t, 
in
cr
ea
si
ng
 fr
o
m
 
$3
45
 m
illi
o
n
 in
 2
00
3 
to
 $1
.9 
bi
llio
n
 in
 
20
08
, 
a
ve
ra
gi
n
g 
a
n
 a
nn
u
al
 
gr
o
w
th
 ra
te
 o
f 4
1%
 
(P
BR
 
Se
pt
em
be
r 2
00
3).
 
•
 
US
D
A’
s 
pr
o
po
se
d 
20
04
 b
ud
ge
t i
n
cl
u
de
s 
$2
.4 
bi
llio
n
 fo
r 
a
gr
o
se
cu
rit
y 
an
d 
fo
od
 
su
pp
ly 
sa
fe
ty
. 
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A
re
a
s 
Ju
dg
ed
 
by
 
B
at
te
lle
 
to
 b
e O
pp
or
tu
n
iti
es
 fo
r F
u
tu
re
 D
ev
el
o
pm
en
t 
Ba
si
c 
Re
se
ar
ch
 
En
ab
lin
g 
Te
ch
no
lo
gy
 
Te
ch
no
lo
gy
 
Pl
at
fo
rm
 
Ap
pl
ic
at
io
n
s 
an
d 
Pr
o
du
ct
s 
M
ar
ke
ts
 
•
 
M
ic
ro
bi
ol
o
gy
 
•
 
Pa
ra
si
to
lo
gy
 
•
 
Im
m
u
n
o
lo
gy
 
•
 
H
e
lm
in
th
 
bi
ol
o
gy
 
•
 
G
en
om
ic
s 
•
 
Bi
oi
n
fo
rm
a
tic
s 
a
n
d 
bi
o
st
at
is
tic
s 
•
 
Im
a
gi
n
g 
Ho
st
-P
ar
as
ite
 
Bi
o
lo
gy
 
an
d 
Sy
st
em
s 
•
 
Im
m
u
n
o
-
th
er
ap
eu
tic
s 
•
 
D
ru
gs
 a
n
d 
bi
ol
og
ic
s 
•
 
Pa
ra
si
te
 
tre
at
m
e
n
ts
 
•
 
D
ia
gn
o
st
ic
s 
a
n
d 
cl
in
ic
al
 
se
rv
ic
e
s 
•
 
O
ne
 m
a
rk
et
 is
 
in
 
liv
e
 m
ic
ro
bi
al
 
fe
e
d 
su
pp
le
m
e
n
ts
 (p
rob
io
tic
s),
 w
hi
ch
 b
en
ef
it 
th
e 
ho
st
 a
ni
m
a
l b
y 
im
pr
ov
in
g 
its
 in
te
st
in
al
 
m
ic
ro
bi
a
l b
a
la
n
ce
. 
In
 
hu
m
a
n
s,
 la
ct
ob
ac
illi
 
co
m
m
o
n
ly
 a
re
 u
se
d 
as
 p
ro
bi
o
tic
s,
 e
ith
er
 
a
s 
sin
gl
e 
sp
ec
ie
s 
or
 
in
 
m
ix
e
d 
cu
ltu
re
 
w
ith
 o
th
er
 b
ac
te
ria
. 
O
th
er
 
ge
ne
ra
 th
at
 h
av
e
 b
ee
n
 u
se
d 
ar
e
 b
ifi
do
ba
ct
er
ia
 a
n
d 
st
re
pt
oc
oc
ci.
 
•
 
Th
e 
pr
o
bi
o
tic
 m
a
rk
et
, i
n
cl
u
di
n
g 
fo
o
d 
an
d 
di
e
ta
ry
 s
up
pl
e
m
e
n
ts
, a
cc
ou
nt
ed
 
fo
r 
$1
.86
 bi
llio
n
 in
 
re
ve
nu
e
 in
 
20
00
 a
nd
 is
 
e
xp
ec
te
d 
to
 g
ro
w
 
to
 $3
.5 
bil
lio
n
 b
y 
20
07
. 
Th
e 
an
n
u
al
 
re
ve
n
u
e
 g
ro
wt
h 
ra
te
 is
 
e
xp
ec
te
d 
to
 
in
cr
e
a
se
 fr
om
 
7.
4%
 
in
 
20
00
 to
 
10
.5
%
 
in
 
20
07
 a
n
d 
co
n
tin
u
e
 in
 
th
e 
sa
m
e
 
m
a
n
n
e
r.
 T
he
 p
ro
bi
o
tic
s 
di
e
ta
ry
 
su
pp
le
m
e
n
t s
eg
m
e
n
t r
ep
re
se
n
te
d 
$9
7.5
 m
illi
on
 
a
t t
he
 m
a
n
u
fa
ct
ur
er
 le
ve
l i
n
 
20
00
, w
ith
 s
im
ila
r 
e
xp
ec
ta
tio
n
s 
fo
r 
fu
tu
re
 g
ro
wt
h.
 (N
u
tra
ce
u
tix
 
Pr
o
bi
o
tic
s 
w
w
w
.
n
u
tra
ce
ut
ix
.
co
m
) 
•
 
U.
S.
 
a
n
d 
Eu
ro
pe
a
n
 p
ro
bi
o
tic
 m
a
rk
et
s 
ar
e 
pr
o
jec
te
d 
to
 g
ro
w
 
ra
pi
dl
y 
in
 
u
pc
o
m
in
g 
ye
ar
s.
 T
he
 U
.
S.
 
m
a
rk
et
 is
 
e
xp
ec
te
d 
re
a
ch
 $4
00
 m
illi
on
 b
y 
20
10
. T
he
 E
U 
m
a
rk
et
 
w
ill 
tri
pl
e
 
in
cr
e
a
si
n
g 
fro
m
 
$4
0 m
illi
o
n
 to
 $1
38
 m
illi
o
n
 (F
un
ct
io
n
al
 
Fo
od
s 
& 
N
u
tra
ce
ut
ic
al
s 
Ja
n
u
ar
y 
20
04
). 
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M
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n
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e
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M
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sc
ie
n
ce
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Bi
o
m
e
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e
n
gi
n
e
e
rin
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•
 
O
pt
ica
l s
ci
e
n
ce
 
•
 
M
a
th
em
a
tic
s 
•
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m
pu
te
r 
sc
ie
n
ce
 
•
 
St
a
tis
tic
s 
•
 
M
e
di
ca
l i
m
a
gi
n
g 
•
 
R
a
di
ol
og
y 
•
 
R
a
pi
d 
pr
ot
ot
yp
in
g 
•
 
Su
rg
er
y 
In
st
ru
-
m
en
ta
tio
n
, 
Se
ns
or
s 
an
d 
De
vi
ce
s 
•
 
Im
a
gi
n
g 
de
vi
ce
s 
•
 
Bi
o
se
n
so
rs
 
•
 
Im
pl
a
n
ta
bl
e
 
de
vi
ce
s 
•
 
Su
rg
ic
al
 
sy
st
em
s 
a
n
d 
in
st
ru
m
e
n
ts
 
•
 
As
 
dr
ug
 d
ev
el
o
pm
e
n
t i
n
cr
ea
si
n
gl
y 
be
co
m
e
s 
fo
cu
se
d 
on
 h
ig
h-
th
ro
u
gh
pu
t d
ru
g 
sc
re
e
ni
n
g 
te
ch
no
lo
gi
e
s,
 b
io
-c
hi
p 
a
n
d 
m
ic
ro
a
rr
a
y 
te
ch
no
lo
gy
 
w
ill 
be
co
m
e
 
in
cr
e
a
si
n
gl
y 
im
po
rta
nt
.  
•
 
Th
e 
to
ta
l m
a
rk
et
 fo
r m
ic
ro
a
rr
a
ys
 is
 
e
xp
ec
te
d 
to
 
e
xp
er
ie
n
ce
 s
tro
n
g 
gr
o
w
th
 to
 
re
a
ch
 o
ve
r 
$1
.6 
bi
llio
n
 
in
 
20
08
 a
s 
a
 r
e
su
lt 
o
f i
n
du
st
ry
 c
on
so
lid
at
io
n
, s
ta
nd
ar
di
-
za
tio
n
 
o
f a
rr
a
y 
da
ta
, e
st
ab
lis
hm
e
n
t o
f r
ob
us
t d
a
ta
ba
se
s,
 a
n
d 
th
e
 d
ev
el
op
m
e
n
t o
f 
cl
in
ic
al
 
di
ag
no
st
ic
s.
 T
he
 c
ur
re
nt
 
e
st
im
a
te
d 
wo
rld
wi
de
 m
a
rk
et
 b
re
a
kd
ow
n
 is
: 
U.
S.
 
a
t 6
5%
,
 
Eu
ro
pe
 a
t 2
5%
,
 
Ja
pa
n
 a
t 1
0%
,
 
a
n
d 
th
e
 r
e
st
 o
f t
he
 w
o
rld
 a
t 5
%
.
 
(F
ro
n
t 
Li
n
e 
St
ra
te
gi
c 
Co
n
su
lti
n
g 
M
a
y 
20
03
) 
•
 
Th
e
 
to
ta
l b
io
ch
ip
 
m
a
rk
e
t s
iz
e 
in
 
20
02
 
is
 
a
bo
u
t $
1.
1 
bi
llio
n
 
a
n
d 
is
 
pr
o
jec
te
d 
to
 
gr
o
w
 
to
 a
bo
ut
 $2
.
7 
bi
llio
n
 in
 
20
07
 w
ith
 
a
 C
AG
R
 
o
f 1
9.
5%
.
 
(F
u
ji-K
ei
za
i 
Ju
ly
 
20
03
) 
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To take full advantage of these technology platforms, Iowa’s universities, private sector, and state 
government will need to address several gaps as well as seize opportunities outlined in the table below 
 
Table 52: Platforms and Gap-Filling Needs and Opportunities. 
Platform Gap Filling Needs and Opportunities 
BioEconomy Platform • Fund, and scale up, the operations of the BIOWA Development 
Corporation. Build BIOWA into a fully staffed industry development 
association, linking 
o Iowa and non-Iowa BioEconomy industries 
o Existing and potential end-user companies for biorenewable 
commodity products and specialty products 
o Academic R&D and associated resources at Iowa State University, 
University of Northern Iowa, and The University of Iowa. 
• Develop, within BIOWA, subcommittees devoted to specific product line 
opportunity areas (markets), including but not limited to 
o Industrial Chemicals 
o Ethanol 
o Biodiesel 
o Hydrogen 
o Enzymes 
o Fibers 
o Carbohydrates (sugars, starches, glycogen) 
o Proteins. 
• Dedicate additional support and funding to the Iowa State University Plant 
Sciences Institute as the core driver of ag-based biomass development for 
the State. Director of the Plant Sciences Institute to be a BIOWA Executive 
Board member. 
• Place additional emphasis on R&D related to new processing technologies 
and projects to reduce the cost of bio-renewable products to be com-
petitive with competing products (such as those that are petroleum based). 
Dedicate support and funding to Iowa State University to develop a 
BioEconomy Institute to serve as the umbrella organization for steering 
applied R&D in processing, engineering, product design, and production 
technologies. Place the key related ISU centers (Center for Crops 
Utilization Research, Center for Catalysis and Center for Sustainable 
Environmental Technologies) as core components of the Institute. Director 
of the ISU BioEconomy Institute to be a BIOWA Executive Board member. 
• Actively engage ISU ag-extension in BioEconomy production consulting 
with the Iowa farm sector, and in industrial extension consulting with 
potential processors and users of bio-renewable resources. Director of 
Iowa State Extension to be a BIOWA Executive Board member. 
• Invite and encourage relevant University of Iowa and University of 
Northern Iowa centers, institutes, and departments to be members of the 
Iowa BioEconomy Institute at ISU. It is especially important to include the 
expertise contained in UNI’s Ag-Based Industrial Lubricants (ABIL) 
program and The University of Iowa’s Center for Biocatalysis and 
Bioprocessing. 
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Platform Gap Filling Needs and Opportunities 
• Develop and refine state incentive policies to encourage the active 
development of Biorefinery clusters in Iowa. 
• Actively promote Iowa as America’s leader in biorenewables and 
BioEconomy development through a State-led marketing and promotions 
campaign and high visibility at key industry trade shows. 
• Organize a Midwestern States lobby for BioEconomy development 
purposes in lobbying the federal government. 
• Seek to develop a formal relationship with Canada’s leading bio-
renewables research and industry cluster in Saskatoon to leverage North 
American skills against growing European, Asian, and Latin American 
competition. 
Integrated Drug 
Discovery, 
Development, Piloting 
and Production 
Platform 
• Dedicate additional support and funding to build upon core strength areas 
at The University of Iowa, including the Center for Advanced Drug Devel-
opment (CADD) and the GMP production facilities of the Division of 
Pharmaceutical Services. 
• Fund the development of a new Drug Discovery Center at The University 
of Iowa, thereby plugging a current resource gap and completing an 
integrated system for moving discoveries from bench to bedside. Iowa 
may be unique in having the opportunity to have a fully integrated “pipe-
line” of basic science research   drug discovery   drug development   
pilot production   clinical trials   and drug production: all in-house at one 
major university. 
• Initial requirement for the new Drug Discovery Center is estimated at three 
full-time positions, plus instrumentation and equipment resources and 
development of compound libraries. 
• The University of Iowa may wish to appoint a Director of Pharmaceuticals 
and Biologics Development to guide the operations of The University of 
Iowa integrated drugs platform and further build and maintain close 
pharmaceutical and biotechnology industry linkages. 
• Areas of directly relevant strength at Iowa State University should be 
linked into The University of Iowa “pipeline.” This would initially include 
ISU’s expertise in veterinary medicine and combinatorial chemistry and the 
planned biologics production facility at the ISU research park. 
Advanced Food 
Products Platform 
• Iowa State University may wish to formalize its work in functional foods, 
nutraceuticals, and phytochemicals under a formal center or institute 
linked to existing platforms in plant and food animal sciences. Key 
programs to include would be Plant Genomics, Plant Transformation and 
Gene Expression, the Center for Designing Foods to Improve Nutrition, the 
NASA Food Technologies Commercial Space Center, and Food Science 
and Nutrition. 
• An Advanced Food Products Institute, based on Iowa’s strengths, should 
likely concentrate on 
o Value added Iowa transgenic crops expressing enhanced levels of 
beneficial nutrients, vitamins and phytochemicals 
o Agricultural processing, separation and purification technologies for 
extracting beneficial nutrients, vitamins and phytochemicals from Iowa 
crops 
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Platform Gap Filling Needs and Opportunities 
o New advanced food products from crops, produce, herbs, etc. with 
enhanced commercial value for introduction on Iowa’s farms 
o Food processing technologies designed to maintain or enhance 
functional characteristics of food and food ingredients during 
processing, cooking and packaging. 
• The Institute should seek to establish relationships between the Iowa 
functional foods R&D platform and producers and distributors of functional 
and nutraceutical food products. 
• State funding and incentive mechanisms should be investigated to assist 
in founding and attracting functional food, nutraceutical, and associated 
agricultural and food processing companies. 
• R&D should also be performed to advance Iowa’s key food animal sectors 
(especially Pork, Beef and Poultry/Eggs) in terms of functional 
characteristics and nutrient/chemical expression. 
Post-Genomic Medicine 
Platform 
• It is imperative that the State of Iowa continue investing in and building 
Iowa’s strong position in bioinformatics, genomics, proteomics and 
metabolomics—together with associated programs in epidemiology and 
health informatics. Enhanced funding streams should be considered that 
would 
o Retain and anchor existing faculty in these fields, especially at The 
University of Iowa and Iowa State University 
o Attract additional faculty and investment in resources to continue 
Iowa’s growing momentum in these critically important fields for 
bioscience progress. 
• The University of Iowa may wish to consider forming the Post-Genomic 
Medicine Institute dedicated to the formation of multi-disciplinary teams 
and the coordination of resources to capitalize on key opportunities in: 
o Ophthalmology 
o Cardiology 
o Oncology 
o Otolaryngology 
o Pulmonology 
o Gastroenterology 
o Neurosciences 
• Iowa should open discussions with the State of Minnesota, the University 
of Minnesota, and the Mayo Clinic to explore the potential to integrate and 
build upon Iowa’s strengths in this area in collaboration with the new 
Minnesota Partnership for Biotechnology and Medical Genomics. Sharing 
access to clinical and epidemiological data in Minnesota and Iowa likely 
would strengthen programs for both states and speed platform 
development. 
• Iowa should fund ongoing development of computational resources and 
software/database systems development to support work in the Post-
genomic Medicine Platform. Patient record data, demographics, imaging 
data, and genomics data should be linked under a unified software and 
data mining platform. 
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Platform Gap Filling Needs and Opportunities 
• The University of Iowa should establish a clinical research patient 
recruitment center in the main lobby of the University Hospital and within 
the key departments linking their research into the post-genomic initiatives. 
Iowa should seek to increase patient enrollment rapidly, where possible, in 
longitudinal clinical and epidemiological studies. 
Animal Systems 
Platform 
• Maintaining Iowa’s leadership position in certain food animals and 
associated meat products may increasingly require a solid foundation in 
animal transgenics—working to enhance food animal characteristics, 
productivity and value. Iowa State University should, to the extent 
possible, coordinate transgenics and animal systems research across key 
groups such as those contained in ISU Animal Sciences, the ISU Beef 
Center, Iowa Pork Industry Center and the Meat Export Research Center. 
The University of Iowa’s expertise at the Transgenic Animal Facility also 
should be incorporated via collaborations. 
• Key transgenic animal systems pathways to pursue in the near term for 
Iowa may include 
o Enhanced meat production and meat quality predictability 
o Expression of valuable proteins and other chemicals via animal 
pathways (such as milk, eggs, blood, semen or urine). 
• Iowa should seek means to build upon the existing Center for Integrated 
Animal Genomics at Iowa State University, leveraging it to focus on the 
most relevant and near-term applications of transgenics, cloning and 
chimerics in food and fiber producing animals. 
• Iowa should also seek to leverage its expertise in mouse transgenics (at 
The University of Iowa) and pig transgenics (at Iowa State University) to 
build and expand upon opportunities in the production and sale of 
transgenic animals for R&D purposes. 
Biosecurity Platform • Iowa State University and The University of Iowa should consider forming 
a joint Institute for Integrated Biosecurity, working on whole systems 
approaches to biosecurity and agrosecurity. 
• Emphasis of initial R&D programs should likely be dedicated toward 
o Agrosecurity—protecting the food and biorenewable resource 
production and processing chain 
o Threat Diseases—with an initial focus on emerging and established 
respiratory diseases and emerging zoonotic diseases. 
• Within the Institute, Iowa may seek to establish interdisciplinary working 
groups to focus R&D on 
o Detection and analytical devices 
o Approaches to, and systems for, decontamination of production and 
processing facilities and equipment 
o Infectious disease protection, prevention, and treatments 
o Rapid production of vaccines via plant and animal pathways. 
• The market opportunity for biosecurity is large enough that state funds 
should be directed to support initial development of the platform. By 
showing state commitment to an integrated biosecurity approach (the main 
goal of Homeland Security), Iowa will be more likely to attract significant 
levels of federal biosecurity R&D funding. 
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Platform Gap Filling Needs and Opportunities 
• Industry memberships in an Institute for Integrated Biosecurity should be 
encouraged, to help the potential development of a biosecurity industry 
cluster in Iowa. Initial focus should be on agricultural and processing 
equipment manufacturers and BioEconomy-related industry sectors.  
Additional Gap Filling 
Activities & 
Opportunities 
• Formation of a Host-Parasite Institute at The University of Iowa, linked to 
animal and plant biology expertise at Iowa State University could help 
build upon the emerging leadership of Iowa in this interesting medical and 
scientific field. 
• Formal funding should be considered for constructing and equipping a 
Cardiovascular Research Institute at The University of Iowa. This would 
anchor the strong base of existing research and development expertise of 
the University in cardiology, vascular systems, neuro-control and other 
related fields. A formal facility, allowing co-location of research scientists 
and clinician scientists along the lines of Iowa’s Comprehensive Cancer 
Center, could foster significant advances. 
• A Free Radical Institute should be considered to formalize and facilitate 
interactions between the large base of scientists at The University of Iowa 
who are working in free radical biology. A few other states, such as 
Oklahoma, recently have recognized the importance of the study of free 
radicals and have formed formal centers. Iowa needs to cement its 
leadership position in the field and use an Institute to gain additional 
support and retain faculty excellence. 
SUMMARY OF IOWA’S BIOSCIENCE TECHNOLOGY PLATFORM OBSERVED 
WEAKNESSES 
While the goal of the core competency was to identify the key core research and technology competencies 
and platforms in biosciences, this review also served to highlight weaknesses and gaps that will also need 
to be addressed. The following were observed as general issues during the course of this study: 
• Agricultural biosciences appear to have much higher legislative and public visibility in the state than 
human medical sciences. While it is good that agricultural bioscience is recognized for its significant 
value to the current and future health of the Iowa economy, attention also needs to be raised to the 
strong position of Iowa in human biosciences (where it actually holds higher rank in terms of research 
funding than it does in agriculture). 
• Iowa higher education institutions appear to be making good attempts to link their research to the 
needs of industry in the state. However, these efforts are held back by a lack of a commercial base in 
many areas of biotechnology, pharmaceuticals, medical devices and even food processing. 
• Research institutions vary in approaches to technology development, with Iowa State University 
demonstrating great flexibility in developing formal, institution-supported cross-disciplinary research 
institutes and centers—the type of structure best suited to modern scientific advancement and external 
funds attraction. The University of Iowa has developed a more traditional approach. 
• State support for the Regent institutions has declined significantly during the last five years. The 
result has been predictable in terms of program cuts, faculty salary freezes, an inability to invest in 
new technologies and infrastructure and a general fear for the future among the Iowa education and 
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scientific community. At a time when higher education research institutions represent the best 
investment for a state, Iowa, for budgetary reasons, has had to lower, rather than increase, investment. 
• There is an evident lack of pre-seed, seed and venture capital available in Iowa to fund new ventures 
in the biosciences. Lack of local capital resources is limiting entrepreneurship on campuses, reducing 
the volume of new innovation based companies in the state, and causing some of the companies that 
do spin-out of Iowa’s universities to move out of the state closer to venture funding sources on the 
coasts. 
• There is a lack of experienced bioscience entrepreneurs and managers who can fulfill management 
duties in new start-ups, or provide mentoring to new bioscience enterprises. 
• There appears to be considerable variability in the level of commercialization and intellectual 
property protection services offered by Iowa’s universities to their faculty. This variability in the 
ability to provide technology transfer support results from the fact that technology transfer services 
typically are funded by retained earnings from licensing successes or other “indirect” sources.  Given 
the importance of technology transfer and commercialization operations to the future economic 
success of Iowa, it is very important that the major Iowa universities engaged in bioscience have 
sufficient resources to facilitate high performance in this area.   
• Faculty in the state are confused as to what is expected of them in terms of faculty entrepreneurship, 
intellectual property generation and idea commercialization. Many feel that their traditional research 
and teaching roles are threatened by a perceived requirement to start and run companies. Reassurance 
needs to be provided that universities are expected to contribute to economic development as research 
and talent engines through the generation of commercializable discoveries, ideas, and a future work-
force—not necessarily that the faculty themselves must be the founders and managers of any resulting 
commercial enterprises. A structure at each university is required that would relieve faculty of the 
burden of commercializing their concepts, whereby faculty can disclose their discoveries and have a 
team of university commercialization experts evaluate it, assess marketability, and ultimately form 
companies around the most viable concept. Faculty should be free to be investors and technical 
advisors to companies that their inventions promote, and to be as engaged in operations and 
management as their interests allow. 
• The University of Northern Iowa is in a somewhat different position.  The Iowa Board of Regents has 
agreed that UNI must actively participate in research related to academic niches, and the state 
provides $600 to faculty members each year to support their research.  And, UNI has invested in 
facilities and scientific equipment. But the challenge for an institution like UNI, whose faculty have 
full-time teaching loads, is to find the time and resources to secure federal grants in the way other 
universities support their faculties’ bioscience efforts. Iowa may want to consider providing incentive 
or “glue” funds to bioscience-related faculty at UNI that would allow them to leverage additional 
outside research dollars for financial support for bioscience research. A small amount of research 
funding annually for biotechnology, e.g., $300,000 made available on a competitive basis, might 
stimulate large potential returns for UNI.  
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THE COMMERCIALIZATION CHALLENGE: TRANSLATING CORE COMPETENCIES 
INTO IOWA ENTERPRISE 
Critical to the translation of identified core competencies into the Iowa economy are the external elements 
that are participated in, but not controlled by, the universities. If maximum yield for the state’s investment 
is to be achieved then it is important to understand and integrate these additional external elements. It will 
be important to evaluate strengths and weaknesses and make appropriate investments to fill in gaps. The 
issues and challenges are many. 
Observations on Current Status—Interviews with start-up companies in Iowa indicate that venture 
capital is scarce. Further, many early stage companies are run by inventors who have little experience in 
managing or growing a biotech company. The key to success in a start-up biotech, biomed or ag-biotech 
company, or any company, is knowing what to do. If the CEO does the wrong thing in a start-up company 
it often causes the company to fail. There is little room for error when money is tight. The past two years 
in the U.S. have been difficult times for acquiring investment capital. Previously it was easier to obtain 
funding and entrepreneurs had more room to move around and learn while they were building their 
business. Those circumstances may return, but for now investors require clear product pathways with 
proven management leadership to obtain funding. CEOs that have experience and have guided this 
process successfully before have little reason to move to Iowa unless they are given adequate incentives. 
One strategy may be to search for alumni who have been successful entrepreneurs elsewhere. It may be 
possible to recruit them to return to the state where they grew up or were educated. Investors will have a 
particularly difficult time believing that the biotech or pharmaceutical industries can grow and flourish in 
Iowa until several successful companies emerge and are able to grow in the state.  
Human Therapy Product Companies—The biotech facts of life are that human therapy product 
companies (generally this is pharmaceuticals or biomedical devices) command ten times more attention 
from investors than agricultural biotech companies because of the huge potential product sales. Even 
though the pathway for products generally includes long regulatory approvals, there is potential for 
investors to realize a large multiple on their investment when the drug or device comes to market or when 
a large pharmaceutical company acquires the company. A skilled CEO in the bio arena can use significant 
events or milestones to attract more and more funding into a promising, growth company. No real history 
of human therapy product companies exists in Iowa. Some start-ups are located in the state but are failing 
to grow at an acceptable pace due to lack of investment capital or inexperienced management. If there is a 
strong desire to change that dynamic it will require skillful and patient investment by the universities 
involved, by the private sector, and by state and local governments.  
Ag Biotech Companies—There is great opportunity in Iowa for this kind of technology-based business. 
The challenge in this market sector is finding a technology that has a compelling enough story to 
command investors’ attention. The key here is size and accessibility of markets as well as how quickly 
products can be brought to market. Iowa has the potential to dominate in commercialization of the 
BioEconomy Platform that has been identified. The products from this platform can fill the pipeline for 
new start-ups and existing mid-sized and even large companies. Universities will have to become closer 
in relationships to industry and be willing to work out new relationships that will benefit both. The bio-
fuel, biomaterials, and bio-based lubricants products that are being commercialized now in Iowa are 
examples of this kind of activity. These entities could provide early successes that the State of Iowa needs 
in order to develop a track record.  
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All three universities (Iowa State, The University of Iowa and the University of Northern Iowa) have new 
initiatives to build stronger bridges to the private sector. Iowa State has strong liaison personnel at the 
Research Park and the Carver Co-Lab. The University of Iowa has made new commitments to economic 
development (including a special economic development appointment within the College of Medicine), 
while the University of Northern Iowa has a skilled economic development advisor to the President who 
has developed several important initiatives. All of these efforts are timely and commendable, but need 
bolstering and further financial support if the hope of the state is to convert the products of its core 
competencies into economic value for Iowa.  
Real estate is a small component of a successful start-up business plan (often in the form of incubators). 
What is much more important is the quality of management that can be attracted, or the quality of 
business mentoring that can be made available to less experienced entrepreneurs. There is also no 
substitute for money. Lack of capital will starve any activity that is started in biotechnology commer-
cialization. The Pappajohn Centers are excellent but are insufficient by themselves.  
Present Status of Technology Transfer—Start-up companies exist around all three Regent universities in 
the state. To be successful in creating more start-up companies in the future will require that the 
universities be rewarded for licensing to start-ups.  
One larger Iowa company (350 employees) has spun out of The University of Iowa’s Biochemistry 
Department and a former professor of biochemistry runs the company today. This is a good start, but the 
future will require many of these successes to convince investors to invest in Iowa biomedical start-ups. 
Platform technologies in Drug Discovery, Development, Piloting, Trials and Production and in Integrated 
Post-Genomic Medicine may create patents that can be licensed to a new group of start-ups. Infrastructure 
for this kind of economic development is yet to be put in place in Iowa. 
In interviews, larger bio-related companies in the state have indicated a strong reliance on Iowa’s 
universities for recruiting new employees. Many of these companies also sponsor research programs in 
the universities. Most are funding graduate student research as good corporate citizens—not anticipating 
that they will benefit directly. One company indicated that they had built a major division of their 
operations in Iowa because of the expertise of Iowa State University and the College of Veterinary 
Medicine. Another company had a highly proprietary project being funded at Iowa State because of the 
expertise of the principal investigator.  
COMPETITION IN BIOSCIENCE DEVELOPMENT 
Other states and regions are aggressively pursuing life science development. 
Other states are investing aggressively in a comprehensive range of bioscience programs to promote 
research and commercialization. A number of states also are aggressively pursuing bioscience 
development strategies, including strengthening research, increasing university-industry collaborations, 
and enhancing their business development support.  
Examples of bioscience investments over the last few years include the following:  
• California is investing $100 million in a bioengineering and biotechnology institute, and $500 million 
in pension funds toward the California Biotechnology Program. 
• Pennsylvania has committed to invest $2 billion over a 20-year period in the biosciences including 
$100 million specifically for the Life Sciences Greenhouses initiative. 
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• Michigan, through its Life Sciences Corridor initiative, initially planned to invest $1 billion in the 
biosciences over a twenty-year period. However, this investment level may be scaled back due to 
programmatic modifications and budgetary concerns. 
• Georgia has invested more than $300 million over a ten-year period to build core research facilities 
and to attract Eminent Scholars, the majority of whom are in the biosciences; and has created a 
$1 billion Georgia Cancer Coalition designed to make Georgia a national leader in cancer prevention, 
treatment, and research. 
• Texas appropriated $800 million for seven new or expanded health science research centers. 
Other states and regions of the country have allocated more state funding and secured significant federal 
dollars as the NIH budget has nearly doubled in the last several years. For example, as many as 41 states 
report technology initiatives that support the development of bioscience research and/or bioscience 
companies.65 
                                                   
65
 See Biotechnology Industry Organization, State Initiatives in Biotechnology 2001, September 2001. 
 Iowa Bioscience Path for Development 
 
 
148 
 
 Iowa Bioscience Path for Development 
 
 
149 
Conclusion 
The biosciences have been identified as the underlying technology platform for the growth of state and 
regional economies in the coming decades. States are realizing that their traditional economic bases may 
undergo significant change and increasingly are embracing the biosciences as a path to future economic 
progress. States such as Michigan, Pennsylvania and Wisconsin have recognized the opportunity to 
leverage their academic and non-profit bioscience research institutions to form growth hubs of innovation 
in this dramatically advancing field. 
Significant bioscience economic activities in several specific technology platform areas are already 
showing promise—some of which have already begun to be mobilized as formal initiatives in the state 
and others that need to be further supported and built-up. These near-term platforms include: 
• BioEconomy—Designing initiatives to make Iowa a leader in the application of bio-renewable 
resources to industrial commodities, products, and energy. 
• Drug Discovery, Development, Piloting, Trials and Production—Leveraging Iowa’s basic science 
and applied clinical research expertise in human medicine (and perhaps veterinary medicine) and 
proven track record in drug development and production services, into a vertically integrated pipeline 
of discovery and commercialization. 
• Advanced Food Products—Leveraging skills in informatics, genomics, genomic transformation, 
metabolomics, nutrition, and food science to attain a leadership position in functional foods, 
phytochemicals, and nutraceuticals. 
• Integrated Post-Genomic Medicine—Leveraging informatics, genomics, epidemiology and 
pathology, in combination with specific disease strengths, to create centers of excellence based on 
quantitative discovery and longitudinal data. 
• Animal Systems—Using Iowa’s skills in transgenics, animal genomics, food animal science, and 
biological sciences to develop a platform for the development and production of designer animals for 
gene/protein expression, xenotransplantation, and improved meat quality and productivity. 
• Integrated Biosecurity—Building upon Iowa’s proven strengths in plant, animal, and human 
infectious diseases, together with broad skills in agronomy, environmental sciences, engineering and 
other disciplines, to develop a holistic approach to the biosecurity of entire systems. 
Additional long-term opportunities have been further identified in the following areas: 
• Host-Parasite Biology and Systems 
• Instrumentation, Sensors and Devices 
• Cardiovascular Institute 
• Free Radical Institute. 
This assessment of Iowa’s position in the biosciences highlights a state that has significant promise to be 
among the nation’s bioscience leaders in selective fields. Iowa institutions have quite substantial strengths 
in the “three legs of the bioscience stool”— human, animal, and plant biosciences. In particular, the 
bioscience operations of both Iowa State University and The University of Iowa show fundamental 
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bioscience technology platform strengths that can be further enhanced by increased collaborations 
between the institutions and with industry. 
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Appendix A: 
Detailed Iowa Bioscience Subsector Performance 
Table A-1: Iowa and National Bioscience Subsector Comparison, 1998 to 2002 
IOWA
Agricultural 
Services
Agricultural 
Processing
Organic and 
Agricultural 
Chemicals
Drugs & 
Pharmaceuticals
Agricultural 
Machinery 
Equipment
Medical 
Equipment 
& Supplies
Research 
and 
Testing Hospitals
Establishments
2002 148 976 56 44 129 139 186 178
98-00 -41.2% -29.5% -1.5% 17.1% -12.0% 14.5% 1.4% 9.6%
00-02 -14.9% -2.5% -12.5% 7.3% -7.2% -7.3% -11.8% 4.1%
98-02 -50.0% -31.2% -13.8% 25.7% -18.4% 6.1% -10.6% 14.1%
Employment
2002 1,187 19,458 4,416 2,515 10,115 1,847 1,429 41,882
98-00 -22.2% -21.4% -17.5% 2.0% -22.3% 9.9% -47.9% 2.6%
00-02 -12.3% 0.5% 134.0% 10.5% -0.8% -3.4% 20.4% 3.4%
98-02 -31.8% -21.0% 93.0% 12.6% -22.9% 6.1% -37.3% 6.1%
Location Quotient
1998 3.07             8.60                 1.47                 0.73                      11.82           0.37           0.40         0.83         
2000 2.67             6.95                 1.32                 0.74                      10.64           0.41           0.19         0.88         
2002 2.21             7.34                 3.51                 0.78                      11.83           0.41           0.21         0.89         
Wages
2002 18,794$       46,318$           52,760$           41,952$                51,672$       29,212$     36,699$   32,494$   
98-00 13.2% 5.2% 34.3% 6.3% 4.5% 18.8% 195.3% 11.0%
00-02 17.2% 7.5% -16.5% 12.3% 3.8% -12.1% 12.0% 12.3%
98-02 32.7% 13.1% 12.2% 19.4% 8.4% 4.5% 230.7% 24.7%
Percent Share of Private Sector
1998 0.15% 2.07% 0.19% 0.19% 1.11% 0.15% 0.19% 3.33%
2000 0.11% 1.59% 0.15% 0.19% 0.84% 0.16% 0.10% 3.33%
2002 0.10% 1.64% 0.37% 0.21% 0.85% 0.16% 0.12% 3.53%
UNITED STATES
Establishments
2002 7,893 15,231 2,004 2,542 2,058 15,090 24,246 17,209
98-00 -7.7% -2.8% -1.9% 1.0% -4.1% -3.0% 3.2% 1.3%
00-02 12.7% -2.1% -1.1% 0.9% -6.9% -0.4% 7.9% 16.1%
98-02 4.0% -4.8% -3.0% 1.9% -10.7% -3.4% 11.3% 17.7%
Employment
2002 48,860 240,623 114,263 293,314 77,598 407,044 607,255 4,283,173
98-00 -8.1% 0.1% -5.7% 3.6% -11.2% 1.6% 11.9% 0.0%
00-02 8.4% -3.0% -10.2% 7.5% -9.0% -2.2% 8.9% 4.4%
98-02 -0.5% -2.9% -15.3% 11.3% -19.2% -0.6% 21.8% 4.4%
Wages
2002 24,690$       41,970$           58,870$           73,129$                42,308$       49,940$     68,913$   38,159$   
98-00 3.8% 4.2% 4.6% -3.5% 6.3% 8.8% 28.2% 6.4%
00-02 11.4% 6.8% 1.2% 10.2% 3.1% 7.1% -3.5% 10.2%
98-02 15.7% 11.3% 5.8% 6.4% 9.6% 16.5% 23.7% 17.3%
Percent Share of Private Sector
2002 0.05% 0.22% 0.11% 0.27% 0.07% 0.38% 0.56% 3.98%
Source: Battelle calculations based on ES-202 data from the US Department of Labor, Bureau of Labor Statistics and Iowa Workforce Development, 
Employment Statistics Bureau
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Appendix B: 
Detailed Iowa Bioscience Industry Definition 
Table B-1: Detailed List of NAICS codes found within the Iowa Bioscience Industry. 
NAICS Code NAICS Description
Agricultural Services
115112 Soil Preparation, Planting, and Cultivating 
115210 Support Activities for Animal Production
Agricultural Processing
311119 Other Animal Food Manufacturing (pt)  
311211 Flour Milling 
311212 Rice Milling  
311213 Malt Manufacturing  
311221 Wet Corn Milling  
311222 Soybean Processing  
311223 Other Oilseed Processing (pt) 
311225 Fats and Oils Refining and Blending (pt)  
311230 Breakfast Cereal Manufacturing  
311613 Rendering and Meat Byproduct Processing
311822 Flour Mixes and Dough Manufacturing from Purchased Flour  
311930 Flavoring Syrup and Concentrate Manufacturing 
Organic & Agricultural Chemicals
325191 Gum and Wood Chemical Manufacturing  
325192 Cyclic Crude and Intermediate Manufacturing  
325193 Ethyl Alcohol Manufacturing 
325199 All Other Basic Organic Chemical Manufacturing
325222 Noncellulosic Organic Fiber Manufacturing 
325311 Nitrogenous Fertilizer Manufacturing
325312 Phosphatic Fertilizer Manufacturing
325314 Fertilizer (Mixing Only) Manufacturing
325320 Pesticide and Other Agricultural Chemical Manufacturing
Drugs & Pharmaceuticals
325411 Medicinal and Botanical Manufacturing  
325412 Pharmaceutical Preparation Manufacturing  
325413 In-Vitro Diagnostic Substance Manufacturing
325414 Biological Product (except Diagnostic) Manufacturing  
Agricultural Machinery
333111 Farm Machinery and Equipment Manufacturing  
333294 Food Product Machinery Manufacturing  
Medical Equipment & Supplies
339111 Laboratory apparatus & furniture mfg
339112 Surgical & medical instrument mfg
339113 Surgical appliance & supplies mfg
339114 Dental equipment & supplies mfg
339115 Ophthalmic goods mfg
339116 Dental laboratories
334510 Electromedical apparatus mfg
334516 Analytical laboratory instrument mfg
334517 Irradiation apparatus mfg
Research & Testing
541380 Testing laboratories
541710 R&D in physical, engineering & life sciences
Hospitals & Labs
621511 Medical laboratories
621512 Diagnostic Imaging centers
622110 General medical & surgical hospitals
622210 Psychiatric & substance abuse hospitals
622310 Other specialty hospitals
